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Abstract  
 
Spinal cord injury (SCI) is one of the leading and most crippling causes of 
acquired neurological impairment. It affects around 40,000 individuals in the 
UK, causing paralysis, multisystem impairment and a reduced life expectancy. 
This has a devastating impact on quality of life and places stress upon both 
individuals and healthcare systems. Despite extensive characterization of SCI 
pathology, there remains no cure. Stem cells offer a potential therapy since 
they can replace lost neurons, promote axonal regeneration and limit scar 
formation, but an optimal stem cell source has yet to be found. Enteric neural 
stem cells (ENSCs) are a possible solution. ENSCs comprise the renewing 
population of the enteric nervous system (ENS), the intrinsic innervation of 
the gastrointestinal (GI) tract. ENSCs can be isolated from the GI tract via 
minimally invasive techniques such as endoscopy, and when transplanted 
into aneural or dysfunctional gut, are capable of reforming a functional ENS. 
This thesis assesses the potential of ENSCs as a stem cell source for SCI. 
 Chimeric neural tube grafting was used to fluorescently label chick 
ENSCs, allowing for isolation and lineage tracing. In vitro characterization 
revealed neuronal subtypes that were common between ENSCs and spinal 
cord tissue. Following transplantation into the embryonic chick spinal cord 
ENSCs survived, differentiated into neurons and formed anatomical bridges 
across the injury zone. In an adult rat model of SCI, ENSC transplantation was 
combined with application of chondroitinase ABC (ChABC), a modifier of the 
inhibitory microenvironment observed within SCI. ENSCs, when transplanted 
on their own, demonstrated extended survival, differentiated into neurons 
and bridged the injury site. Combined treatment (ENSCs + ChABC) resulted 
in a significant improvement in lesion histology, including reduction of the 
injury cavity, and increased numbers of endogenous axons crossing the injury 
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site. Together, these findings establish ENSCs as a promising alternative 
stem cell source for SCI.
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1 General Introduction 
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1.1 Spinal cord injury (SCI) background 
 
SCI has an estimated UK prevalence of around 40,000 (Gall and Turner-
Stokes, 2008). Twenty to forty year old males are the most commonly 
affected, with motor vehicle collisions or sporting accidents as the leading 
cause of injury (Nas et al., 2015). Sufferers typically experience paralysis from 
the point of injury down (cervical injuries comprise the majority), multisystem 
impairment, and reduced life expectancy (Sezer et al., 2015). The life 
expectancy of suffers is rising alongside better care standards, but this is 
revealing additional problems as SCI patients begin to experience 
cardiovascular issues and other age-related illnesses, the treatment of which 
is complicated by (most commonly) tetraplegia (Gall and Turner-Stokes, 
2008; Hachem et al., 2017). In addition to the numerous physical symptoms, 
associated psychosocial factors resulting from the injury severely impact on 
sufferer’s mental well-being (Cao et al., 2014). SCI patients have increased 
rates of depression and anxiety (Craig et al., 2017; Lim et al., 2017). This has 
translated to increased rates of suicide among SCI patients, the incidence of 
which has risen while other causes of death have fallen (Soden et al., 2000). 
Among factors such as reduced self-esteem and frustration, chronic pain is 
thought to impact on these rates (Ruan and Luo, 2017). Taking into account 
both the physical and mental effects of SCI, patients have a significantly 
lower quality of life than the healthy population (Moreno et al., 2017; 
Palimaru et al., 2017; Sweet et al., 2014). SCI also poses a significant financial 
burden to the patient (in terms of lost earning potential, home adaptations 
and living assistance) and on the National Healthcare System.  
SCI has an immense impact on the physical, mental and social health of 
both patients and the community, an effect that could be lessened by even 
partial restoration of one or more functions lost through SCI (Anderson, 2004; 
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Simpson et al., 2012). However, despite extensive research, no treatment 
options are currently available to restore complete motor and sensory 
functions following SCI (Rouanet et al., 2017). Therefore, the development of 
more effective treatments, or better yet, cures for SCI is of paramount 
importance.  
1.2 Spinal cord development 
 
The spinal cord serves as the interface between the brain and the rest of the 
body. It is the hub where the central and peripheral nervous systems (CNS 
and PNS, respectively) meet to allow seamless communication. Indeed, while 
the CNS and PNS are often thought of as isolated entities, the two in reality 
form a continuous structure, with all nervous tissues originally derived from a 
single germ layer, the ectoderm (Wittler and Kessel, 2004).  
The CNS is established first during early embryonic development via 
the process of neurulation (Fig. 1.1) (Gammill and Bronner-Fraser, 2003). This 
process begins during the trilaminar stages of embryogenesis, initiated by 
the notochord inducing the overlying ectoderm to form the neurectoderm 
(Yamada et al., 1991). A small furrow, the neural groove, forms in the 
neurectoderm along the anterior-posterior axis (Colas and Schoenwolf, 
2001). The two edges of the neurectoderm then rise to form the neural folds, 
which meet and fuse to form the neural tube (Pai et al., 2012). Initially 
consisting of a single cell layer, the germinal neuroepithelium (Sauer, 1935), 
undergoes progressive cell division (mostly in the dorsal aspect of the tube) 
to give rise to a laminated structure consisting of the germinal, mantle and 
marginal zones. While changing greatly in appearance, this early structure is 
maintained throughout life, with the germinal, mantle and marginal zones 
developing into the ependymal canal, and grey and white matter of the adult 
spinal cord, respectively (Fig. 1.2) (Gilbert, 2000).  
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Throughout development and adulthood these structures remain 
anatomically and functionally distinct. The ependymal canal, formed of the 
early germinal neuroepithelium, retains a modest stem cell pool late into 
adulthood (Panayiotou and Malas, 2013). The grey matter, centralised within 
the cord (in contrast to the brain), contains the cell bodies of spinal neurons. 
The white matter is mostly occupied by axons projecting from these neurons 
or entering from sensory neurons of the PNS (Gilbert, 2000). These layers 
stretch the entire length of the neural tube, the progressive folding of which 
forms all aspects of the CNS.   
 
Figure 1.1: The spinal cord 
and neural crest are formed 
through the process of 
neurulation early in 
development. 
Neurulation begins with induction of 
the neural plate by the underlying 
notochord. This folds along the 
anterior-posterior axis to form the 
neural groove, the outer edges of 
which rise to form the neural folds. 
These gradually meet and fuse to 
initially give rise to a single cell layered 
structure, the neural tube. Neural crest cells are formed at the boundary between 
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Figure 1.2: The trilaminar structure of the developing neural tube 
is mirrored in the adult spinal cord. 
The neural tube is formed of neuoectoderm. In the early stages of neural tube 
formation, early progenitor cells within the CNS - the neuroepithelial cells of the 
germinal zone (pink) – give rise to the mantle (blue) and marginal zone (brown). The 
mantle zone consists of neuroblasts that will form the future grey matter of the 
spinal cord. These cells send out projections into the marginal zone, which forms the 
white matter of the adult spinal cord. This contains the vast majority of ascending 
sensory and descending motor tracts of the CNS. 
 
Ependymal cells of the early germinal neuroepithelium give rise to 
almost all neuronal and glial cell types throughout the mature spinal cord 
(Kriegstein and Alvarez-Buylla, 2009). Neuroepithelial cells give rise to the 
radial glia, themselves multipotent progenitors (Huttner and Kosodo, 2005; 
Noctor et al., 2004). Through a series of symmetric and asymmetric divisions, 
radial glia give rise to the neurons and glia of the future spinal cord (Paridaen 
and Huttner, 2014). 
In the developed spinal cord, these progenitor–derived cells assume 
specific functions. Spinal neurons are responsible for the transmission of 
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sensory and motor information between the brain and body. All such cells 
are multipolar, including efferent, projection and interneurons (Caspary and 
Anderson, 2003; Gouti et al., 2015). They are capable of producing/ 
responding to a range of neurotransmitters as well as noxious stimuli, 
allowing them to facilitate reflex arcs and limit damage sustained from the 
external environment. However, neurons cannot carry out these functions in 
isolation. Glia, the most common cell type in the CNS and originally thought 
to be nothing more than a glue to hold neurons in place, are now known to 
be as equally important as neurons for correct functioning of the CNS 
(Gonzalez-Perez et al., 2015). As well as giving rise to the first neurons, radial 
glia are vital for axon guidance and proper spatial development of the grey 
matter (McDermott et al., 2005). Oligodendrocytes myelinate the neurons to 
enhance axonal conduction (Bradl and Lassmann, 2010), and astrocytes take 
part in the tripartite synapse (among numerous other roles) to facilitate 
efficient synaptic transmission (Perea et al., 2009). Microglia (the exception to 
CNS genesis) are generated from blood (Ginhoux et al., 2010) and function 
to ensure immune stability of the spinal cord microenvironment and remove 
dead cells/ debris. 
In health, these neurons and glia function seamlessly to allow the 
spinal cord to carry out a wide range of functions. As well as enabling reflex 
arcs, the adult spinal cord is involved in almost every aspect of bodily 
function. The cord contains a series of ascending sensory and descending 
motor pathways between the brain and body, to allow interaction with the 
external environment, and monitoring/ modulation of the internal 
environment. These pathways are organised into numerous tracts and often 
extend over considerable distances (Levy et al., 2015). Severing of these 
tracts, in many cases, is both catastrophic and irreversible. 
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1.3 Spinal cord injury 
 
While originally derived from a common cell source, the response of the PNS 
and CNS to injury is remarkably distinct. Unlike the PNS, the regenerative 
capacity of the CNS is severely limited (Huebner and Strittmatter, 2009). 
Trauma to the spinal cord therefore leads to an irreversible loss of neurons, 
inevitably causing destruction of ascending and descending axonal tracts. 
Compounding matters, the injury response processes that apparently exist to 
limit the spread of the resulting lesion actually appear to perturb 
regeneration. The cascade of events occurring following SCI can be grouped 
into two phases. The first consists of necrotic cell death directly related to the 
spinal cord trauma (McDonald and Sadowsky, 2002). The secondary phase 
begins immediately after this insult, and comprises reactive, ongoing 
processes which hinder endogenous regeneration (Tator, 1991). Secondary 
processes can continue for months (summarised in Fig. 1.3), and are 
associated with continuing deterioration of the patient’s condition. 
The initial mechanical damage to the spinal cord results in both 
necrotic death of neurons and the axonal interruption of many surviving 
neurons. This leads to Wallerian degeneration – degradation of the axon 
distal to the injury - and retraction of the proximal axon (Vargas and Barres, 
2007). This axonal insult also leaves the surviving cell body vulnerable to 
apoptotic death (Ruff et al., 2008). In addition, the injury causes haemorrhage 
from ruptured blood vessels supplying the cord and disruption of the blood-
spinal cord barrier. These events lead to the secondary phase of spinal cord 
injury.  
Many blood components are neurotoxic (Mautes et al., 2000), leading 
directly to cell death from contact with blood products, and indirectly 
causing hypoxia/ death of cells previously supplied by the severed vessels. 
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This also leads to significant inflammation, arguably the most harmful aspect 
of secondary injury, involving the invasion of the spinal cord by 
macrophages, neutrophils and T-cells (Zhang et al., 2012). Along with 
activated resident microglia, these invading cells release free radicals and 
other noxious substances, compounding the ongoing cell death (David and 
Kroner, 2011; Nguyen et al., 2007). Astrocytes within the spinal cord are also 
recruited to the site of injury, where they proliferate around the lesion and, in 
turn’ recruit fibroblasts to form a ‘glial scar’ (Sun and Jakobs, 2012). While 
this is likely a protective mechanism to prevent further necrotic spread from 
the injury site, the scar is now known to also present both a physical and 
chemical barrier to regenerative cell migration/ axon extension across the 
lesion. Astrocytes within the scar produce extracellular matrix proteins such 
as chondroitin-sulfate proteoglycans (CSPGs) (Burnside and Bradbury, 2014; 
Morgenstern DA et al., 2002), which induce axonal growth cone collapse and 
prevent attempts by neurons to project axons across the injury site. 
Unsupported cells within the lesion site continue to die/degenerate. 
Combined, these processes result in the formation of fluid-filled cavities 
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Figure 1.3: Secondary 
mechanisms of spinal cord 
injury compound cell death 
and hinder endogenous 
recovery. 
Following mechanical injury, the 
severing of blood vessels leads to 
haemorrhage, inflammation and 
oedema, as well as ischemia of target 
tissues of the disconnected vessels. 
Severed axons undergo 
demyelination and Wallerian 
degeneration, releasing inhibitory debris into the injury microenvironment. These 
processes result in the formation of fluid-filled cavities within the cord, which are 
quickly enveloped by the glial scar. This contains astrocytes and fibroblasts, and 
presents a physical and chemical barrier to regeneration (Mothe and Tator, 2012). 
 
By-products of the injury process, such as CSPGs produced by 
astrocytes, quickly form a chemically inhibitory environment towards 
regeneration. Despite the extensive invasion of phagocytotic cells, there is 
poor clearance of various inhibitory factors from the injury site (Fawcett and 
Asher, 1999). Myelin released from dying oligodendrocytes is one such 
factor, and its degradation produces several substances detrimental to axon 
growth (McGee and Strittmatter, 2003). Evidence for the inhibitory properties 
of myelin have been provided by Liebscher et al and Merkler et al, who 
demonstrated significant functional recovery of SCI rodents following 
treatment with monoclonal antibodies raised against myelin-based products 
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(Liebscher et al., 2005; Merkler et al., 2001). Furthermore, onset of myelin 
production during chick embryo development coincides with the stage at 
which the spinal cord can no longer recover from injury (Macklin and Weill, 
1985).  
 Much of the spinal cord’s inability to functionally regenerate after 
injury is attributed to this inhibitory microenvironment. In vitro it has been 
demonstrated that CNS cells are capable of axonal regeneration if placed in 
more permissive culture conditions (Taylor et al., 2005), and CNS axons have 
been shown to extend into peripheral nerve grafts following SCI (Richardson 
et al., 1980). In addition, when placed alongside neurons isolated from the 
PNS or in supportive scaffolds, CNS neurons have demonstrated extension of 
axons and establishment of new connections (Meng et al., 2014), implying 
that surviving neurons are intrinsically capable of regeneration, but their 
surroundings render such recovery impossible. 
 As well as severe difficulties in projecting axons across the injury to 
restore connections, the spinal cord appears unable to replace cells lost 
through injury. While stem cells within the central canal have been shown to 
proliferate in response to SCI, the cells formed are almost entirely glial, and 
appear to contribute the majority of cells that form the glial scar (Barnabe-
Heider et al., 2010). Attempts to stimulate additional proliferation, or to 
encourage neuronal differentiation, have led to modest improvements in 
functional recovery (Corns et al., 2015; Kojima and Tator, 2002). However, 
the mechanisms underlying this regeneration are unclear, especially as these 
attempts have mostly resulted in further glial production.  
These secondary events reveal a host of complicated issues that will 
need to be addressed by any attempt at a therapy for SCI. In order to 
preserve surviving endogenous neurons, the inhibitory environment, 
including inflammation, must be in some way made more permissive. This 
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will likely support endogenous regeneration, including preservation of 
injured tissue and extension of axons across the injury site. However, the 
fluid-filled cavities leave little in the way of substrates for axonal 
regeneration, an issue which must also be addressed. Additionally, any 
attempt to stimulate regeneration would be aided by replenishment of the 
lost cell population. Considering the difficulties of stimulating neuronal 
production from resident stem cells in the ependymal canal, it is likely that 
any attempt to replace dead cells will need to utilize an external source. Stem 
cell-based therapies have been proposed for SCI based on their ability to 
meet many of these criteria, including modulation of the inhibitory 
microenvironment and replacement of cells lost through injury. 
 
1.4 Existing stem cell sources for SCI therapy 
 
The use of several stem cell sources for SCI therapy have been attempted 
with varying degrees of success, including non-neural lines. Mesenchymal 
stem cells have been shown to nullify the inhibitory micro-environment, 
resulting in increased endogenous regeneration (Oliveri et al., 2014). These 
treatments, however, did not produce new neurons to replace those lost 
through injury. The production of new neurons may well be required for full 
recovery. In addition, the consequences of introducing non-endogenous cell 
types to the spinal cord may not yet be fully understood. In an attempt to 
utilise a stem cell source less foreign to the spinal cord, transplantations of 
olfactory ensheathing glia (OEG), isolated from the olfactory bulb, have been 
tested in a variety of injury conditions. These have resulted in considerable 
motor and sensory improvements, both in rodent models and human trials 
(Tabakow et al., 2014). However, while these cells are surgically harvested 
from an isolated brain region, and the most probable side-effects of the 
	   32	  
surgery (e.g. anosmia) may well be deemed an acceptable cost, brain surgery 
always carries risk of more severe consequences for the patient, already 
severely compromised with SCI. Neural stem cells (NSCs), taken from the 
subventricular or subgranular zones of the brain, or the ependymal canal of 
the spinal cord, are similarly difficult to harvest without significant risk to the 
patient (Poser and Androutsellis-Theotokis, 2013). Embryonic stem cells have 
been proposed for their ability to form all neuronal subtypes required. 
However, any transplantation of embryonic stem cells would almost certainly 
be allogeneic, with recipients likely requiring immunosuppression (Donnelly 
et al., 2012). Additionally, their sourcing is overshadowed by ethical issues, 
again marring success following transplantation (Lo et al., 2009). Finally, 
induced pluripotent stem cells (iPSC), while advantageous in many ways, 
carry considerable tumorigenic risk (Kuroda et al., 2013). Although this risk 
has been significantly reduced following several notable breakthroughs, 
other concerns regarding unknown consequences of epigenetic alterations 
during their generation (Lund et al., 2012) throws any near-future application 
of these cells into doubt.  
 Thus, a variety of stem cell sources have shown great potential 
towards achieving partial, if not complete, functional recovery following SCI. 
Indeed, despite their various limitations, several stem cell sources have 
progressed to clinical trials. These will be briefly discussed in the following 
section.  
 
1.5 Existing stem cell-based clinical trials for SCI 
 
A number of clinical trials have been approved and conducted to date, 
further highlighting the promise of stem cells as a therapeutic option for SCI. 
Work by Keirstead et al utilised embryonic stem cells (ESC) to address 
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demyelination occurring following SCI. Keirstead et al optimised protocols 
for derivation and expansion of ESCs and subsequent differentiation towards 
an oligodendrocyte lineage (Nistor et al., 2005). Transplantation of this 
population was seen to result in significant functional improvements in rat 
models of SCI (Faulkner and Keirstead, 2005; Keirstead et al., 2005). 
Importantly, axon myelination by OPCs following transplantation into shiverer 
mice (homozygous for mutations affecting the myelin basic protein gene) was 
demonstrated, showing both that transplanted OPCs differentiate towards a 
mature oligodendroglial lineage in vivo (via co-labelling with BrDU) and that 
they are able to fulfil their intended role. These results laid the foundation for 
progression to clinical trials.  
A phase I clinical trial began in 2010, with brief hiatuses owing firstly to 
concerns over stem cell purity; secondly to fears surrounding possible cyst 
formation noted in the clinical trial data; and lastly to financial difficulties of 
Geron, of Menlo Park, California (Baker, 2011). The trial subsequently 
continued following acquisition of Geron by Asterias Biotherapeutics, also of 
Menlo Park (Hayden, 2014). The trial was concluded and reported safety of 
the transplanted cells, as well as possible cavity reduction, though no 
functional benefit (though cells were transplanted at a projected sub-clinical 
dose, so the lack of functional improvement is not unexpected 
(ClinicalTrials.gov, clinical trial identifier NCT01217008). Based on these data 
and additional supporting pre-clinical data (Priest et al., 2015), a phase I/IIa 
dose escalation study is currently underway (clinical trial identifier: 
NCT02302157). The difficulties faced throughout these studies raises an 
important point: despite the promising basic research supporting the use of 
this cell technology and the encouraging safety data obtained during the 
phase I trial, progression of these ESC-derived cells towards therapeutic 
application has been both difficult and incredibly expensive. This highlights 
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the importance of extensive preclinical data, however even this is no 
guarantee of advancement to the clinic. 
 While the above trial by Asterias was the first clinical trial to transplant 
differentiated cells derived from ESCs into humans (Hayden, 2014) it is no 
longer the only stem cell clinical trial aimed at demonstrating therapeutic 
potential of stem cells for SCI. Cummings et al showed the potential of 
human foetal brain-derived neural stem cells for SCI (Cummings et al., 2005). 
The authors noted appropriate neuroglial differentiation and long-term 
survival following transplantation into immune-compromised mice. 
Transplantation resulted in significant functional improvement, as assessed 
using BBB scoring. Significantly, these functional improvements were lost 
following selective ablation of transplanted cells. However, progression to 
the clinic was, in this case, hampered by advancement from research to 
clinical grade cells (Anderson et al., 2017). The authors attribute this 
discrepancy to variability in cell lines as well as inconsistencies following 
good manufacturing practice (GMP) scaling towards clinical quantities. 
Further, the authors point to the lack of FDA requirements for in vivo testing 
of the final clinical product prior to initiation of clinical trials (Anderson and 
Cummings, 2016). Despite this, StemCells Inc proceeded with a clinical trial 
testing the efficacy of a cell line based on the preceding results (clinical trial 
identifier NCT02136876) in 2014. However, while initial reports were positive, 
this trial was ended in 2016 citing a lack of significant improvements with 
time. These studies again highlight the difficulties in translating promising 
research from bench to bedside. Of key importance, these publications 
underline the need for critical evaluation of any given stem cell source at all 
stages progressing to the clinic, including basic research of stem cell efficacy 
and testing of the final product prior to clinical trial initiation. Indeed, the 
need to address consistency in cell products following scale-up of the initial 
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protocol has been recognised, particularly for generation of stable iPSC lines 
(Silva et al., 2015). 
 Despite the difficulties experienced it has been posited that 
progression of further basic research to clinical trials is vital for the 
development of the field (Fehlings and Vawda, 2011). Numerous clinical trials 
have demonstrated the safety of stem cell transplantation and some have 
shown slight functional improvements (Bunge, 2016; Dai et al., 2013; Park et 
al., 2012; Tabakow et al., 2013; Zhou et al., 2012). Importantly, in addition to 
providing vital safety data, these trials have helped refine human 
transplantation techniques. Clearly, any future progression from basic 
research to a clinical trial should proceed with caution, and of course not all 
laboratories have the necessary funding to support progression to, for 
example, large animal models (a highly desirable platform for testing prior to 
clinical trials). Nonetheless, with transparent presentation of findings, use of 
validated, and therefore comparable techniques in established models of 
SCI, and especially with careful evaluation of the final cell-based product 
before advancement, it could be argued that the field is ready for 
progression of more basic research to the clinic.  
However, while many existing stem cell sources have been extensively 
researched, it is apparent from the existing literature that currently, no stem 
cell source represents an ideal solution. Despite this, the demand for an 
effective therapy is such that several imperfect sources have reached clinical 
trials, costing millions of pounds. Clearly, therefore, any potential new 
sources should be closely examined to determine whether they represent a 
significant advantage over existing ones. 
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1.6 Enteric neural system stem cells (ENSCs) as a potential source of stem 
cells for SCI 
 
Enteric neural stem cells (ENSCs), isolated from the adult gut, are a 
promising alternative stem cell source. These are the resident stem cells of 
the ENS, and have been isolated from patients up to 80 years of age 
(Metzger et al., 2009a). They are derived from neural crest cells (NCCs) - a 
transient population of cells that give rise to numerous cell types throughout 
the body including the ENS of the gastrointestinal tract (Yntema and 
Hammond, 1954), and transplantation of these cells into the gastrointestinal 
tract shows that they have the ability to differentiate into neurons and glial 
cells (reviewed in Burns and Thapar, 2014). Furthermore, following 
transplantation these neurons have been shown to integrate functionally into 
the endogenous ENS networks (Burns and Douarin, 1998; Cooper et al., 
2017), and even to rescue a loss of GI function (McCann et al., 2017). 
Recently ENSCs cultured from postnatal human tissue have been shown to 
retain similar migratory, proliferative and differentiation capabilities to 
embryonic neural crest-derived cells, demonstrating their potential benefits 
towards tissue regeneration following transplantation (Cheng et al., 2017) 
 
1.6.1.1 Enteric Nervous System Development 
 
The ENS is arguably the most complex division of the PNS, containing more 
neurons than the spinal cord (Furness, 2006). This cell density is matched by 
the diversity of neuronal subtypes and range of neurotransmitters produced 
(McConalogue and Furness, 1994; McConalogue et al., 1994). The neurons 
and glia of the ENS form an intricate network responsible for the peristaltic 
propulsion of boluses along the GI tract, enzymatic secretion, nutrient and 
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water absorption, and regulation of blood flow within the intestinal wall, 
among other functions (Furness, 2006). Indeed, it has been shown that many 
of these processes occur with partial or even complete autonomy from the 
CNS. When CNS innervation of the GI tract is severed, many regions of the 
GI system are entirely capable of sustaining normal functions, demonstrating 
the sophistication of the ENS neural network (Bayliss and Starling, 1899). The 
ENS is organised into and mediates this intrinsic control through two 
concentric plexuses (the myenteric and submucosal) spanning the entire 
length of the GI tract (Furness, 2012). These neural plexuses are embedded 











Figure 1.4: The enteric nervous system consists of two concentric 
plexuses, forming interconnected neuronal networks. 
The myenteric plexus (located between the longitudinal and circular muscle layers) 
and the submucosal plexus (located between the circular muscle and muscularis 
mucosa) innervate the gastrointestinal tract. Taken from (Furness, 2012). 
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The ENS is derived in its entirety from NCCs that migrate from the 
dorsal neural tube early in development (Gershon et al., 1993; Yntema and 
Hammond, 1954). The neural crest comprises a highly migratory, multipotent 
cell population that gives rise to multiple cell types, including mesenchymal 
lineages such as adrenal medulla tissue, craniofacial structures including 
dentine of teeth, melanocytes, cardiac regions, and neuroectodermal 
lineages such as the peripheral nervous system (Le Douarin and Smith, 1988; 
Le Lievre and Le Douarin, 1975; Miletich and Sharpe, 2004). The incredibly 
diverse fates of NCCs has led many to refer to these cells as the fourth germ 
layer (Shyamala et al., 2015). 
The fate of NCC is at least partially determined prior to leaving the 
neural tube by their relative positioning along the anterior-posterior axis of 
the developing embryo. NCCs are formed along the entirety of the neural 
tube, and prior to their migration neural crest regions can be divided both 
anatomically and functionally into cranial, vagal, cardiac, trunk and sacral 
populations (Vaglia and Hall, 1999). The vast majority of the ENS is formed 
from vagal neural crest, with modest contributions from the sacral population 
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Figure 1.5: The enteric nervous system is derived from the vagal 
and sacral neural crest. 
The neural crest, formed at the boundary between the neural tube and the overlying 
ectoderm, migrates from the dorsal neutral tube to the developing gut. The vagal 
neural crest (adjacent to somites 1-7) migrates first, reaching the foregut and 
migrating caudally throughout the gut to form both the myenteric and submucosal 
plexuses. The sacral neural crest (beginning caudal to the 28th pair of somites) enters 
the gut once colonization of the entire GI tract by the vagal neural crest is essentially 
complete, and thence contributes only to the formation of hindgut ENS. Once 
complete, the ENS consists of two concentric structures; the myenteric and 
submucosal plexuses. These are formed of interconnected ganglia composed of 
neurons, glia and endogenous stem cells. Taken from (Goldstein et al., 2013). 
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 Generally, vagal NCCs migrate to and enter the developing GI tract 
at the level of the foregut. In humans this initial invasion takes place around 4 
weeks into gestation (Heanue and Pachnis, 2007; Wallace and Burns, 2005). 
The cells then migrate in a rostral-caudal direction, colonising the entire 
length of the gut, a process taking around 3 weeks in humans (Anderson et 
al., 2006; Wallace and Burns, 2005). This migration is then followed by 
differentiation and maturation of ENS structures occurring in a similar 
rostrocaudal sequence. Proximal to the vagal migration wavefront, NCC 
progenitors stop migrating, proliferate and differentiate to form ganglia - 
interconnected clusters of several neuronal subtypes and glia. These ganglia 
further interconnect to ultimately form the myenteric and submucosal 
plexuses, comprising the functional neural circuits that regulate GI function. 
In both mammals and birds, the sacral NCC contribution is restricted to the 
distal hindgut, where the pioneer cells initially migrate to regions of close 
proximity to the hindgut – the avian-specific nerve of Remak in the chick 
(Burns and Le Douarin, 1998), and the pelvic plexus in mice (Anderson et al., 
2006; Wang et al., 2011). They then pause until vagal colonisation of the 
hindgut is complete before entering the gut to produce neurons and glia. In 
humans, vagal colonization is complete after around 7 weeks of gestation 
(Wallace and Burns, 2005), reviewed in (Heanue and Pachnis, 2007). Up to 
17% of myenteric ganglia neurons are sacral-derived in the chick, with far 
fewer cells found in the submucosal plexus (Burns and Douarin, 1998). In 
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1.6.1.2 Suitability of enteric neural stem cells for spinal cord injury therapy 
 
The substantial proliferative capacity of enteric neural crest cells (ENCCs), as 
demonstrated by the formation of such an extensive and diverse structure as 
the ENS from a relatively small number of initiating cells, almost certainly 
persists to a certain degree into adulthood. Indeed, cells with stem cell-like 
capability – ENSCs - have been isolated from patients as old as 84 years 
(Metzger et al., 2009a), and have been expanded in vitro to form 
neurospheres. In the Burns/Thapar laboratory, ENSCs have been isolated 
from human gut biopsies and expanded in vitro to form neurospheres 
(Metzger et al., 2009b). Similar neurospheres have also been generated from 
ENSCs isolated from mice, and have been extensively characterised by 
immunofluorescence and qRT-PCR, revealing the presence of neurons, glia 
and stem cells (Binder et al., 2015; McCann et al., 2017). ENSC neurospheres 
are capable of restoring ENS structures and producing neurons and glia 
when transplanted into aganglionic mouse gut ex vivo (Natarajan et al., 
1999), reviewed in (Burns and Thapar, 2014; Heanue and Pachnis, 2007). 
Even more encouragingly, ENSCs transplanted in vivo have been shown to 
form functional connections with the endogenous network (Belkind-Gerson et 
al., 2016; Cooper et al., 2016; Cooper et al., 2017), and to rescue normal gut 
function in a mouse model of enteric neuropathy (McCann et al., 2017). 
The presence of a stem cell population in the adult ENS offers a 
promising source for stem cell-based therapies for SCI. Not only is the ENS 
known to share many similarities with the CNS, and thus is a desirable source 
for stem cell-based SCI therapy, it can also be repeatedly accessed via 
routine endoscopy to generate an autologous cell source for transplant, thus 
avoiding the harvesting/ethical issues that hinder other NSC sources. Such 
utilisation of the ENS stem cell pool is already being pursued for enteric 
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neuropathies and has demonstrated considerable early success (Burns and 
Thapar, 2014; McCann et al., 2017). The goal of this thesis was to explore 
whether stem cells derived from the ENS could also be used for the 
treatment of CNS insults such as SCI. 
 
1.6.1.3 Physical connections between the enteric and central 
nervous systems 
 
When evaluating stem cell sources for SCI therapies, it would be 
advantageous if donor cells were capable of producing cells that had the 
ability to integrate and communicate with existing spinal cord circuits. ENSCs 
are likely able to fulfill this criteria for a number of reasons. The ENS and CNS 
are physically connected and in constant communication through the gut-
brain axis (Furness, 2012). While the ENS conducts most of its functions 
independently of CNS intervention (Bayliss and Starling, 1899), the two are 
intimately linked to allow CNS modulation of ENS activities and transfer of 
information between the two systems (Browning et al., 2017) (Fig. 1.6). 
Higher brain centres, such as the basal ganglia, exert control through either 
vagal pathways (usually for oesophageal targets); sympathetic pathways 
acting on local reflex loops of the myenteric and submucosal plexus; or 
through pelvic pathways (usually for colon targets). Communication is 
bidirectional, with ENS axons projecting to the spinal cord (Furness, 2012). 
This axis affects brain development (partially through the gut-brain-
microbiota axis (Sherwin et al., 2016), and has even been implicated in the 
initiation/development of neurodegenerative disorders (Mulak and Bonaz, 
2015). This close interaction and information transfer strongly suggests that, 
if ENSCs were utilized for SCI therapy, transplanted cells would be able to 
integrate with endogenous spinal cord neurons to restore function. 
	   43	  
 
Figure 1.6: The enteric and 
central nervous systems are 
intimately connected. 
Several pathways extend from the 
spinal cord to integrate with the ENS 
either directly (yellow), or via 
prevertebral ganglia (green). The 
degree of CNS input varies along the 
GI tract. The oesophagus and anus 
are almost entirely under central 
control, while the small intestine 
receives little input. Communication is 
bidirectional, with neurons from the 
intestines (red) projecting back to the 
spinal cord. The ENS also contains multiple reflex circuits (blue), allowing it to 
function largely independently of CNS control. Taken from (Furness, 2012). 
 
1.6.1.4 Cellular composition of the enteric and central 
nervous systems 
 
Given their shared ectodermal origin and numerous physical connections, it 
is not surprising that the ENS and CNS also contain similar cell complements. 
Glia comprise the majority of cells within the CNS, including astrocytes, 
oligodendrocytes and microglia (Gonzalez-Perez et al., 2015). CNS astrocytes 
share almost all properties and characteristics of enteric glia of the ENS 
(Gershon and Rothman, 1991; Gulbransen and Sharkey, 2012), but other glial 
populations are more distinct. Oligodendrocytes are responsible for 
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myelination in the spinal cord, but such insulation does not occur in the ENS 
(Bradl and Lassmann, 2010; Ruhl, 2006). NCCs are capable of producing 
myelinating cells - PNS Schwann cells are derived from NCCs and are known 
to invade the gut during development, but only contribute towards neuronal 
lineages (Uesaka et al., 2015). Presumably, the lack of myelination is 
attributable to the relatively short distance ENS axons are required to 
project.  
Microglia are the resident immune cells of the spinal cord, with 
phagocytic clearance roles. In the ENS this responsibility is assumed by 
macrophages (Mikkelsen and Rumessen, 1992; Mikkelsen et al., 1985). 
Macrophages are found throughout the body, and assume variable 
phenotypes depending on their localisation. However, significant similarities 
between CNS microglia and ENS macrophages have been highlighted. 
Indeed the two are difficult to distinguish, with a common myeloid 
progenitor, similar morphology and shared surface markers (Bain et al., 2014; 
Bain and Mowat, 2014; Geissmann et al., 2010a; Geissmann et al., 2010b; 
Ginhoux et al., 2010). 
 Slight cellular discrepancies may prove beneficial for SCI cell-based 
therapies. While astrocytes are fundamental to limiting lesion spread, their 
assimilation into the glial scar prevents axonal regeneration (Sun and Jakobs, 
2012). While enteric glia are remarkably similar to CNS astrocytes, it is not 
known whether enteric glia would contribute to or limit the astrocytic 
aggregation resulting in formation of the glial scar. The lack of myelinating 
cells within the ENS is regrettable for treatment of SCI, but a de-
differentiation of the Schwann cell-derived neurons is entirely plausible, 
presenting a potential source of myelinating cells. Additionally, it has been 
demonstrated that following SCI and the subsequent demyelination, there is 
an invasion of re-myelinating Schwann cells from the PNS (Guest et al., 2005; 
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James et al., 2011). Therefore, stimulation to encourage further Schwann 
invasion and increased endogenous re-myelination may remove the need for 
transplanted cells to contain myelinating cells. 
Like their respective glial populations, the neuronal complement of 
the ENS and CNS is also similar, with only slight variations in relative 
quantities of neuronal subtypes between the two systems. In the spinal cord, 
motor neurons compose the majority of cells within the grey matter, 
alongside large numbers of interneurons (while axons of sensory neurons 
project extensively throughout the cord, their cell bodies are located in 
peripheral tissues, and often synapse at the dorsal root ganglia, where 
interneurons continue the pathway) (Caspary and Anderson, 2003; Gouti et 
al., 2015). The ENS contains a more varied array of motor, sensory and 
interneurons to allow it to function with autonomy (Costa et al., 2000a; Costa 
et al., 2000b; Furness, 2000). This multiplicity of lineages will likely prove 
beneficial in restoring spinal circuits, affording flexibility of transplanted 
ENSCs to provide required cell types. For example, relay circuits may be 
formed between spinal ganglia-derived sensory axons entering the SC, and 
transplant-derived enteric sensory neurons within the injury zone, to re-
establish ascending sensory pathways. 
 
1.6.1.5 Neurotransmitters in the enteric and central nervous 
systems 
 
Although transplanted mesenchymal stem cells have resulted in 
significant functional recovery following SCI without neurotransmitter 
production (Oliveri et al., 2014), an ideal cell source for SCI would produce 
the appropriate cells types able to synthesise neurotransmitters to allow 
continuous communication through the injured region. Indeed, several 
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neurotransmitters have been shown to be of vital importance following SCI 
(several of the most prominent are summarised in Table 1.1). 
The ENS utilises almost all of the same neurotransmitters as the CNS 
(McConalogue and Furness, 1994). This complex signalling network is 
reflective of the diverse range of GI functions, including modulating 
peristalsis and responding to the microbiome within the bowel. While some 
bowel actions are CNS instigated (e.g., stomach churning directed by the 
vagal nerve) many of the feedback loops responsible for bringing about such 
changes begin and end in the ENS, requiring a diverse and sophisticated 
communication system (Furness, 2012). 
 
Table 1.1: Neurotransmitters noted as particularly important 
following spinal cord injury and their roles in the enteric and 
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Injury to the spinal cord results in a complex cascade of secondary 
mechanisms leading to the formation of fluid-filled cavities. These cavities 
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contain a variety of inhibitory factors, hindering endogenous regeneration. In 
addition, the spinal cord is unable to replace lost cells or restore severed 
axonal pathways. Any therapy targeted towards restoring spinal cord function 
after SCI must address these issues. Currently, all stem cell sources that have 
been tested for SCI therapy have proven unsatisfactory, leaving an urgent 
need to explore other options. ENSCs isolated from the ENS may fulfill this 
need. The ENS and CNS share many similarities in terms of origin, cell 
complement and neurotransmitter production. Indeed, the potential of 
ENSCs for SCI was first recognized as far back as 1993 (Jaeger et al., 1993). 
Previous studies in the Burns/ Thapar laboratory have optimized techniques 
to harvest, expand and characterise ENSCs, revealed the colonizing ability of 
these cells when transplanted into aganglionic or dysfunctional gut, and 
shown their capacity to functionally integrate into existing circuitry. Taken 
together, this suggests the strong potential of ENSCs to serve as a viable 
stem cell source for SCI therapy. 
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1.8 Thesis aims: 
 
Published observations in the literature demonstrate numerous similarities 
between the enteric and central nervous systems, and the ability of the two 
to communicate. Considering the multitude of ethical and practical issues 
surrounding harvesting and/or transplantation of previously proposed stem 
cell sources for SCI, an assessment of the biology and therapeutic potential 
of ENSCs for SCI is both appropriate and necessary.  
 
1. The first aim of this thesis is to provide proof of principle data that 
ENSCs can survive in a CNS environment (SC). This was achieved via 
chimeric grafting of GFP/WT chick embryos to label NCC-derived 
cells, and transplantations of GFP+ enteric, ENSC-containing 
neurospheres into the developing chick neural tube. These results are 
presented and discussed in chapter 2. 
2. The second aim of this thesis was to progress these embryonic studies 
into an adult rodent model of SCI. A pilot study was conducted to 
determine optimal time post-injury of transplantation into a rat spinal 
cord contusion model, and to assess the short-term survival of 
transplanted, rat-derived enteric cells (including ENSCs) in an injured 
spinal cord environment. These results are presented and discussed in 
chapter 3. 
3. The third aim of this thesis was to conduct an extended study into the 
survival, differentiation and effect of ENSCs both on the spinal cord 
lesion histology, including endogenous recovery, and on functional 
recovery post-injury. Simultaneously, the benefits of a combinatorial 
application of chondroitinase ABC (ChABC) and transplanted enteric 
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cells was assessed. These results are presented and discussed in 
chapter 4. 
4. Finally, the overall results of the thesis, particularly as relates to the 
existing literature, and the future direction of both this work and 
research into SCI in general, are discussed in chapter 5. 







2 Chapter two: Engraftment and Survival of Enteric Nervous 
System-derived Stem Cells in the Regeneration-Permissive 
Chicken Embryo Spinal Cord 
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2.1 Introduction 
 
While considerable evidence supports the potential compatibility of ENS-
derived cells with the endogenous cells of the CNS, to our knowledge 
transplantation of ENSCs into the injured spinal cord is entirely untested (a 
previous publication tested SCI transplantation of intact nervous tissue taken 
from the gut, but not isolated stem cells (Jaeger et al., 1993)). The ideal way 
to test the ability of ENSCs to survive in a CNS environment would be an in 
vivo transplant. In order to determine the likely success of ENSC 
transplantation into injured spinal cord, the chicken embryo was utilized as a 
practically feasible model to provide proof of principle data. 
Historically the chicken has been a vital tool for scientific research, and 
may well be the oldest model organism studied. Its embryonic development 
was first analysed by Aristotle in his work Historia Animalum, and variations in 
chicken breeds were later used as examples by Darwin in The Variation of 
Plant and Animals under Domestication, in which he set out his theories of 
evolution. Apart from being inexpensive, there are a number of features that 
make the chicken an advantageous model. Perhaps most importantly, unlike 
most other vertebrate species the live chicken embryo can be easily 
observed by the creation of a small window in the shell of a fertilized egg, 
allowing its real-time development to be studied in ovo. Due largely to this 
ease of accessibility, the chicken proved indispensible for early studies 
concerning embryology (Fig. 2.1). Much of the fundamental knowledge of 
vertebrate embryonic development is based on studies conducted in chicken 
embryos, considerable amounts of which are directly comparable to human 
development through conserved evolutionary pathways (Burt, 2007; Stern, 
2005).  
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Figure 2.1: Chicken embryos can be accessed and manipulated in 
ovo. 
The chicken embryo is one of the oldest model organisms for the study of 
developmental biology. Through the creation of ‘windows’ in the shell (A) the 
embryo can be accessed, allowing, among other procedures, chimeric grafting to 
label NCCs. At E3 the embryo lies on top of the yolk with an extensive surrounding 
vasculature system (B). LVA – left vitelline artery, RVA – right vitelline artery, PVV – 
posterior vitelline vein, ST – sinus terminalis. 
 
Initial experiments were based simply on observation, which in itself 
yielded fruitful information such as the elucidation of the existence of the 
blastocyst and germ layers (Pander, 1817), and the development of the 
circulatory system (Harvey, 1628). The chicken embryo was found to be 
robust enough to withstand manipulation, allowing for the ablation of 
specific tissues and observation of the subsequent defects. As techniques 
grew more sophisticated, ablations were supplemented with ‘grafting’, in 
which parts of one embryo (e.g. neural tube) were removed, manipulated (for 
instance, by inversion) and re-inserted. These studies yielded fundamental 
understanding of patterning during embryogenesis, determining the 
importance of the order of tissue formation (Saunders, 1948) and the vital 
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role of organisers such as Hensen’s node (Waddington, 1950). Many of these 
studies informed current medical knowledge and surgical techniques. It was 
the grafting of various tissues into the chicken embryo that revealed the 
importance of the immune system in the graft vs host response (Murphy, 
1914), a key finding which informed human organ transplantation and a 
multitude of other surgical interventions.  
These procedures were further refined in pioneering work by Nicole 
Le Douarin, who demonstrated that tissues could be transplanted from a 
quail embryo into a chicken embryo, and vice versa, and the cells of the two 
species distinguished histologically (Le Douarin, 1973). This allowed more 
precise tracking of the consequences of grafting through interrogation with 
species-specific antibodies. These experiments provided unprecedented 
information concerning specific migratory pathways and, in particular, greatly 
expanded the existing knowledge of neural crest and its migration to form 
the ENS. In a series of landmark experiments, Le Douarin and others showed 
in exquisite detail, via grafting of the neural tube from a quail into the 
corresponding region of a chicken embryo, the ventral migratory pathways 
taken by the neural crest to enter and colonize the developing gut (Burns and 
Douarin, 1998; Le Douarin and Teillet, 1973).  
Recent advances in the field of genetics have yielded transgenic 
chickens modified to express green fluorescent protein (GFP) under the 
control of a ubiquitous promoter (McGrew et al., 2004). This breakthrough 
allowed intra-species grafting between GFP-expressing chick donor tissue 
and WT chick hosts, negating the often-cited possibility that grafted chicken 
cells behaved differently in the host quail tissues than they would have done 
in their native environment. Using such techniques, fate maps for the various 
neural crest populations have been precisely documented, revealing the 
exact neural crest contributions to structures such as the lungs (Freem et al., 
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2012). 
Perhaps due in part to the rich wealth of preceding data, the 
chicken embryo continues to serve as a model organism not just for 
developmental research, but for disease and even injury/ regenerative 
research, including SCI (Prasongchean et al., 2012). The developing chicken 
neural tube can be easily accessed and manipulated at various stages of 
development, allowing identification of key developmental periods. In this 
way it was demonstrated that before embryonic day (E) 13, the chicken spinal 
cord is entirely capable of regeneration following injury, and that after this 
point, injury results in varying degrees of paralysis (Hasan et al., 1991; 
Shimizu et al., 1990). Keirstead et al noticed that the end of the regeneration 
permissive phase coincided with the onset of myelin production. These 
authors showed that delaying myelin production in the developing chick 
embryo resulted in an extension of the ‘regeneration permissive’ phase, 
providing compelling evidence for the inhibitory role of myelin in spinal cord 
injury recovery (Keirstead et al., 1992). 
Thus, the chicken embryo serves as an ideal model with which to 
begin studies into the therapeutic potential of ENSCs for SCI repair. Given 
that the immune system does not develop in the chicken embryo until 
around E12 (and indeed, is still immature at birth) (Moticka, 1975), this allows 
ENSC transplantation into the spinal cord to be tested without the immune 
response associated with SCI in adults, thus providing vital proof of principle 
data that ENSCs are capable of surviving in a spinal cord environment.  
 
2.1.1 Chapter aims and objectives 
The aim of this chapter is to evaluate the potential of stem cells derived from 
the enteric nervous system as a therapy for SCI, using the chick as a model 
organism. This will be addressed by assessing the ability of ENSCs 
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transplanted into the spinal cord to survive, differentiate into appropriate cell 
types, and bridge the injury zone in the embryonic spinal cord. 
 
Objectives: 
1. Label NCC derivatives, including ENSCs, within the gut of chick 
embryos by grafting the vagal neural tube of GFP chick embryos into 
WT age matched chick embryos. 
2. Isolate labeled cells using fluorescent activated cell sorting (FACS) and 
culture to form neurospheres. 
3. Characterize isolated cells, including determination of neurosphere 
cell composition. 
4. Transplant labeled neurospheres into early chick embryo spinal cords 
and assess cell survival and differentiation. 
5. Transplant labeled neurospheres into late stage chick embryo spinal 
cords and assess survival and differentiation. 
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2.2 Methods 
 
All experiments conducted on chicken embryos were completed before three 
quarters of the way through embryo development (i.e. before E15) and 
therefore did not fall under the UK Animal (Scientific Procedures) Act. 
2.2.1 Preparation of chicken embryos for surgical manipulation 
 
Fertilised wild type (WT) chicken eggs, obtained from commercial sources 
(Medeggs, UK) were kept in a humidified incubator at 37°C for 36 hours, to 
embryonic day (E) 1.5. A small hole was made at the pointed end of each 
egg and 2mL albumin extracted using a 32-gauge needle (lowering the 
embryo away from the shell surface and preventing embryo damage). This 
hole was sealed using clear tape, and another hole made in the upper egg 
surface. Curved scissors were used to make a 2.5cm diameter window on top 
of the egg. The window was sealed using clear tape and eggs returned to 
the incubator. 
 
2.2.2 GFP labelling of neural crest cells using tissue grafting  
 
Host tissue. 
To visualise windowed WT embryos at E1.5, a small amount of Indian ink, 
diluted 1:1 with 1Xphosphate-buffered saline (PBS) with penicillin/ 
streptomycin (PS) was injected under the embryo of windowed eggs using a 
mouth pipette and pulled glass needle. The vitelline membrane was torn to 
expose the region of interest and the vagal region of the neural tube 
(somites 1-7) removed using a custom made micro-scalpel. When performed 
correctly, this ablation leaves surrounding tissue intact (Fig. 2.1).  
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Donor tissue. 
Fertilised GFP chicken eggs were obtained from The Roslin Institute 
Transgenic Chicken Facility, Scotland, UK, and incubated to E1.5. GFP+ eggs 
were windowed as above, and the embryo harvested and transferred to a 
sylgard-based watch-glass filled with 1XPBS with penicillin/ streptomycin. 
The embryo was separated from the vitelline membrane and pinned using 
minutien pins. The vagal region of the neural tube was isolated using micro 
scissors and transferred to a watch-glass filled with 2% pancreatin (Sigma 
Aldrich, UK) in 1XPBS with penicillin/ streptomycin at RT. After 8 minutes the 
neural tube was teased from the surrounding structures using micro pins and 
transferred to DMEM+10% normal sheep serum to halt enzymatic digestion. 
 
Grafting procedure. 
Grafting procedures were conducted at room temperature (RT). The 
harvested GFP+ neural tube was transferred to the host WT egg using a 
mouth pipette and pulled glass needle, and positioned along the correct 
anterior-posterior axis. The neural tube was grafted into the ablated region 
via manipulation with micro-needles, and fluid surrounding the embryo was 
drained using a mouth-pipette to aid graft adhesion. The egg shell window 
was re-sealed and the eggs containing chimeras returned to the humidified 
incubated at 37°C. 
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Figure 2.2: GFP+ neural tube tissue from E1.5 donors was 
grafted into age-matched WT hosts to label neural crest-derived 
cells. 
The vagal neural tube (located between somites 1-7) of GFP+ embryos was isolated 
and grafted into WT hosts with the corresponding region ablated. Embryos were 
returned to the incubator for 12.5 days, at which point the intestines were 
harvested, stripped of mesentery, and dissociated into a single cell suspension. 
GFP+ cells were isolated by FACS and expanded in culture to form GFP+ 
neurospheres. 
 
2.2.3 Cell culture and FACS analysis 
 
FACS (fluorescence activated cell sorting) was used to isolate GFP+ neural 
crest-derived cells from GFP/ WT chimeras (Fig. 2.2). At E14 embryos were 
sacrificed, the intestinal tract harvested in ice-cold 1XPBS (Mg2+/ Ca2+ free) 
with penicillin/ streptomycin (Sigma Aldrich, UK), and manually chopped into 
pieces ~2mm in length. These were washed in 1XPBS and digested in 1mL 
dispase/ collagenase (1mg mL-1) (Roche, UK) at 37°C for 10 minutes. NSM+P 
(DMEM F12 (Sigma Aldrich, UK), N2, B27 (Invitrogen, UK), P/S with 2% foetal 
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bovine serum (FBS, Sigma Aldrich, UK)) was added to halt the reaction. The 
solution was centrifuged, re-suspended in NSM+P and passed through 40μm 
cell strainers. Cells were sorted based on GFP fluorescence using a MoFlow 
XDP (Beckman Coulter). Collected cells were plated onto 2% fibronectin 
(Sigma Aldrich, UK) coated plates. The following day the media was replaced 
to remove dead cells. 
 If colonies grew to confluence they were passaged. This involved a 
wash in 1XPBS and trypsin (Sigma Aldrich, UK) digestion for 2 minutes at 
37°C. Cells were dissociated, centrifuged and re-plated onto fresh 2% 
fibronectin-coated dishes at the required density. 
 
2.2.4 Viral labelling of cells 
 
Chick spinal cord-derived cells were labelled with an mCherry lentivirus as 
previously published (Natarajan et al., 2014) prior to co-culture experiments 
with GFP-labelled ENSCs. The lentivirus used was a self-inactivating, HIV-1 
based vector, containing the spleen focus forming virus LTR promoter. The 
mutated Woodchuck posttranscriptional Regulatory Element was inserted 
downstream of mCherry (Demaison et al., 2002). Flow cytometry was used to 
tire the virus. Cells were incubated with 100μL per 105 cells (multiplicity of 
infection 2-5) of the lentiviral construct diluted in NSM+P, for 48 hours to 
allow efficient transduction and viral inactivation. Following this, media was 
drained and treated with Virkon to destroy remaining viral particles. Cells 
were fed using fresh NSM+P.  
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2.2.5 Transplantation of GFP+ ENSC-derived neurospheres into early stage 
chick embryos 
 
WT embryos for transplantation were incubated to E1.5, windowed and 
visualised. The vitelline membrane was torn to expose the region of interest. 
A micro-scalpel was used to remove a region of the neural tube equivalent to 
the length of 1 somite, at the level of somite 7 (this graft location 
reproducibly ensured transplants could be found in the cervical region of the 
spinal cord upon harvest). A GFP+ ENSC-derived neurosphere was 
transplanted into the ablated space. Excess fluid was removed to encourage 
adhesion. The window was re-sealed and the egg returned to the humidified 
incubator at 37°C (Fig. 2.3). Transplanted embryos were harvested at timed 
intervals (4, 6, 9 and 12 days after transplantation, to provide timed intervals 
up to ~¾ of chicken embryo development, after which the UK Animal 
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Figure 2.3: GFP+ ENSC-derived neurospheres were transplanted 
into early stage chick embryo neural tubes to determine survival. 
At E1.5, WT embryos had a short region of the neural tube, equivalent to the length 
of one somite, removed at the level of somite 7. A GFP+ ENSC-derived 
neurosphere was transplanted into the ablated region, and the embryo returned to 
the incubator. Transplanted embryos were then harvested at timed intervals, and 
the tissue sectioned (coronal, saggital and longitudinal sections were utilised for this 
study) and stained for analysis. 
 
2.2.6 Ex ovo cultures 
 
Classic windowing techniques offer poor access to the spinal cord of late-
stage embryos due to the embryo turning onto its side. To increase 
accessibility of embryos at 11 days of development, embryos were grown as 
ex ovo cultures. 8oz plastic cups were filled ¾ with distilled water. Saran wrap 
was placed on top and pushed to contact the water. An elastic band held the 
wrap in place. Eggs incubated to E3 were cracked and the embryo 
transferred gently onto the saran hammock. 1mL 1XPBS with penicillin/ 
streptomycin and crushed eggshell (a calcium source) were added. An 8cm 
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culture dish with ventilation holes was placed on top. The culture was placed 
in a humidified incubator at 37°C until required. 
 
2.2.7 Inducing lesions and transplantation of GFP+ neurospheres into late 
stage chick embryos 
 
Ex ovo injuries were induced under a stereo-microscope. The embryo was 
raised to the surface of the cup by tightening the hammock. Fine forceps 
(Dumont 5) were used to tear the vitelline and chorioallantoic membrane 
(selecting an area with few blood vessels) above the cervical spinal column. A 
curved, blunt glass rod was inserted under the neck and the embryo gently 
lifted to the surface. Forceps restricted to open to a maximum width of 1mm 
and marked to indicate a depth of ~2mm, were inserted through the dermis 
into the dorsal side of the spinal column in the cervical region. The forceps 
were fully closed for 5 seconds, opened and retracted. If required, a 
neurosphere was introduced into the injury site via a pulled glass needle. The 
injury site was observed for ~20 seconds to ensure the neurosphere did not 
float out. The glass hook was removed and the hammock lowered back into 
the cup. The embryo was returned to the humidified incubator at 37°C. 
 
2.2.8 Gelatin embedding for sectioning 
 
Harvested samples were fixed for 1 hour at RT in 4% paraformaldehyde (PFA, 
Sigma Aldrich, UK) and washed in 1XPBS. If tissue was to be used for whole 
mount staining no further procedures were necessary. If required for 
sectioning, samples were dehydrated in sucrose solution (30% sucrose in 
1XPBS) overnight at 4°C and transferred to molten gelatin (15% sucrose, 
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7.5% gelatin in 1XPBS, Sigma Aldrich, UK) for 1 hour at 37°C. Samples were 
cast in gelatin blocks for longitudinal/ coronal sectioning and snap frozen in -




Frozen gelatin-embedded samples were sectioned using a Leica Cryostat at -
22°C. Section thickness was 10-20μm. Slides were stored at -20°C until 
required. 
 
2.2.10 H&E staining 
 
H&E staining was used to visualise histological aspects of spinal cord injury. 
Frozen slides were thawed for 40 min (RT) and immersed in pre-filtered 
Haematoxylin solution (Bayers, UK) for 7 minutes. Slides were washed in 
ddH2O for 10 seconds, and running water for five min. Slides were dipped in 
acid alcohol (1% HCl in 70% ethanol) for 10 seconds and washed for 2 min in 
running water. Slides were stained in 1% pre-filtered Eosin for 5 minutes, 
dipped in ddH2O and dehydrated in ethanol. Following histoclear immersion, 
slides were mounted using DPX and stored at RT.  
 
2.2.11 Immunostaining of sectioned/ whole mount samples 
 
Frozen slides were thawed for 40 min (RT), post-fixed with 4% PFA for 10 
minutes and washed in 1XPBS. Slides/ whole mount samples were blocked 
(0.1% Triton X100 (Sigma Aldrich, UK), 1% bovine serum albumin (Sigma 
Aldrich, UK), 0.15% glycine (Fisher Scientific, UK) in 1XPBS) for 1 hour and 
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incubated in primary antibody (Table 2.1) diluted in blocking solution 
overnight at 4°C. Samples were washed in 1XPBS (RT). Secondary antibody 
(Table 2.2) was applied in blocking solution for 2 hours (RT) and washed in 
1XPBS. Fluorescent immunolabelled slides were mounted using Vectashield 
(hard set with DAPI, Dako, UK). Slides were stored at 4°C. 
 
Table 2.1: Chapter 2 primary antibodies. 
 
Antibody Species Manufacturer Concentration 
TuJ1 Mouse Covance 1:500 
TuJ1 Rabbit Covance 1:500 
Hu C/D Mouse Invitrogen 1:500 





Table 2.2: Chapter 2 secondary antibodies. 
 
Antibody Species Manufacturer Concentration Absorbance 
Anti mouse Goat Alexa Fluor 1:500 568 
Anti mouse Goat Alexa Fluor 1:500 488 
Anti rabbit Goat Alexa Fluor 1:500 488 
Anti mouse Goat Alexa Fluor 1:500 647 
Anti rabbit/ 
HRP 
Goat Dako 1:250 N/A 
DAPI N/A Sigma Aldrich 1:1000 350 
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2.2.12 Quantification of cell spread 
 
In order to determine the extent of ENSC cell/ projection spread from the 
transplantation site within the developing neural tube, transplanted embryos 
were harvested at the timed intervals and sectioned as described above. 
Following staining with an anti-GFP antibody, GFP images of transplanted 
cells were collected using an ORCA-R2 cooled CCD camera mounted on an 
Olympus 1X70. The entirety of the spread along the anterior/ posterior axis 
was captured, and where appropriate composite images were collated into a 
tile scan using MosaicJ on FIJI. For each embryo, the section demonstrating 
the greatest spread was selected and measured along with the preceding 
and following section, and the average distance between the three 
calculated. For each age under examination, an n of three embryos was used. 
 
2.2.13 DNA/RNA methods 
 
2.2.13.1 RNA extraction 
 
For tissue samples, the material was homogenized and immersed in Trizol 
(Invitrogen, UK). This was incubated with chloroform (RT) and centrifuged at 
12,000x g for 10 minutes at 4°C. The upper aqueous phase was isolated, 
mixed with 70% ethanol and transferred to an RNeasy Mini spin column 
(Qiagen, UK). The manufacturer’s protocol was then followed. For cells, the 
manufacturer’s protocol was followed without modification. RNA yield was 
quantified using a Nanodrop. 
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2.2.13.2 cDNA synthesis 
 
100ng of RNA was used for each reaction. This was added to 4μL 5X VILO 
reaction mix and 2μL 10X Superscript Enzyme Mix (Life Technologies, Paisley, 
UK). The volume was adjusted to 20μL of DEPC-treated water. Synthesis was 




To determine cell composition and neurotransmitter competency of 
neurospheres, primers were designed with amplification product sizes of 100-
200bp (Sigma Aldrich) (table 2.3). To test primer specificity, PCR reactions 
(table 2.4) using sample chick DNA were run and the products examined by 
gel electrophoresis (1% agarose dissolved in tris-acetate-EDTA (TAE) buffer 
with 0.005% ethidium bromide for visualization). Once predicted product 
sizes were confirmed the primers were used for qRT-PCR. 
 
Table 2.3: Primers used for qRT-PCR  
Probe target Primer sequence Product 
size 
Tm 












Sox10 F: AGCCTTCACAGGGTTTGCT 135 63.8 
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R: GAGAGGCAGTGGTGGTCTTC 63.9 



























 qRT-PCR was used to verify primer accuracy and annealing conditions  
(table 2.5). Samples were assayed in triplicate and normalized to the house-
keeping gene GAPDH, and analysed using the ABI Prism 7500 sequence 
detection system (Applied Biosystems) using Quantitect SYBR green PCR kit 
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Table 2.4: Chapter 2 PCR cycling programme  
Step Temp °C  Time 
1 94 3 minutes 
2 94 30 seconds 
3 60 1 minute 
4; go to step 2, 35 
cycles 
72 30 seconds 
5 72 2 minutes 
6 4 Hold 
 
Table 2.5: Chapter 2 qRT-PCR cycling programme 
Step Temp °C  Time 
1 95 15 min 
2 95 20 seconds 
3 60 30 seconds 
4; go to step 2, 40 
cycles 
72 30 seconds 
 
2.2.14 Statistical analysis 
 
qRT-PCR data was analysed by Student’s t test (two-tailed). Cell spread data 
was analysed using both Student’s t test (two-tailed) and analysis of variance 
(ANOVA) Survival of transplanted and non-transplanted groups was 
compared using the Log-rank (Mantel-Cox) test. GraphPad Prism software 
was used for all analyses. p values of <0.05 were taken as significant.  
	   71	  
2.3 Results 
 
2.3.1 Vagal GFP neural tube transplantation effectively and stably labels 
neural crest cells and their derivatives 
 
GFP/ WT chimeras were generated at E1.5 to label vagal NCCs and their 
derivatives with GFP, allowing FACS isolation of neural crest derived ENSCs. 
Following grafting of GFP neural tube into WT chick embryos, chimeras were 
returned to the incubator to develop to the appropriate stage. 1 day after 
grafting, streams of GFP+ cells could be seen migrating to the future foregut 
(Fig.2.4). An additional concentration of GFP+ cells was observed in the 





























Figure 2.4: Fluorescence microscopy visualisation of early 
migrating enteric NCCs following grafting at E1.5.  
GFP/WT chimeric grafting allows the visualization of NCCs in ovo. Following vagal 
grafting at E1.5 (A), GFP+ NCCs leave the neural tube and migrate in streams 
towards the developing gut (B). GFP+ cells can also be seen circumpharyngeal crest 
(CC), on route to the developing heart. C, D, cartoons of grafted chick embryos. NT 
- neural tube, Met – metencephalon, Mes – mesencephalon, Pro – prosencephalon. 
Scale bars, 1mm. 
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Chimeras were initially sacrificed at E6.5 to ensure cells had been correctly 
labeled, that they were developing/migrating as expected, and were forming 
structures comparable to that of wild type equivalents (Fig. 2.5). The grafting 
procedure labeled neural crest-derived structures, allowing clear distinction 
from surrounding tissue without neural crest contributions (Fig. 2.5, A). At 
E6.5 GFP+ ENCCs can be seen migrating through the developing gut (Fig. 
2.5, B). The migration wavefront has just passed the caecal buds (Fig. 2.5, 
first inset, arrow). Distal to the wavefront, GFP+ cells are immunopositive for 
the marker TuJ1 (Fig. 2.5, second inset, arrowhead), indicating differentiation 
towards a neuronal lineage.  
 To further confirm GFP+ labeling of neural crest-derived cells, cross-
sections of chimeric guts were analysed for presence of GFP+ structures. 
Chimeras were sacrificed at E14, gelatin embedded and cryosectioned to 
visualise the enteric plexuses. GFP+ cells co-label for the neuronal marker 
TuJ1 (Fig. 2.5, C) and the neural crest marker HNK-1 (Fig. 2.5, D) within the 
colon of chimeric chick embryos (proximal and distal small intestine showed 
similar staining, data not shown). At E14, the entire GI tract was colonized 
with GFP+ enteric NCCs, with the ENS clearly labeled with GFP throughout 
(Fig.2.6). 
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Figure 2.5: Immunofluorescent detection of GFP+ enteric NCCs 
following chimeric grafting.  
Vagal grafting results in specific labeling of neural crest-derived tissues such as the 
ENS of the GI tract, providing clear distinction of surrounding tissue (A). At E6.5, 
GFP+ cells have entered the gut and migrated beyond the caeca (B, arrow and first 
inset). Distal to the migration wavefront, TuJ1+ neurons were identified (B, 
arrowhead and second inset), indicating differentiation towards a neuronal lineage. 
A portion of the nerve of Remak (NOR) can be seen adjacent to the colon. By E14.5, 
the GI tract appears completely colonized by migrating neural crest cells. Transverse 
colon sections reveal the formation of GFP+ myenteric and submucosal plexuses (C, 
D). GFP+ cells co-express the neuronal marker TuJ1 (C’’) and the neural crest cell 
marker HNK-1 (D’’).  
 
 





















Figure 2.6: Macroscopic examination of GFP+ enteric NCC 
colonization of the GI tract following vagal grafting at E1.5.  
Following grafting of a GFP+ vagal neural tube into a WT chicken with the 
corresponding region ablated, GFP+ NCCs migrated into and along the gut to form 
the ENS. Starting orally, NCCs colonise first the oesophagus (A), and, moving 
aborally, the stomach and intestines (B). GFP labelling of the ENS was robust and 
strong, enabling ready identification of plexuses in the stomach (C) and intestines 
(D).  
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2.3.2 Isolation and characterization of GFP-labeled ENS precursors and stem 
cells 
 
FACS was used to isolate GFP+ ENCCs (including ENSCs and their 
derivatives) from surrounding gut tissues at E14, (Fig. 2.7, A). ENCCs could 
be clearly identified by their strong GFP+ signal. To eliminate dead (and 
therefore potentially autofluorescent cells) the positive collected population 
was further restricted by size. Isolated GFP+ cells were cultured to form 
neurospheres, allowing ease of transplantation into the spinal cord and 
subsequent detection. Within 2-3 days of initial in vitro culture GFP+ cells 
formed interconnected aggregates, including extension and connection of 
axonal processes. These aggregates typically formed neurospheres after 1 
week in culture, which become free-floating ~1 week later. These 
neurospheres stained positive both for the neural crest marker HNK-1 (data 
not shown) and for the neuronal marker TuJ1, confirming that they were of 
neural crest origin, and that differentiated cells could be found within the 
spheres (Fig. 2.7).  
 To assess the potential for in vivo integration of transplanted enteric-
derived neurospheres (henceforth referred to as ENSC-derived neurospheres) 
with endogenous CNS cells in the injured spinal cord, cultured GFP+ ENCCs 
and CNS-derived cells were co-cultured in vitro. CNS-derived cells were 
labeled with an mCherry lentiviral vector (labeling efficiency 71.2±6.8%), and 
the two populations cultured together for 1 week. CNS cells and enteric cells 
integrated extensively (Fig. 2.7, C), including the extension of ENS/ CNS 
axons alongside and towards one another (arrows). Mixed-population 
neurospheres were also observed (Fig. 2.7, D). 
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Figure 2.7: In vitro analysis of ENSCs and their compatibility with 
SC-derived cells.  
After grafting, embryos were allowed to develop to E14 before harvesting. 
Intestines were dissociated into a single cell suspension and sorted based on GFP 
expression and size (A). Negative populations were collected and cultured as 
controls. Following FACS isolation, GFP+ graft-derived cells formed free-floating 
neurospheres after 1-2 weeks in culture. Cells within the neurospheres were mostly 
immunopositive for the neuronal marker TuJ1 (B). Graft-derived GFP+ ENSCs 
integrated with spinal cord-derived cells (labelled with an mCherry lentiviral 
construct), including formation of close associations and extension of cell projections 
and axons (C). C’ and C’’ show higher magnification selections of C, and highlight 
CNS and ENS axons extending alongside and towards one another. After several 
days in culture ENS/CNS cells aggregated in clusters to form mixed-population 
neurospheres (D). Scale bar: B, C - 50μm, D - 100μm. 
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  The close association of processes observed in these co-culture 
experiments suggested the possibility of ENSC- and SC-derived cell 
communication, and previous studies have demonstrated the ability of the 
ENS to produce many of the same neurotransmitters as those utilised in the 
CNS. However, the relative expressions of neurotransmitters in central and 
enteric-nervous system-derived cultures have not, to our knowledge, been 
directly compared. Uncultured gut and spinal cord tissue was therefore 
analysed by qRT-PCR to determine cell composition. Independently cultured 
ENSC neurospheres were then also analysed and compared to uncultured 
preparations of spinal cord tissue.  
Gene expression analysis of the major cell types typically found within 
neurospheres revealed common expression of TuJ1 (neurons), S100 (glia), 
Sox10 (stem cells), and p75 (neural crest cells), in both gut and SC-derived 
tissue. Levels of S100 and Sox10 expression were significantly higher in SC-
derived tissue compared to gut tissue (0.055 vs 0.040, p=0.0098, and 0.100 
vs 0.045, p=0.0049, respectively), while TuJ1 expression was significantly 
higher (0.230 vs 0.059, p=0.0006) in SC-derived tissue (Fig. 2.8, A). Similarly, 
in comparisons of SC and cultured ENSC expression levels, relative 
expression of TuJ1 was dramatically higher in SC samples than in ENSC-
derived neurosphere populations (0.236 vs 0.058, p=0.049), which appeared 
similar to expression levels of uncultured gut tissue (Fig. 2.8, B). Levels of 
S100 expression in ENSC-derived neurospheres also appeared similar to 
levels found within the gut (0.033 vs 0.040, p=0.07). However, compared to 
relative expression of Sox10 in uncultured gut, levels within enteric 
neurospheres increased to higher levels than that seen in SC tissue, although 
this was not significant (0.045 vs 0.225, p=0.0753). These results for enteric 
neurospheres are comparable to published data collected by our lab and 
others. Binder et al and Cooper et al both used immunostaining to reveal 
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similar proportions of neurons and glia in a p75+ FAC-sorted population 
(Binder et al., 2015; Cooper et al., 2016). Metzger et al also revealed 
comparable levels of TuJ1+ neurons and S100+ glia, although at lower levels 
(possibly due to differences in generation of cell cultures; manual dissociation 
of myenteric plexus-containing muscle strips was used in place of the FACS-
isolation utilized in the previous studies) (Metzger et al., 2009a).  
To determine which neuronal subtypes were contained within the 
TuJ1+ population, relative expression levels of 5 neurotransmitters, 
considered of key importance for spinal cord injury based on published 
literature, were examined. nNOS (NO), TPH1 (serotonin), GLS1 (glutamine), 
ChAT (acetylcholine) and GAD (GABA) were expressed in both gut and SC 
tissue. Relative expression of nNOS, TPH1, GLS1 and ChAT was comparable 
between gut and SC-derived tissue, with significantly higher expression of 
GAD (GABA) in SC tissue (Fig. 2.8, C). Acetylcholine expression was highest 
in both populations. Relative expression of all neurotransmitter markers 
stayed broadly similar in cultured ENSC-derived neurospheres as for 
uncultured gut tissue, with only a non-significant decrease in nNOS (0.041 vs 
0.059, p=0.051), and a slight, but significant decrease in serotonin expression 
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Figure 2.8: qRT-PCR analysis of cultured ENSC and whole 
gut/spinal cord samples.  
The glial marker S100, stem cell marker Sox10 and neural crest marker p75 were 
expressed at similar levels in both samples, with significantly higher levels of the 
neuronal marker TuJ1 in the SC (A). Expression levels of cultured ENSC-derived 
neurospheres were comparable to gut samples, albeit with increased expression of 
SOX10 in ENSC cultures (B). Expression levels of specific neuronal subtypes were 
also analysed by qRT-PCR, revealing common expression between uncultured gut 
and SC samples of nNOS (NO), TPH1 (serotonin), GLS1 (glutamine) and ChAT 
(acetylcholine) and GAD (GABA), with significantly higher levels of GAD in the SC 
(C). Expression levels of the same neuronal subtype markers were broadly the same 
for ENSC-derived neurosphere cultures as for uncultured gut samples, with only a 
non-significant decrease in nNOS, and a slight, but significant decrease in serotonin 
expression in ENSC cultures (D). nNOS, TPH1, GLS1, GAD n=3, ChAT n=2.   
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2.3.3 GFP+ ENSC neurosphere transplantation into early neural tubes 
 
The immature chick neural tube environment, upon injury, is far less hostile 
than that of the adult. A lack of an immune response (Negash et al., 2004; 
Seto, 1981) or presence of myelin (Macklin WB and CL, 1985), combined with 
scarcity of blood vessels in the chick at E1.5 (Bellairs and Osmond, 1998), 
make the chicken embryo an idea model in which to test the ability of ENSCs 
to survive in an immature spinal cord environment. At E1.5, a small segment 
of the neural tube (one somite length, at somite 7) was ablated, and an 
equivalent-sized neurosphere grafted into the ‘injured’ region (Fig. 2.9). 
Following transplant, chicks were harvested at E5.5, 7.5 and 9.5 to assess the 
degree of cell spread, integration and differentiation. At each time point, 
embryos were harvested for both longitudinal and coronal sectioning and 
stained for the neuronal marker TuJ1 (for longitudinal sectioning at each time 
point, n=3). There was no difference in survival between transplanted and 
non-transplanted groups (log-rank Mantel-Cox test, p=0.5607, n=13 
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Figure 2.9: GFP+ neurosphere grafting into the developing 
neural tube of early stage chick embryos.  
At E1.5, a region of the neural tube equivalent to the length of 1 somite was 
microsurgically removed at the level of somite 7 (A) and a GFP+ neurosphere 
transplanted into the void (B). Embryos were then allowed to develop to the desired 
stage and harvested for further analysis. 
 
Upon examination under a stereomicroscope at E5.5, GFP+ cells had spread 
through the tissue (Fig. 2.10, A, B). Cells were localized to the cervical region 
of the spinal cord, as expected following vagal transplantation at somite 7. 
The strongest GFP signal was deep within the tissue. Coronal sectioning 
revealed numerous GFP+ transplanted cells within the spinal cord 
(demarcated by TuJ1 staining, red, Fig. 2.10, D). GFP+ cells surrounded the 
entirety of the cord with roughly equal distribution dorsally and ventrally. The 
vast majority of transplanted cells were localized to the white matter, with 
only occasional cells found within the grey matter. Cells were also found 
within the dorsal root ganglia and other spinal cord projections. Rarely, a 
small number of cells were found in the mesenchymal tissue between the 
spinal cord and dorsal dermis. Longitudinal sections of transplants harvested 
at E5.5 revealed transplanted cells mostly localized to the injury zone, 
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extending, and potentially forming bridging connections between, the 
anterior and posterior spinal cord tissue. Again, spread into the surrounding 
dorsal root ganglia was observed.  
  Embryos harvested at E7.5 revealed a much greater spread of GFP+ 
cells from the transplantation site (Fig. 2.11, A, B). Coronal sections showed 
similar white matter localization to embryos harvested at E5.5 (Fig. 2.11, C). 
However, at E7.5 transplanted cells were predominantly found towards the 
dorsal aspect of the spinal cord. This finding was replicated in longitudinal 
sections, in which the vast majority of transplanted cells were found in the 
dorsal-most sections. Again, these were found forming bridging structures 
between the anterior and posterior spinal cord tissue, in the region of the 
injury zone (Fig. 2.11, D). Analysis of embryos harvested at E9.5 revealed an 
almost exclusive localization of transplanted GFP+ cells to the dorsal 
presumptive white matter, continuing the trend observed between E5.5 and 
E7.5 (Fig. 2.12, A). Within dorsal longitudinal sections, GFP+ cells were still 
observed to form continuous structures between the anterior and posterior 
SC tissue (Fig. 2.12, B).  
  At E13.5, GFP+ cells had spread substantially along both the anterior 
and posterior spinal cord tissue (Fig. 2.13, A). Transverse sections throughout 
the spinal cord at E13.5 reveal that, at the injury zone, transplanted cells 
showed no grey/white matter localization preference (Fig. 2.13, C). However, 
moving anteriorly GFP+ cells became progressively localized to the white 
matter only (Fig. 2.13, B). The presence of robust bridging structures was 
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Figure 2.10: Immunofluorescent analysis of E5.5 cryosectioned 
embryos transplanted with ENS-derived neurospheres.  
Stereoscopic examination revealed GFP+ cells spreading from the transplantation 
site (A, B). C shows a schematic of transplantation site and sectioning planes for 
analysis. Co-staining of coronal sections with GFP and TuJ1 revealed localisation of 
transplanted cells to neuronal rich regions. 4 days after transplanting, cells had 
formed a ‘halo’ around the spinal cord, staying almost exclusively in the presumptive 
white matter (D). Longitudinal sections revealed transplanted cells had formed 
bridging connections through the injury zone, between the anterior and posterior 
spinal cord tissue (E, arrow). In both coronal and longitudinal sections, GFP+ cells 
spread into the PNS through the dorsal root ganglia (DRG, D, E). Insets show high 
power magnification revealing numerous GFP+ extensions from the transplanted 
neurosphere. FL – forelimb, HL – hindlimb, NT – neural tube, SN – spinal nerve, NC 
– notochord, DRG – dorsal root ganglia. Scale bar: A - 3mm, B – 1mm, D, E - 
500μm.  
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Figure 2.11: Immunofluorescent analysis of E7.5 cryosectioned 
embryos transplanted with ENS-derived neurospheres.  
Fluorescent stereoscopic examination of embryos harvested at E7.5, 6 days after 
transplant, reveals extensive GFP+ cell spread from the transplantation site (A, B). 
Coronal sections show the presence of GFP+ cells in a ‘halo’ within the future spinal 
cord white matter, in a pattern similar to that seen at E5.5 (C).  However, at E7.5 
transplanted cells appear to show a preferential distribution around the dorsal spinal 
cord, with very few cells at the ventral side. Longitudinal sections reveal GFP+ cells 
forming bridging connections between the anterior and posterior segments of the 
injured spinal cord (square bracket, D). In the longitudinal section, a few of GFP+ 






















Figure 2.12: Immunofluorescent analysis of E9.5 embryos 
transplanted with ENS-derived neurospheres.  
Coronal sections of embryos harvested 8 days post-transplant at E9.5 show GFP+ 
cells localised almost exclusively to the dorsal spinal cord, with only rare cells found 
more ventrally (A). Longitudinal sections reveal GFP+ cells forming bridging 
connections between anterior and posterior spinal cord tissue (square bracket), 
consistent with immunofluorescent examination of transplants harvested at E5.5 and 
E7.5 (B). The majority of cells appear localised to the white matter. Scale bars: A, B - 
500μm.  















Figure 2.13: Immunofluorescent analysis of GFP+ bridging 
structures across the injury site of E13.5 embryos transplanted 
with ENS-derived neurospheres.  
The extent of transplanted GFP+ cell spread is shown along the anterior posterior 
axis (tiled images, A). The solid and dashed lines in A show the approximate levels 
of the transverse sections shown in B (anterior to the injury zone) and C (through the 
injury zone). The solid box in A indicates a higher magnification of the injury zone 
and bridging structure shown in D. Scale bars: A – 1mm, B, C, D - 500μm. 
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  Many non-NSC have been proposed and indeed tested for their 
potential to aid in repair of the injured spinal cord. While these have shown 
benefit, an advantage of a NSC source such as ENSCs is their predicted 
ability to produce appropriate cell types, and for these to function as either 
relay circuit components or bridging structures. In order to determine the 
fate of cells post-transplant, GFP+ cells within the injury zone were examined 
at higher magnification (Fig. 2.14). In embryos examined at E5.5, 
transplanted cells frequently co-labelled for the pan-neuronal cell marker 
TuJ1 and GFP, demonstrating differentiation towards a neuronal lineage (Fig. 
2.14, A). Further, transplanted cells were not found to differentiate towards a 
glial lineage, and were not found in areas of GFAP+ staining (Fig. 2.14, B). 
  For transplanted neurons to function efficiently as either circuits or 
bridges, alignment along the anterior/ posterior axis is almost certainly 
advantageous. The majority of spinal tracts run from the brain and along the 
anterior/ posterior axis of the spinal cord to the body, or vice versa, with only 
a few tracts (such as spinal reflex circuits) arranged perpendicular to the 
anterior/ posterior axis. Therefore, these longitudinal tracts are by far the 
most likely to be damaged in SCI, and the most in need of repair. Analysis of 
transplanted ENSCs within the injury zone revealed numerous cell bodies 
aligned along the anterior posterior axis, often but not always within residual 
TuJ1+ neuronal tracts (Fig. 2.14, C). Quantification of maximal longitudinal 
spread across embryos harvested at all time points revealed a progressive 
increase in spread with time post-transplant, with the greatest anterior-
posterior spread within transplants harvested at E13.5. Compared to an 
average spread of around 996.3μm at E5.5, embryos harvested at E13.5 
showed an average spread of 7373.2.3μm (n=3). The increase in spread from 
E5.5 was significant compared to both E9.5 (p=0.0077) and E13.5 
(p=0.0127). ANOVA comparison across all groups was also significant 
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(p=0.002) (Fig. 2.9, D). 
   
 
Figure 2.14: Cell fate analysis of transplanted ENSCs.  
Longitudinal cryosections of chick embryos harvested 12 days after transplantation 
at E1.5 with a GFP+ ENS-derived neurosphere reveal TuJ1+/GFP+ cells projecting 
through the spinal cord injury zone (A). In contrast, transplanted cells were distinct 
from areas of GFAP staining, with no GFAP+/GFP+ cells observed (B). Particularly in 
transplanted embryos harvested at later stages, longitudinal sections showed GFP+ 
cells within the injury zone, often adhered to residual TuJ1+ structures between the 
anterior and posterior spinal cord tissue (although cells were also found within TuJ1- 
injury zone tissue). These usually aligned along the anterior/ posterior axis of the 
spinal cord (C). Quantification of GFP+ spread along the anterior-posterior axis 
across the four time points under examination reveals a progressive increase in 
spread with increasing time post-transplant (C). Compared to an average spread of 
approximately 996.3μm at E5.5, embryos harvested at both E9.5 and E13.5 showed 
significantly higher cell spread. * =<0.05, **=<0.005. 
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2.3.4 GFP+ ENSC neurospheres transplanted into later stage (E11) neural 
tubes survive and extend axons into the white matter after only 24 
hours 
 
 To allow manipulation of chick embryos at a later stage of development, 
chicks were cultured ex ovo until E11, at which point a severe cervical injury 
was induced. GFP+ neurospheres were transplanted into the injury site and 
the embryos allowed to develop for 24 hours before harvesting. Higher 
mortality rates were observed for late compared to early stage transplants. In 
three of four surviving transplants, the transplanted neurosphere was found 
adjacent to the spinal cord. No GFP signal was detected in the fourth. Figure 
2.15 shows such localization to the white matter of the cord, including the 
extension of processes (arrow) into the presumptive white matter even after 
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Figure 2.15: Immunofluorescent/histological examination of 
embryos transplanted at E11 with a GFP+ ENS-derived 
neurosphere.  
Coronal cryosections of a chick embryo injured and transplanted with a GFP+ 
neurosphere at E11 and harvested 24 hours later show the neurosphere localized to 
the cord (arrow). In the above example, GFP+ processes extend into the white 
matter. H&E/ DAB staining of an adjacent section confirms the presumptive white 
matter localization of transplanted cells (grey matter indicated by dashed line). 
Blood deposits in the cord gave strong background staining (unlabeled arrows), and 
also seemed mostly restricted to the white matter). 





The results presented provide preliminary evidence that stem cells, derived 
from the ENS of the GI tract, can survive and integrate in the embryonic 
spinal cord, encouraging further assessment of their potential as a stem cell 
source for SCI therapy.  
  The chick model allows access to the developing embryo, permitting 
generation of GFP/ WT chimeras (Delalande et al., 2015). This method was 
utilized successfully to label vagal neural crest derivatives, including the ENS 
and its stem cell population. GFP+ cells and their derivatives were isolated 
using FACS and expanded in culture to form GFP+ neurospheres. ENS cells, 
including ENSCs integrated with CNS-derived cells in vitro, implying the 
potential for functional integration in vivo, and qRT-PCR analysis revealed 
common expression of neurons, glia, stem cells and a subset of neuronal 
subtypes between spinal cord tissue and gut/cultured ENSC samples. Finally, 
GFP+ neurospheres transplanted into the neural tube migrated through the 
spinal cord white matter and injury site, potentially forming bridging 
connections. This spread increased along the anterior/ posterior axis with 
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2.4.2 Efficient isolation of ENSCs and subsequent co-culture with SC-
derived cells 
 
Previous work has shown the specificity of GFP/WT neural tube grafting 
labelling of ENCCs and their derivatives (Delalande et al., 2015). The data 
presented here is in line with previous publications demonstrating formation 
of the ENS from the vagal region of the neural crest, and lack of GFP+ ENCC 
migration to non-ENCC-derived structures (Burns et al., 2002; Burns and Le 
Douarin, 2001; Delalande et al., 2015). In addition, this chapter provides 
further evidence that the differentiation wavefront, as demarcated by TuJ1 
staining, lags significantly behind the migration wavefront of ENCCs as they 
colonise the GI tract. This is in agreement with publications demonstrating 
both the tendency of TuJ1+ cells to be found distal to the migration 
wavefront, and to migrate more slowly than their undifferentiated 
counterparts (Hao et al., 2009; Young et al., 2002; Young et al., 2005). As 
revealed by cross sections of colons from chimeric embryos, the grafting 
procedure resulted in robust labelling of ENCCs and their derivatives, 
evidenced by co-localization with both the neural crest cell marker HNK1 and 
the neuronal marker TuJ1. This translated into efficient cell isolation by FACS. 
Typically between 3-5% of total ‘events’ were collected. Previously published 
data stated the percentage of neural crest-derived cells within the mouse gut 
to be around 7-8% of total gut cells at the age of chimeric chick embryo 
harvest within the study (E14) (Binder et al., 2015). In this study, a Wnt1-
Cre;Rosa26Yfp/Yfp mouse line was used, labelling with near-100% efficiency all 
neural crest cells (Binder et al., 2015; Jiang et al., 2000). The total number of 
GFP+ cells within the gut of GFP/WT chimeric chick embryos in the current 
study was likely higher than the 3-5% collected following FACS, as the sort 
gating was set to a highly restricting level to ensure purity of the collected 
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population. The percentage of FACS+ cells collected in the current study 
therefore likely demonstrates a similarly high level of labelling efficiency to 
previous publications.   
 Co-culture experiments of isolated ENSCs and their derivatives with 
SC-derived cells demonstrated the propensity of the two populations to 
interact. This experiment neatly displays the potential of ENSCs to integrate 
with endogenous networks within the spinal cord following transplantation. 
Stem cell transplantations have induced functional improvements in SC- 
injured recipients, as assessed by BBB evaluation and electrophysiological 
recordings across the injury site following transplantation of umbilical 
mesenchymal stem cells (Lu et al., 2012) or stepping performance on the 
horizontal ladder test following neural stem cells (Hong et al., 2014), among 
others. A leading theory of the mechanism by which this occurs is through 
establishment of lesion-spanning stem cell-based bridges for endogenous 
axons to cross (Popovich, 2012). In this study, extension of ENSC axons 
alongside SC-derived cell axons was frequently observed, implying the ability 
of ENSCs to function as such bridges. This is also supported by the extension 
of axons towards one another, likely leading to formation of synaptic 
junctions. Further work would be required to determine whether true 
synapses had been formed at these junctions, and whether the two 
populations exhibit attractive cues towards one another or had ‘found’ each 
other by chance. Either way, the ability of ENSCs to integrate with SC-
derived cells lends further credence to their use as a stem cell source for SCI. 
 
2.4.3 Differentiation of ENSCs towards appropriate neuro-glial lineages  
 
Isolated GFP+ cells and their derivatives demonstrated extensive 
differentiation towards neuronal lineages, as evidenced in vitro by TuJ1+ 
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immunostaining of neurospheres. To provide further evidence that ENSCs 
could serve as a viable cell replacement source following SCI, uncultured SC 
and gut tissue were assessed using qRT-PCR to determine the relative 
expression of common nervous cell types. This confirmed common 
expression of neurons (TuJ1+), glia (S100+) and stem cells (Sox10+), in 
agreement with previous publications demonstrating the presence of these 
cell types in ENSC-derived neurospheres (Binder et al., 2015; Cooper et al., 
2016). Expression of TuJ1 was significantly higher in uncultured SC tissue 
than for gut tissue. Although this seems in contradiction to published data 
citing equivalent numbers of neurons between the SC and ENS (Furness, 
2006) at the ages examined (E14) the ENS has not yet reached its future size 
and complexity (Burns et al., 2002). Additionally, RNA was extracted from 
whole gut samples, and the levels of TuJ1 will be ‘diluted’ by the presence of 
mesenchymal tissue.  
 Comparisons of expression levels of uncultured SC tissue, compared to 
cultured ENSC neurospheres, revealed similar expression of TuJ1 and S100 
in ENSC cultures compared to uncultured gut. Again, spinal cord levels of 
TuJ1 were significantly higher than ENSC cultures. This is likely explained by 
the higher levels of Sox10 in ENSC cultures compared to uncultured SC 
tissue, reflecting a more immature phenotype of ENSC cultures. Indeed, it 
has been shown that Sox10 is important in the maintenance of an enteric 
progenitor phenotype (Bondurand et al., 2006), and that downregulation of 
Sox10 coincides with increased neuronal differentiation (Young et al., 2003). 
Such high levels of Sox10 are therefore encouraging as a source of dividing 
cells for SCI. 
  qRT-PCR analysis of relative expression levels of genes involved in 
neurotransmitter production revealed the presence of all five 
neurotransmitters under examination in both gut and SC tissue. Levels of 
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nNOS, serotonin, glutamine and acetylcholine were largely similar between 
SC and gut tissue samples. Expression of GABA was significantly higher in SC 
samples compared to gut tissue. This is perhaps unsurprising, considering 
the role of GABA as the inhibitory neurotransmitter utilized in the CNS (Kew 
and Kemp, 2005). Cultured ENSCs showed largely similar expression levels 
to whole gut samples, with only slight decreases in the level of serotonin and 
glutamine in cultures ENSC samples. This is likely due to the expansion of the 
immature progenitor population as demonstrated by increased Sox10 
expression in ENSC cultured samples compared to whole gut samples. 
Indeed, the culture media utilized in these studies have been previously 
optimized to encourage maintenance of a stem phenotype (Bondurand et al., 
2003). The lack of significant difference in serotonin expression is also 
expected – while the vast majority of serotonin in the body is found in the 
gut, this is mostly produced and stored in enterochromaffin cells (Gershon, 
2013), which will not have been selected during FACS isolation of ENCCs. 
Neural crest cell-derived neurons of the myenteric plexus produce serotonin, 
but in more modest quantities (Gershon and Tack, 2007).  
  Taken together, this data strongly supports the hypothesis that 
transplanted ENSCs are capable of integrating functionally into endogenous 
SC networks. During development, neurotransmitters play a key role both in 
plasticity and network formation (Herlenius and Lagercrantz, 2004). It is 
plausible that neurotransmitter expression in the injured environment may 
play a role in establishing new connections to replace severed tracts. Indeed, 
following injury, disruption of neurotransmitters has been implicated in SCI 
complications. The absence of serotonin signaling following lesioning of 
serotonergic tracts, for example, has been shown to result in serotonin 
hypersensitivity caudal to the lesion, contributing to spasticity (Husch et al., 
2012). Concordantly, studies aimed at restoring levels of serotonin following 
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SCI have resulted in functional improvements (Antri et al., 2005; Schmidt and 
Jordan, 2000). These studies demonstrate the importance neurotransmitter 
expression holds following SCI, and highlight the importance of 
characterizing neurotransmitter competency of a stem cell source prior to 
transplantation. 
 
2.4.4 Survival and localization of GFP+ ENSCs to the spinal cord white 
matter 
 
In contrast to alternative sources of stem cells transplanted into the 
embryonic chick spinal cord, where transplanted cells were undetectable 
after several days (Prasongchean et al., 2012), we demonstrate for the first 
time that ENSCs, sourced from the gut, can survive in the embryonic spinal 
cord for up to 8 days post-transplantation. This data provides evidence of 
compatibility between ENSC-derived cells and a CNS environment, and 
supports the suitability of ENSCs for SCI repair. 
 
2.4.5 Localization to neuronal tissue 
 
  The vast majority of transplanted GFP+ cells were found within the 
spinal cord and dorsal root ganglia. Very few transplanted GFP+ cells were 
detected outside of neuronal regions following transplantation, indicating 
either active ENSC localization specificity or poor survival in non-neuronal 
regions. The few cells found outside of TuJ1+ tissue were restricted to tissues 
dorsal to the spinal cord. Following transplantation of a GFP+ neurosphere 
into the neural tube at E1.5, the ectoderm closed over the neural tube, likely 
capturing some GFP+ cells. Thus the presence of these cells in mesenchymal 
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tissues between the dorsal spinal cord and overlying dermis were probably 
transplantation artifacts rather than migratory events. In support of this, GFP+ 
transplanted cells were not found in TuJ1- tissue ventral to the spinal cord. It 
is unlikely this will affect therapeutic application of ENSCs, as treatment 
would involve direct transplantation into the adult injury site when no such 
developmental morphogenic processes occur.  
 
2.4.6 Localization to white matter 
 
  At all ages under examination, transplanted GFP+ ENSCs were found 
extensively within the future white matter (myelin will not begin to form until 
around E13 (Macklin and Weill, 1985)), and only rarely in the grey matter. 
Previous studies investigating transplantation of alternative stem cells into 
the embryonic chick neural tube have shown relatively poor localization 
propensities. Prasongchean et al demonstrated survival of rat amniotic fluid 
stem cells (AFSCs) for four days after transplantation into the injury site at 
E2.5 (Prasongchean et al., 2012), but AFSCs largely failed to home to grey or 
white matter, and were instead found mostly in the central canal or, more 
commonly, near the dorsal root ganglia, with no apparent integration. These 
findings contrast our observations of white matter localization following 
ENSC transplantation.  
  The results of ENSC transplantation described here are more 
consistent with observations by Toma et al., who used the chick embryo as a 
model organism to assess differentiation following transplantation of induced 
pluripotent cell-derived motoneurons (iPSCMNs) into the developing neural 
tube (Toma et al., 2015).  Their study revealed transplanted iPSCMNs 
localized to spinal cord white matter, with projections into the PNS. We 
observed a similar extension of our transplanted ENSCs through the dorsal 
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root ganglia to enter the PNS. The similarities between the current study and 
that of Toma et al demonstrates the ability of transplanted ENSCs to 
integrate in the spinal cord in a similar manner to transplanted motoneurons. 
It also suggests either a shared tendency of a percentage of transplanted 
cells to migrate through CNS tissue towards and into PNS tissue, or of 
transplanted cells being transported with surrounding tissue as development 
progresses and such peripheral structures are formed. Transplantation into 
an adult model of SCI, with examination of the extent of migration into 
peripheral structures, would clarify this point. In any case, the ability of 
transplanted cells to survive in CNS/ PNS tissues, combined with previous 
studies demonstrating the expression of sensory and motor 
neurotransmitters in cultured ENSC-derived cells (Suarez-Rodriguez and 
Belkind-Gerson, 2004) suggests that ENCCs may be able to re-establish 
sensory and motor connections.  
  ENSCs are derived from enteric NCCs, known to be a highly migratory 
population (Bronner-Fraser, 1994; McLennan et al., 2015). It was therefore 
plausible that transplanted ENSCs would migrate out of the spinal cord, 
towards tissues with a neural crest contribution. We did not observe any such 
spread, consistent with a recent study by Belkind-Gerson et al, examining the 
potential of ENSCs for brain injury (Belkind-Gerson et al., 2016). They 
demonstrated that tail vein delivery of ENSCs resulted in homing of ENSC-
derived cells to the injury site and white matter of the brain. Interestingly, 
ENSC-derived cells were absent in other neural crest-derived tissues, 
including the intestines, suggesting injury as a localization cue, and implying 
ENSC localization to the SCI site could be similarly expected following 
transplantation. These results support the white matter-specific localization of 
ENSCs observed in our experiments, including the near-complete absence of 
GFP+ cells in other tissues.  
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Other neural crest sources have also been utilized for SCI therapy. 
Olfactory ensheathing glia (OEG), shown to be neural crest in origin (Barraud 
et al., 2010), have been transplanted into adult rodent spinal cord, resulting 
in functional motor recovery in 10 of 12 transplanted animals (examination of 
both remaining animals revealed misplaced transplants) (Keyvan-Fouladi et 
al., 2003). Again, consistent with our observations, predominant localization 
to the white matter tracts was observed, though arborisation into the 
adjacent grey matter also occurred. The success of OEG transplantation was 
attributed to their ability to survive within the CNS tissue and injury site, 
promoting endogenous axonal sprouting. Based on their shared ectodermal 
origin and similar fate-lineage, similar results could be expected following 
ENSC transplantations.  
 
2.4.7 Dorsal/ ventral localization 
 
In transplants harvested at early stages (E5.5), transplanted GFP+ 
ENSCs were found surrounding the entirety of the neural tube, with no 
apparent dorsal/ ventral preference. However, with increasing time post-
transplant, ENSCs appeared to become progressively more dorsalized, 
resulting in almost exclusive localization of transplanted cells to the dorsal 
spinal cord by E9.5. In their study of iPSCMN transplantation into the chick 
neural tube Toma et al demonstrated a mostly dorsal localization (with more 
variability of grey/ white matter localization) although projections left the 
spinal cord by ventral roots. However, the method of inducing injury utilized 
by Toma et al was different from that used in the present study. Toma et al 
made an incision in the dorsal neural tube and subsequently implanted cells 
in the neural tube lumen, contrasting with our method of ablation of an entire 
somite-length section of the neural tube. In the stages utilised by both Toma 
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et al and the current study (~E3.5 and E1.5, respectively) the neural tube is 
entirely capable of regeneration following SCI (Shimizu et al., 1990). This has 
been shown to result in complete recovery of the injury site, including 
extension of injured axons to re-establish lost connections (Hasan et al., 
1993). It is not known whether replacement of lost cells contributes to this 
process (Ferretti et al., 2003). However, if proliferation was indeed occurring, 
it is likely that this would take place towards the ventral side of the neural 
tube with subsequent dorsal expansion, and that relatively greater rates of 
proliferation would be required to enable regeneration from the method of 
injury used in the current study compared to that used by Toma et al. 
Replacement cells may well originate from the neural floor plate and 
overlying neuroepithelial cells, at least a remnant of which likely persists 
along the notochord following the injury method used in this study. 
Motoneurons of the future spinal cord originate from this region (Yamada et 
al., 1993), with the underlying notochord thought to induce proliferation of 
overlying neuroepithelial cells and differentiation of motoneurons (Hirano et 
al., 1996; van Straaten et al., 1985; Wilson and Maden, 2005). Further 
supporting a ventral-dorsal progression of regeneration, ventral 
neuroepithelial cells of the spinal cord produce large populations which 
place a pressure on the overlying dorsal cells, progressively forcing them 
more dorsally (Bronner-Fraser and Fraser, 1997; McConnell and Sechrist, 
1980) and several such populations migrate towards the dorsal neural tube 
(Rowitch, 2004; Soula et al., 2001). This sequence of events likely explains the 
progressively dorsal localization of transplanted ENSCs.   
 
2.4.8 Presence in injury site, bridging, A/P 
 
At all stages examined, transplanted GFP+ cells could be found within the 
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injury site, an important finding if ENSCs are to serve as a cell replacement 
source or bridging substrate for endogenous recovery. Typically, 
transplanted cells were found within residual TuJ1+ neuronal tracts. 
Considering the majority of spinal cord injuries result in varying degrees of 
spared white matter tracts (James et al., 2011), such residual TuJ1 structures 
will likely be found in human SCI, meaning transplanted ENSCs are adhering 
to appropriate substrates. However, of note, some transplanted ENSCs were 
found within TuJ1- tissue within the injury site, demonstrating the ability to 
survive in areas where endogenous neurons have been lost entirely, and 
therefore encouraging their use as bridging structures between severed ends 
of the spinal cord following injury. Concordant with such use, the majority of 
transplanted ENSCs found in the spinal cord and TuJ1+ structures of the 
injury site were aligned along the anterior posterior axis. This demonstrates 
both the potential to integrate with endogenous networks, the vast majority 
of which are aligned along the anterior posterior axis, but also the ability to 
provide ‘pathways’ for endogenous neurons to follow across the injury site. 
Correct alignment is a target of many stem cell transplantation therapies, 
with some even going as far as using scaffolds to encourage longitudinal 
alignment and integration (Hyatt et al., 2014). A recent review defined a 
successful bridge as: “a multicellular structure comprised of transplanted 
cells that crosses the lesion site (rostrally to caudally)” (Assinck et al., 2017). 
Indeed, the success or failure of a particular transplantation is often 
determined purely by the extent of anterior posterior axonal sprouting (Lu et 
al., 2012). Many articles use tracing methods, both retrograde and 
anterograde, to discern the extent of anterior-posterior axon regeneration 
(Zhao et al., 2015). Thus, the common alignment along the anterior-posterior 
axis of transplanted ENSCs is a significant finding, and strongly advocates the 
potential of ENSCs to form bridges for endogenous regeneration in SCI. 
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Recognising the importance of cell behaviour along the anterior 
posterior axis, cell spread along the spinal cord was quantified in the present 
study. In early transplants spread along the anterior-posterior axis was 
relatively low, reaching ~998μm in total. A positive correlation of spread with 
increasing time at harvest post transplant was noticed, with spread reaching 
~1600μm by E7.5 and 2687μm by E9.5, the latest time point examined in this 
study. This trend suggests spread may have continued in a similar manner if 
embryos had been left to develop longer. While it is plausible that this 
spread is a reflection of the overarching development of the spinal cord, and 
thus that transplanted ENSCs were simply ‘pulled’ in the direction of tissue 
growth, it is likely that, at least to a certain degree, this represents active 
processes on the part of the transplanted cells. Firstly, axonal projection was 
included in these measurements, known to be an active process involving 
extension of the growth cone and response to attractive/ repellent stimuli 
(Lowery and Van Vactor, 2009). Secondly, for the anterior-posterior increase 
in spread to be entirely related to growth a similar extension along the left-
right axis of the embryo spinal cords would have been expected. If anything, 
we noticed a decrease in the amount of transplanted ENSCs spreading into 
the surrounding PNS through the dorsal root ganglia. Cell spread in other 
studies of stem cell transplantation varies according to the technique used. In 
models where an incision was made in the dorsal neural tube and a 
dissociated cell suspension injected into the lumen, spread was 
understandably greater due to passive travel along the lumen (Prasongchean 
et al., 2012; Zhao et al., 2013). To our knowledge, few other studies have 
attempted neurosphere transplantation into the developing chick neural 
tube. In such cases, anterior-posterior spread was not assessed (Toma et al., 
2015). Thus, in comparison to injection into the lumen, it is likely that the 
results of our study more accurately represent migration of cells from the 
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transplantation site and not passive diffusion through the neural tube lumen. 
Thus, the current study is likely more indicative of expected results following 
transplantation into the adult spinal cord.  
 
 
2.4.9 Differentiation of ENSCs 
 
A logical solution to the loss of neurons during SCI would be to transplant a 
stem cell population capable of replacing them. However, this has not 
proved so straightforward. Success of mesenchymal stem cell differentiation 
towards a neuronal phenotype has proven inconsistent even in vitro (Scuteri 
et al., 2011). Several reports have demonstrated potential neuronal 
differentiation of mesenchymal stem cells following transplantation into the 
injured spinal cord or other CNS regions (Ryu et al., 2009; Zhao et al., 2002). 
However, many have questioned these reports (Qu and Zhang, 2017) and/ or 
failed to reproduce them or demonstrate significant neuronal differentiation 
of their own sources (Parr et al., 2008; Prasongchean et al., 2012). While it 
has been suggested that such neuronal differentiation may not be vital 
(Assinck et al., 2017), it is almost certainly an advantage. Previous 
publications have listed neuronal differentiation as the likely cause of 
increases in motor function following transplantation into an injured spinal 
cord (Abematsu et al., 2010; Lu et al., 2012). 
  In the current study, ENSCs readily differentiated towards a neuronal 
phenotype both in vitro and in vivo, following transplantation. Both 
immunofluorescent and qRT-PCR analysis of cultured ENSCs prior to 
transplantation showed a high expression of TuJ1, a pan-neuronal marker, 
and transplanted cells were almost exclusively TuJ1+, suggesting that these 
cells are potentially a good source to replace lost or injured neurons. The 
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results presented in the current study are consistent with those of Belkind-
Gerson et al, who demonstrated the ability of ENSCs to survive, proliferate 
and differentiate towards neuro-glial lineages when transplanted into injured 
adult mouse brain (Belkind-Gerson et al., 2016). The discrepancy between 
these results of mesenchymal stem cell ENSC transplantation likely reflects an 
inability of the former to respond to neural cues and/ or survive in neuronal 
regions (Donaldson et al., 2009; Steigman and Fauza, 2007). Indeed, poor 
survival of MSCs has been noted before (Ruzicka et al., 2017). Differentiation 
of transplanted cells will undoubtedly aid in integration, and potential 
formation of relay circuits and lesion-spanning bridges. It would be 
interesting to further examine the neuronal differentiation observed in the 
current study to determine specific neuronal subtypes produced. However, 
further differentiation analysis is technically difficult due to the limited 
availability of antibodies raised against chick antigens. To more definitively 
determine the specific neuronal and glial fates of transplanted cells further 
novel antibodies are required, or progression to a rodent model in which 
such antibodies are more readily available.  
 
2.4.10 Myelination of transplanted cells 
 
Myelination does not occur in the chick spinal cord until E13 (Ferretti and 
Whalley, 2008). Consistently, processes extended by GFP+ cells in the ‘injury’ 
zone displayed the ‘beaded’ structure typical of unmyelinated neurons 
(Shepherd and Raastad, 2003), and often observed in enteric neurons 
(Heinicke and Kiernan, 1990). However, while enteric neurons are 
unmyelinated in the gut (Gershon and Rothman, 1991; Ruhl, 2006), their 
myelination may be possible in the adult spinal cord. Adaptation of neurons 
depending on their environment is a well-described phenomenon, such as 
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the regenerative capacity of spinal neurons when removed from the 
inhibitory environment of the spinal cord and placed in peripheral nerve 
structures (Richardson et al., 1980; Taylor et al., 2005).  It is possible that 
enteric neurons may prove similarly adaptable and receive myelination within 
the spinal cord. However, even if transplanted cells prove incapable of 
myelination, their viability as a SCI treatment would likely be unaffected. 
Given the short distance required to bridge the lesion and re-connect 
severed tracts, the slower conduction speeds associated with non-myelinated 
axons (Hartline and Colman, 2007) may not impact on functional recovery. 
Indeed, not requiring myelination may prove advantageous in the SCI 
environment, in which lack of myelination and resulting Wallerian 
degeneration is a significant issue (Mietto et al., 2011).   
 
2.4.11 Future work 
 
The experiments performed in this chapter provide vital proof of principle 
data for the hypothesis that ENSC-derived cells can flourish in an embryonic 
CNS environment. The following experiments could be carried out to extend 
the current analysis: 
 
2.4.11.1 Proliferation analysis 
 
Initial high proliferation rates, which decrease with time following cell 
transplantation into the spinal cord, have previously been shown by Mothe et 
al, though the authors offered no explanation for this phenomenon (Mothe et 
al., 2008). BrdU-based proliferation assays revealed the presence of dividing 
cells in the transplants performed within this study, however, this proved 
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difficult to quantify due to a high rate of transplant death following 
application of BrdU. A certain amount of proliferation post-transplant would 
likely prove beneficial through replacement of lost neurons, but unchecked 
proliferation raises concern over tumour formation, a risk previous 
publications have taken pains to rule out (Bastidas et al., 2017; Levi et al., 
2017). However, recent studies assessing NSC transplantation have noted a 
dose-dependent effect of transplantation on proliferation of transplanted 
cells, implying the ability of neural-stem cells to respond to local inhibitory 
cues (Piltti et al., 2015). Based on extensive similarities between CNS and 
ENS cells noted within this report, it is possible that ENSCs would similarly 
respond to local cues and restrict uncontrolled proliferation. Therefore, the 
limited proliferation observed in ENSC transplants within this study is likely 
supportive of SCI regeneration. Progression to an adult model of SCI would 
circumvent issues of BrdU labeling in the embryo, allowing determination of 
the extent of division occurring within transplanted ENSCs. 
  Survival of transplanted cells is also an important concern. Mothe et al 
also noted a significant reduction in the number of surviving transplanted 
cells in the first week post transplant (Mothe et al., 2008), and Ruzicka et al 
noted extensive death of MSCs post-transplant (Ruzicka et al., 2017). In the 
current study cell numbers did not appear to decrease with time following 
transplantation, but this will need to be assessed over a longer term. 
However, based on the compatibility of ENS/ CNS cells observed in vitro, 
and the initial cell spread observed, extensive death is not expected. 
 
2.4.11.2 Assessment of functional integration 
 
Previous work in our lab has demonstrated functional integration of ENSC-
derived cells transplanted into mouse hindgut, evidenced by propagation of 
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calcium signaling between endogenous and grafted cells (Cooper et al., 
2016) and through restoration of colonic transit (McCann et al., 2017). 
Though functional integration of transplanted cells may well be occurring 
within the chick spinal cord, as suggested by the close proximity of 
transplanted cells to the white matter and the extension of processes, 
determination of such function is technically difficult in an embryonic model. 
Therefore, future experiments will likely progress to an adult rodent model. 
This will allow electrophysiological testing/axonal tracing of transplanted cells 
to ascertain functional integration with endogenous cells; behavioral tests 
following SCI/ ENSC transplantation, assessing functional recovery; and more 
extensive characterization of transplanted ENSC differentiation potential, 
utilizing pre-existing anti-rodent antibodies. 
 
2.4.11.3 Additional research directions under consideration 
 
Successful future therapies will likely incorporate a combinatorial approach of 
cell transplantation, scaffold deposition and modification of the inhibitory 
microenvironment. Scaffolds facilitate cell engraftment and migration 
through fluid filled cavities, which otherwise offer little cell adhesion, and 
microenvironment modifiers offer the potential to increase survival of 
transplanted and endogenous cells. 
  Future work could therefore combine ENSC transplantation with 
additional therapies. Potential scaffolds include Bioglass™, which is 
biodegradable and has a high angiogenic potential (Gorustovich et al., 
2010); and factors modifying the microenvironment are likely to include 
extracellular matrix modifiers such as CSPG inhibitors (reducing glial scar 
inhibition) (Bartus et al., 2014) or protein deiminase inhibitors (reducing 
calcium-related damage) (Lange et al., 2011).  




These results are supportive of the hypothesis that ENSC-derived cells could 
be used for SCI therapy. At all ages examined following transplantation into 
the embryonic chick spinal cord at E1.5, ENSCs survived and differentiated 
towards appropriate neuronal lineages, with limited proliferation post 
transplant. ENSCs formed bridging connections across the injury site 
between the anterior and posterior spinal cord tissue, and extended axonal 
processes through the injury site. Transplanted ENSC cell-spread along the 
anterior posterior axis increased with time post-transplant. When 
transplanted into the injured spinal cord at E11, GFP+ ENSCs extended 
processes into the white matter after only 24 hours. Future studies will 
progress this data towards adult models of SCI. This will establish whether 
the ability of ENSCs to survive, proliferate and differentiate and spread within 
the embryonic chick can be replicated in more mature models. Advancement 
towards an adult model will allow the beneficial effects of ENSC 
transplantation on tissue regeneration post-SCI to be assessed both 
histologically and functionally, and provide further evidence that ENSCs can 
serve as a viable source of stem cells for SCI. 







3 Chapter three: Identification of Optimal Parameters for 
Progression of Studies Conducted in the Chicken Embryo to 
an Adult Rat Spinal Cord Injury Model 
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3.1 Introduction 
 
Results of the preceding studies utilizing the chicken as a model organism 
provide vital proof of principle data that transplanted ENSCs can survive in 
the spinal cord environment. However, as previously mentioned, the chicken 
embryo does not fully recapitulate typical SCI processes that occur in the 
adult human (Tator, 1995), including failure to form a glial scar (Clearwaters, 
1954; Shimizu et al., 1990) or initiate an immune response (Negash et al., 
2004; Seto, 1981). Therefore, there remains a need to determine whether 
transplanted ENSCs can survive in a ‘true’ injury zone (one more reflective of 
that observed following SCI in humans); whether this survival can continue 
long term; and whether such transplantation has any effect on motor 
recovery. This necessitates progression to a model that more accurately 
recapitulates the events observed following human SCI. As such models are 
typically more expensive than chick embryo research, a pilot study was 
conducted prior to initiating a large, long term and costly study of ENSC 
transplantation into an adult model of SCI, with the aim of identifying optimal 
parameters for an extended study, and providing preliminary data indicating 
the likely success or failure of such a project.  
Rodents such as mice and rats are the most commonly used 
mammalian models of SCI. For the purposes of our study we selected the rat 
as the most suitable SCI model for progression, due to the ability of this 
model system to more closely mimic the SCI pathology observed in humans, 
including the formation of fluid-filled cavities at the site of injury. This is a key 
feature of the human condition, and it is thought that these fluid-filled voids 
may contribute significantly to the failure of axons to cross the injury site (Xia 
et al., 2016). The lack of supporting cells or matrices within the cavity leaves 
little to no substrates for cell/ axon attachment, let alone guidance/repulsion 
	   114	  
cues that are vital for growth cone extension (McCall et al., 2012). Thus for a 
SCI therapy to be successfully translated from bench to bedside, it must be 
shown that the therapy is able to prevent, compensate for, or correct cavity 
formation. In the mouse, these cavities are filled with cells (Inman et al., 2002; 
Ma et al., 2001), thus limiting translational predictions based on data 
obtained from mouse models. The rat, conversely, has been well 
documented to form these fluid-filled cavities, providing a more accurate 
model for translational studies (Kjell and Olson, 2016).  
As mentioned in the preceding chapter, cervical injuries are the most 
common in humans (Gensel et al., 2006). However, thoracic injuries are by far 
the more commonly studied (Sharif-Alhoseini et al., 2017), providing a 
greater wealth of published data. In addition, cervical injuries in the rat carry 
a greater mortality rate compared to thoracic injuries due to respiratory 
complications arising from the former, and it is generally regarded that they 
are less reproducible than thoracic injuries (Lane et al., 2008; Rahimi-
Movaghar, 2009). For these reasons, a thoracic injury at the level of vertebrae 
T10 was selected.  
A variety of methods can be employed to injure the spinal cord, 
including contusion, compression, and hemisection (Sharif-Alhoseini et al., 
2017), among others. Contusions are the most established SCI model 
(Anderson, 1982), and with the use of equipment such as Infinite Horizon 
impactors, are arguably one of the most reproducible (Brösamle and Huber, 
2006), allowing a more robust internal comparison within a given study. 
Human spinal cord injuries involve blunt force trauma, e.g. motor vehicle 
accidents (Nas et al., 2015), further supporting the notion that contusions 
more closely recapitulate human injuries (Nobunaga et al., 1999). Moreover, 
contusion injuries allow for graded levels of injury severity, and the 
accompanying pathology has been well documented (Noble and Wrathall, 
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1989). This permits cell transplantations to be tested in progressively more 
severe models, depending on the purpose of the study. As this pilot study 
sought to determine the optimal time of transplantation to achieve maximal 
cell survival a mild thoracic contusion model was utilized. 
Finally, both immunocompetent and immunocompromised rodent 
models exist for the study of SCI. Immunosuppression can be achieved using 
both genetic and pharmacological means, and choice of model has 
significant implications for the interpretation of results (reviewed in (Anderson 
et al., 2011)). The future goal of ENSCs as a therapy for human SCI would 
theoretically involve autologous transplantation of enteric-derived cells into 
the SC of the same patient and so would require no immunosuppression, a 
key advantage of the ENS as a cell source. For the current study, however, 
transplants would be allogenic, involving ENS-derived cells extracted from 
the gut tissue of one rat being transplanted into the injured SC of another 
(harvesting ENS cells without sacrifice of the host is technically challenging in 
rodent models, due largely to the small size of the GI tract). Immune 
suppression was likely unnecessary for the present study, as cells for 
transplantation were harvested from, and transplanted into, Sprague Dawley 
rats to maintain strain consistency. However, Sprague Dawley rats are an 
immunocompetent outbred strain, and it was therefore still possible that an 
immune response would be mounted by the host. It was additionally possible 
that the GFP label could elicit an immune response (reviewed in (Ansari et al., 
2016)). However, components of the immune system are likely highly 
valuable in the initial stages of SCI, for example for clearance (albeit 
incomplete) of cell debris released from necrotic or apoptotic cells (Church et 
al., 2017) reviewed in (Goldstein et al., 2016). In order to reduce the number 
of variables under examination (several immune-modulating agents are 
thought to have effects on cell proliferation and fate etc. (Isomoto et al., 
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2007; Song et al., 2006)), and to conduct cell transplantation in a manner as 
close to the human reality as possible (transplanted cells in a human patient, 
whether autologous or otherwise, will face an activated immune system at 
the injury site (Fleming et al., 2006)), for this pilot study it was decided to 
transplant cells into an immunocompetent rat.   
  In summary, an immunocompetent rat model (Sprague Dawley rats – 
an outbred colony) with a T10 mild contusion injury was selected as the most 
suitable model to answer the objectives of Chapter 3, specifically, to: 
• Determine early cell survival following transplantation  
• Provide initial data as to suitable cell numbers for transplantation 
• Identify the optimal time post-injury for transplantation 
• Test injury/ regeneration quantification parameters 
 
These results will inform the planning and execution of an extended study 
encompassing longer animal survival post-transplantation and behavioral 
assessment following injury and treatment. 
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3.2 Methods 
 
3.2.1 Project responsibility disclosure  
This project, using a rat injury model, involved the establishment of a 
collaboration with Professor Elizabeth Bradbury, Wolfson Centre for Age 
Related Diseases, Guy’s Campus, King’s College London. Professor Bradbury 
was approached based on her outstanding track record with regards to 
extracellular environment-modifying SCI therapies, and an alignment of the 
current study’s aims with SCI models and techniques used within her 
laboratory. As well as providing access to the expertise of Professor 
Bradbury’s laboratory, this collaboration provided invaluable guidance and 
assistance with advanced animal surgery techniques. Where 
methods/procedures were conducted by, or with assistance from, Professor 
Bradbury’s laboratory, this is clearly stated (Fig. 3.1). 
 
Figure 3.1: Breakdown of study 
contributions by collaborators at 
King’s College London. 
Contributions from members of Professor 
Bradbury’s team is noted here. Dr Nicholas 
James (NJ) induced the majority of initial SCI 
using the impactor, and Dr Emily Burnside 
(EB) assisted with injection of tracers above 
and below the injury site, as well as with 
culling of the rats. 
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3.2.2 Harvesting of rat gut tissue 
  
Female P7 Sprague-Dawley rats were sacrificed by cervical dislocation and 
death confirmed by decapitation. Following a midline dermal incision the 
gastrointestinal (GI) tract was harvested into Mg2+/Ca2+ free phosphate-
buffered saline (PBS) under sterile conditions. The small and large intestines 
were opened along the anterior posterior (AP) axis, stretched, and pinned 
lumen side up. The mucosal layer was peeled and removed via fine 
dissection. The underlying muscularis was manually chopped into small 
pieces (2-3mm), washed twice in PBS with centrifugation (1000rpm for 5 
minutes) and incubated in collagenase (1mg mL-1) at 37°C for 15-20 minutes. 
Digestion was halted by addition of FACS media (DMEM F12 (Sigma Aldrich, 
UK), N2 (Gibco Life Technologies, UK), B27 (Gibco Life Technologies, UK), 
penicillin/ streptomycin (Sigma Aldrich, UK), with 2% fetal bovine serum 
(Sigma Aldrich, UK) and the solution passed through a pipette to encourage 
cell dispersal. The cellular solution was centrifuged (1000rpm for 5 minutes), 
re-suspended in NSM+P and passed through a 100μm cell strainer (Falcon, 
Corning, USA). Cells were subsequently plated at a density of ~50,000 cells 
mL-1, onto 6 well cell culture dishes previously coated with 2% fibronectin. 
 
3.2.3 Cell culture and FACS analysis (rat) 
  
Cells were cultured largely according to protocols used for chick work (see 
Chapter 2). Notably, following initial bacterial contamination, penicillin/ 
streptomycin was replaced with primocin (InvivoGen, UK), a potent antibiotic 
and anti fungal agent, which prevented contamination in further experiments. 
Two days after tissue harvest, cells were collected for FACS analysis. Culture 
media was removed and wells washed with Mg2+/Ca2+ free PBS. Cells were 
	   119	  
incubated in Trypsin (1mg mL-1) for 2 minutes at 37°C. Trysinisation was 
halted by addition of FACS media, and cells collected and centrifuged 
(1000rpm for five minutes). Excess media was decanted, and the resultant 
cell pellet re-suspended in 50μL of NSM+P. 50μL of anti-p75 FITC-
conjugated primary antibody (Eurogentec) was added, gently mixed and left 
on ice for 1 hour. Cells were centrifuged (1000rpm for 5 min), re-suspended 
in 500μL fresh NSM+P (DMEM F12, N2, B27, Primocin) and FAC-sorted using 
a Beckman Coulter MoFlow system. Resulting cells were centrifuged 
(1000rpm for five minutes), re-suspended in fresh NSM+P and plated at a 
density of 80,000-100,000 cells per well of a 6 well dish pre-coated with 2% 
fibronectin. Cells were maintained by removal of 1mL media (50% total 
volume) and replacement with 1mL fresh NSM+P every 2-3 days. If cells 
became confluent or began to form neurospheres they were passaged in the 
same manner as chick cells (see Chapter two, Methods), in order to prevent 
aggregation. Prior to transplantation, cells were labeled with a self-
inactivating (SIN) second generation HIV-1 based lentivirus, containing 
mutated Woodchuck Posttranscriptional Regulatory Element (WPRE) 





For this pilot study, a small number of animals (n=10) were examined, with 
the principle aim of finding the optimal time point for cell transplantation 
following contusion injury. Adult (180-200g) female Sprague-Dawley rats 
were used (Harlan laboratories). Female rats were selected on the premise of 
reduced aggression following surgery, as observed from previous 
investigations (unpublished), and to avoid potential gender difference 
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complications in subsequent analyses. 4-5 rats were housed together with 
cage enrichment under a 12 hour light/ dark cycle, with access to food and 
water ad libitum. All experimental procedures were carried out in accordance 
with the U.K. Animals (surgical Procedures) Act 1996. The studies were 
carried out under project license 70/832, held by Professor Stephen B 
McMahon, and under the personal licenses of Dr N James, Dr E Burnside and 
Benjamin Jevans (PIL: 17C771A1E). 
 
3.2.5 Rat surgeries 
 
Contusion injury was induced as previously described (James et al., 
2011). Briefly, rats received perioperative analgesia (Carprofen, 5mg kg-1) and 
were anaesthetized using ketamine (60mg kg-1) and medetomidine (0.25mg 
kg-1) by intra-peritoneal injection, and the thoracic region of their backs 
shaved and cleansed with iodine. Core temperature was maintained at 37°C 
during all procedures using a self-regulating heating blanket. All surgical 
tools were sterilized prior to surgery by autoclaving, and were cleaned and 
heat sterilized between animals. A laminectomy was performed at T10 (with 
the appropriate surgical site identified by the characteristic morphology of 
vertebrae 10), beginning with an initial incision to expose the muscle along 
the vertebrae. A scalpel was used to clean the overlying spinotrapezius 
muscle from the vertebrae, and the adjacent muscle and dermis pulled back 
using retractors. This musculature and the corresponding nervous tissue are 
associated with respiratory function, and so breathing was carefully 
monitored during this stage. Bone nippers were used to carefully remove a 
small portion of the T10 vertebrae to expose the spinal cord, ensuring the 
spinal cord dura remained intact (Fig. 3.2, A). Animals were carefully 
positioned and the spinal column stabilized using Adson forceps, and an 
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impactor probe of an Infinite Horizon Impactor (2.5mm tip, Precision Systems 
Instrumentation, Lexington, KY) was positioned 3-4mm above the exposed 
spinal cord (Fig. 3.2, B). This was used to deliver a controlled force trauma to 
the midline of the spinal cord (130 Kdyne), inducing a mild thoracic injury. 
Rats received two stitches to knit the spinotrapezius muscle together over the 
vertebrae, and sub-dermal sutures to close the initial incision. Atipamezole 
hydrochloride (1mg kg-1), an anesthesia reversal agent, was injected sub-
cutaneously, followed by 3-5mL saline solution. Rats were housed in a 
recovery chamber (water base thermostat 32°C, Thermocare) and carefully 
monitored for signs of distress over 3-4 hours. Following surgery, rats were 
weighed and maintained overnight in a recovery suite with softened chow, 
long neck water bottles and self-regulating heating blankets calibrated at 
35°C. All animals received post-operative analgesia (Carprofen 5mg kg-1) the 
morning after surgery, and antibiotics (Baytril, 5mg kg-1, one week course). 
 
3.2.6 ENSC transplant 
  
Rat-derived ENSCs and their derivatives, labelled with an eGFP lentivirus as 
above, were prepared 2 hours before transplantation. Media was drained, 
cells washed with Mg2+/Ca2+ free PBS and incubated with Trypsin (1mgmL-1) 
for 2 minutes at 37°C. Digestion was halted by addition of FACS media, and 
the cells collected and concentrated by centrifugation (1000rpm for 5 
minutes). Cells were re-suspended in NSM+P and counted using a 
hemocytometer with Alcian Blue to ensure dead cells were not included in 
cell counts. Prior to injection, cells were centrifuged (1000rpm for 5 minutes), 
and the media decanted and re-suspended in NSM+P to a concentration of 
125,000 cells μL-1.  
Animals were randomly assigned to cell transplantation at either 3 
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days post-injury or 1 week post-injury (3DPI and 7DPI, respectively). For each 
condition, n=2 rats were harvested 24 hours post-transplantation, and n=2 
rats were harvested 7 days post-transplantation. A final two rats were used as 
controls. 250,000 cells were injected in total per animal, 125,000 above and 
125,000 below the injury zone. Rats receiving stem cell transplantations were 
anesthetized 3 or 7 days following contusion in the same manner as above. 
Wounds were reopened and the spinal cord re-exposed. Two injections 
(injection depth 1mm), each of 0.5μL of cell solution, were delivered at a rate 
of 200nL min-1 using an ultra micropump III (World Precisions 
Instrumentation, USA) immediately anterior and posterior to the injury site 
(Fig. 3.2, C). Wounds were then closed and animal recovery monitored as 
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Figure 3.2: Induction of contusion SCI using an impactor probe. 
180-200g Sprague-Dawley rats were anaesthetised and shaved. Following a dorsal 
midline incision the spinal column was cleared of musculature and a laminectomy 
performed to expose the SC (A). An Infinite Horizon Impactor was positioned 1mm 
above the cord and a controlled force impact administered to induce a contusion 
injury (B). The surgery site was closed and animals allowed to recover. 3 days later 
animals were re-anaesthetised, the surgical site re-opened and ENSCs injected into 
the SC (C). The overlying musculature was then sutured, and the dermis closed with 
subcutaneous sutures (D). All animals were monitored closely during recovery. 
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3.2.7 Sacrifice and tissue harvest 
  
Rats were sacrificed via intraperitoneal injection of a lethal dose of sodium 
pentobarbitol (Euthatal; 80mgKg-1). Once all reflexes had been lost, but just 
prior to heart failure, animals were fixed via cardiac perfusion. Rats were 
stabilized ventral side up and an A/P midline incision made to expose the 
ribcage. Ribs were cut at the extreme left and right of the animal and the 
ribcage lifted to expose the heart.  A small incision was made in the right 
atrium. The left ventricle was then similarly opened and a perfusion catheter 
inserted. This was clamped in place and 0.9% saline pumped through the 
cardiovascular system to flush blood vessels, followed by 400mL 4% ice-cold 
PFA in 0.1M PBS. Pallid discoloration of the liver, toes and blood vessels 
lining the ribcage were used as markers of adequate perfusion. The spinal 
cord was harvested at the level of T10 (+/- 5mm), along with a sacral spinal 
cord sample, the brain, right lung, right lateral lobe of the liver, right kidney, 
spleen and GI tract. Samples were post-fixed at 4°C overnight and 
subsequently stored in PBS prior to use. Samples intended for PCR were 
frozen in saline at 20°C. 
3.2.8 Cryosectioning 
 
Spinal cord samples were cryoprotected overnight at 4°C in 30% sucrose and 
transferred to OCT (Thermo Scientific, USA). Samples were orientated for 
sagittal sectioning, frozen using -65°C isopentane and stored at -80°C prior 
to sectioning. 
Frozen OCT-embedded samples were sectioned serially (20μm) using a Leica 
Cryostat at -22°C and slides stored at -20°C for further processing. 
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3.2.9 Immunostaining 
 
This investigation was limited to assessment of spinal cord section histology 
and immunoflourescent analysis, sufficient to address the aims of the pilot 
study. Immunostaining protocols were exactly as described previously (see 
Chapter 2). The primary and secondary antibodies used were as follows: 
 
Table 3.1: primary antibodies. 
Protein 
target: 
Host species: Concentration: Supplier: 
TuJ1 Mouse 1:500 Covalence 
GFP Mouse 1:500 Invitrogen 
GFP Rabbit 1:500 Invitrogen 
GFAP Rabbit 1:500 Dako 
Iba1 Rabbit 1:500 Wako 
Ki67 Rabbit 1:500 Novocastra 
  
 
Table 3.2: secondary antibodies.  
Target: Host species: Concentration: Supplier: Emission 
wavelength: 
Rabbit Goat 1:500 Invitrogen 488 
Rabbit Goat 1:500 Invitrogen 568 
Mouse Goat 1:500 Invitrogen 568 
Nuclei (DAPI) N/A 1:1000 Sigma Aldrich 350 
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3.2.10 Eriochrome C staining 
 
Eriochrome C staining was used to demarcate white and grey matter within 
spinal cord sections, allowing quantification of injury parameters. Serial 
sections of a single harvested spinal cord from each group were utilized for 
eriochrome C staining. Slides were thawed at RT, dehydrated in ascending 
EtOH series and cleared in Histochoice. Following rehydration in a reverse 
EtOH series, sections were stained in Eriochrome C solution (0.16% 
Eriochrome Cyanine-R, 0.5% sulphuric acid, 0.4% iron chloride, made up in 
ddH2O). Slides were washed briefly in ddH2O and differentiated in 0.5% 
aqueous ammonium hydroxide. Finally, slides were washed in ddH2O, oven-




Eriochrome C-stained sections were imaged using a Zeiss Axioplan 
microscope mounted with a Zeiss colour camera and analysed using Fiji 
(ImageJ) software. Treatment groups were randomized prior to analysis. If 
required, images were stitched using the MosaicJ plugin (MOSAIC 
Group, Center for Systems Biology Dresden (CSBD), Max Planck Institute of 
Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany). Injury 
cavity area was quantified using the ‘magic wand’ tool, set to a tolerance of 
6. Quantification began at the injury epicenter, designated as the section 
with the largest total cavity area, with the area of the preceding and following 
section also measured (+/- 20μm).
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3.3 Results 
 
3.3.1 In vitro characterization of ENSCs 
 
ENSCs isolated via p75+ FACS sorting were characterized briefly prior to 
transplantation to ensure the correct cell types had been selected. Following 
isolation, cells were plated onto fibronectin-coated culture dishes and 
imaged 1-2 weeks later. Cultures grown for 1 week revealed numerous cells 
with neuronal-like morphology (Fig. 3.3, A), which began to form 
neurospheres after around 2 weeks in culture (Fig. 3.3, B). Cultures were 
fixed, and subsequent immunofluorescent investigation revealed that the 
majority of these cells were TuJ1+ neurons (Fig. 3.2, C), though notably, 
several also stained positive for the proliferation marker Ki67 (Fig. 3.2, D), 
indicating that a sub-population of these were still capable of division, and 
therefore likely maintained a stem cell state to some degree.  
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Figure 3.3: In vitro analysis of cell morphology/behaviour and 
proliferation/differentiation potential of cultured rat-derived 
ENSCs.  
Following FACS, cell cultures display a characteristic neuronal morphology by 1 
week in culture (A), and form dense neurospheres by around 2 weeks (B). The vast 
majority of cells stain positive for the pan-neuronal marker TuJ1 (C), indicating 
extensive neuronal differentiation. A small number of dividing cells was also found, 
as revealed by Ki67+ staining (D). Scale bar – A: 200μm, B: 100μm, C: 100μm, D: 
50μm. 
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3.3.2 Eriochrome C staining reveals progressive cavity formation with time 
post-injury 
 
More than 50% of human spinal cord injuries are classed as ‘incomplete’ 
(National Spinal Cord InjuryStatistical, 2014), referring to a degree of spared 
white matter. As well as facilitating varying degrees of sustained motor/ 
sensory function after injury, these spared tracts may provide limited 
structural/ biochemical substrate to support regeneration. Therefore, the 
ability to distinguish between grey and white matter is of key interest in 
tracking regeneration following spinal cord injury. Eriochrome C staining of 
serially sectioned spinal cords revealed clear distinction between grey and 
white matter (Fig. 3.4), (white matter showed intense blue staining, grey 
matter showed more modest blue staining), and extensive eriochrome C 
negative areas of neurodegeneration (Fig. 3.4, A). At the earliest stage 
examined (transplanted 3DPI, harvested 24 hours after transplantation) 
almost no cavitation was observed, whereas in all other animals (harvested at 
least one week post-injury) areas devoid of all staining could be detected, 
representing ongoing cavitation (Fig. 3.4, B, C, D). Injured tissue (demarcated 
by eriochrome C negative areas of tissue), and in later stage animals, cavities 
(demarcated by total absence of tissue, Fig. 3.4, B, C, D, arrows), appeared 
to extend across both grey and white matter. The largest cavity size (1577.2 
μm2) was observed in the rat transplanted 7DPI and harvested 24hours later. 
In comparison, the cavity size of the rat transplanted 7DPI and harvested 7 
days later was diminished (626.9 μm2). 
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Figure 3.4: Histological comparison of SCI histology between 
controls and animals transplanted with ENSCs. 
Eriochrome C staining revealed injured tissue in all animals examined (injury zone 
demarcated by *), with regions of spared white matter seen in all groups. Cavities 
could be seen in all animals harvested >1 week post-injury (B, C, D, 
arrows). Quantification of the total cavity area revealed the largest cavities in animals 
transplanted 1 week post-injury and harvested 24 hours later. Animals transplanted 
at the same stage but harvested 1 week later showed decreased cavity area. Scale 
bar 100μm, n=1.  
 
3.3.3 Transplanted ENSCs survive within the spinal cord, and differentiate 
towards a neuronal lineage 
 
Spinal cord injury severely disrupts normal tissue architecture, including 
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severing of neuronal tracts and destruction of large areas of neuronal cell 
bodies. Serial sections of harvested spinal cord tissue were stained with a 
panel of antibodies to ascertain both the effect of injury on tissue 
architecture, and the survival of ENSCs post-transplantation. Antibody 
staining with TuJ1, a pan-neuronal marker, revealed clear distinction of grey 
and white matter, and clearly demarcated damaged tissue around the lesion 
(Fig. 3.5). TuJ1+ staining was observed throughout the cord, with more 
intense staining of the white matter, including multiple linear A/P fibres. 
Regions of TuJ1- staining were observed within the center of the cord, in 
regions of close proximity to the overlying bruise observed at the time of 
harvest (Fig. 3.5). These regions contained extensive DAPI+ nuclei within 
these TuJ1- zones, demonstrating the presence of cells within the injury zone 
at this stage (Fig. 3.5, A, B, D, asterisk. However, these did not stain positive 
for any markers examined.  
At all time points examined, numerous transplanted GFP+ cells were 
found within the spinal cord (Fig. 3.5). Cells displayed a neuronal 
morphology, and area of GFP+ signal did not appear to obviously diminish 
with extended time post transplant. However, cell localization varied 
dramatically depending on time of transplant post injury. Cells transplanted 
three days post-injury and harvested 24 hours later were found within the 
injury zone, occupying what would presumably have been the lesion cavity, 
or surrounding the injury zone in a ‘halo’ (Fig. 3.5, A). Spinal cord tissue of 
animals transplanted 3 days post-injury and harvested 7 days later revealed 
transplanted GFP+ cells forming apparent bridging structures between the 
anterior and posterior ends of the injury zone (Fig. 3.5, B). Cells transplanted 
7 days post-injury, however, were either found anterior to the injury zone, in 
small, distinct clusters, or, in one case, sparsely scattered around the dorsal 
extremities of the spinal cord (Fig. 3.5, C, D). No obvious changes in 
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transplanted cell localization were observed between tissue harvested 24 
hours or seven days after transplantation. Transplanted cells appeared to 
remain connected to one another, with very few ENSCs found in isolation. 
Transplanted GFP+ cells did not occupy the entirety of the lesion site, with 
significant areas of the lesion site occupied by DAPI+/TuJ1-/GFP- tissue (Fig. 
3.5, C). At all time points examined, TuJ1+/ GFP+ cells could be observed, 
implying appropriate neuronal differentiation (Fig. 3.6, B), although it is 
unknown if this differentiation occurred before or after transplantation. 
Additionally, GFP+ cells appeared to align with neuronal tracts, most clearly 
seen in the spinal cord periphery (Fig. 3.6, B, C). Finally, GFP+ cells were 
invariably found continuous with endogenous TuJ1 staining within the injury 
zone, possibly implying reciprocal benefit towards survival. In support of this, 




























Figure 3.5: Comparison of ENSC survival/localization in the 
injured rat SC across the four transplantation time points 
examined. 
Immunostaining of serial spinal cord sections with the pan neuronal marker TuJ1 
(red) reveals the SCI zone (demarcated with an *) and surviving transplanted cells. A 
- GFP+ cells transplanted three days post-injury surround the spinal cord injury zone 
of rats harvested after 24 hours, concentrated at the posterior end. B - spinal cord 
tissue of rats transplanted three days post-injury, and harvested 7 days post-
transplantation. GFP+ ENSCs form bridging connections through the injury zone. C - 
spinal cord sections of rats transplanted seven days post-injury and harvested 24 
hours after transplantation. D – spinal cord sections taken from rats transplanted 
seven days post injury and harvested 7 days post transplantation. Scale bars: A - 
200μm, B, C, D - 500μm. 
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Figure 3.6: Immunofluorescent assessment of differentiation and 
localization of transplanted ENSCs within the injury zone. 
A – GFP+ transplanted cells formed a continuous bridge of cells crossing the injury 
zone. These areas stained positive for TuJ1. Co-labelling was confirmed at higher 
magnification, demonstrating GFP+/TuJ1+ cell bodies and axons (B). Collated tile 
scan images reveal the full extent of tissue injury (TuJ1- regions), including initial 
cavity formation and the degree of spreading from transplantation site. Scale bar – 
A, 200μm, B, 50μm C, 1mm. 
 
3.3.4 Transplanted cells do not exacerbate astrocytic activation, and cross 
the glial scar 
 
Typically following SCI, astrocytes are recruited to the injury site, forming a 
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dense astroglial scar around its periphery which is thought to present both a 
physical (Moeendarbary et al., 2017) and chemical (Silver and Miller, 2004) 
barrier to regeneration. To determine the effect of this glial activation on 
transplanted cells, spinal cord sections were analysed by 
immunofluorescence. GFAP staining was detected throughout the spinal 
cord, with greater staining in the white matter (Fig. 3.7, A). In naïve, uninjured 
animals (harvested 7 days after transplant), transplanted cells were found with 
slightly elevated endogenous GFAP+ staining around the transplant 
periphery (Fig. 3.7, A). This staining appeared comparable (if slightly more 
advanced) to glial activation surrounding the injury zone of animals harvested 
24 hours after injection 3DPI (Fig. 3.7, B). In animals harvested at least seven 
days post-injury, GFAP+ staining appeared more intense, and was 
concentrated around the injury zone (Fig. 3.7, C). Interestingly, in later stage 
transplants where GFP+ cells were not found within or crossing the injury 
zone (injury zone demarcated by asterisks), GFAP staining revealed no 
concentration around the transplanted GFP+ cells, implying that the cells 
themselves do not cause a glial reaction (Fig. 3.7, D, E). Concordantly, GFAP 
staining did not co-localise with transplanted cells: no co-labelled cells were 
found, implying that transplanted ENSCs do not differentiate towards an 
astrocytic lineage (Fig. 3.7, C). When found within the injury zone, GFP+ cells 
were located within, but distinct from, the glial scar; and when found crossing 
the injury zone, GFP+ cells were similarly distinct from GFAP+ staining, 
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Figure 3.7: Assessment of the colocalization of transplanted 
ENSCs with the glial scar. 
Immunostaining of serial spinal cord sections with the astrocytic marker GFAP. 
Cryosections of naïve (uninjured) animals revealed GFAP staining throughout the 
spinal cord. Slight elevation was seen around the transplant periphery (A’’, arrow). B 
- in rats transplanted three days post-injury and harvested 24 hours later, GFAP+ 
staining did not overlap with GFP+ cells (B’’, arrow). C - spinal cord tissue of rats 
transplanted 3 days post-injury and harvested after 7 days post-transplant displayed 
more intense GFAP staining around the border of the injury zone (injury zone 
demarcated with an *). GFP cells cross the glial scar (C’’, arrow). D - spinal cord 
tissue of rats transplanted 7 days post-injury and harvested 24 hours later show 
intense GFAP+ staining around the injury zone periphery, but little GFAP+ signal 
around transplanted cells. E - spinal cord tissue of rats transplanted 7 days post-
injury and harvested 7 days later does not appear to show increased GFAP+ staining 
around transplanted cells, and no GFAP+/ GFP+ cells. Scale bars –200μm. 
  
3.3.5 Transplanted cells survive in the injury zone despite presence of 
activated macrophages, and do not exacerbate an Iba1+ immune 
response 
 
Immune infiltration is a major complicating factor of SCI, with the lesion site 
typically being occupied rapidly by invading macrophages and neutrophils 
(Carlson et al., 1998). Indeed, the presence of these cells is often linked to 
cavity formation (Mietto et al., 2015). To determine the effect of stem cell 
transplantation on immune activation around the injury site, and vice versa, 
harvested spinal cord tissue was stained for Iba1, a macrophage marker. 
Positive staining was revealed weakly (although distinctly) throughout the 
cord, presumably demarcating microglia (Fig. 3.8, D, arrow). In cryosections 
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of naïve (uninjured) animals, Iba1+ staining was detected at the 
transplantation site (Fig. 3.8, A). Staining was intense within the injury zone of 
all animals under examination, revealing numerous Iba1+ microglia both 
within the future lesion cavity and surrounding the scar (Fig. 3.8, B, C, E). The 
staining intensity appeared to partially diminish with time post-injury (Fig 3.8, 
E, compare staining around transplanted cells with Fig. 3.8, A). Interestingly, 
these Iba1+ cells did not overlap with areas of GFP+ staining in the injury 
zone. Indeed, in cases where GFP+ cells were found within the injury zone, 
Iba1+ cells were found surrounding, but never continuous with, transplanted 
cells, possibly implying that transplanted ENSCs can survive in the presence 
of Iba1+ cells (Fig. 3.8, B). Similarly, when GFP+ cells were observed crossing 
the injury zone, they appeared to either cause, or exploit an existing gap 
between the surrounding Iba1+ cells (Fig. 3.8, C). Of note, in later stage 
transplants where GFP+ cells were found adjacent to the injury zone, Iba1+ 
staining was not found to be more intense around transplanted cells than in 
the rest of the cord, implying that, similar to GFAP staining, the presence of 
transplanted cells per se does not cause an immune reaction (Fig. 3.8, E, 
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Figure 3.8: Assessment of the degree of immune cell activation 
in response to ENSC transplantation. 
Throughout the spinal cord, low levels of Iba1+ ramified cells can be seen, with 
concentrated Iba1+ staining within the spinal cord injury zone (asterisks) revealing 
extensive macrophage-based immune activation, usually demonstrating a rounded 
morphology. A – cryosections of naïve (uninjured) animals reveal Iba1+ cells 
throughout the cord, displaying a ramified morphology. Iba1+ staining is increased 
in areas of transplanted cells. B – tissue harvested 4 days after injury, before cavities 
have completely formed, Iba1+ cells can be seen extensively within and around the 
injury zone. Iba1+ cells do not appear to occupy the same space as transplanted 
cells (arrow, A’’). C – tissue harvested 7 days after transplantation at 3DPI reveal the 
beginnings of cavity formation, with dense clusters of Iba1+ cells prolific throughout 
the injury zone. Iba1+ cells (arrow) did not consistently surround GFP+ transplanted 
cells (arrowhead). D – GFP+ transplanted cells survived distal to transplantation site, 
despite presence of activated Iba1+ cells. E – tissue harvested 7 days after 
transplantation 7DPI, in which GFP+ cells were found anterior to the injury zone, 
revealed intense Iba1+ staining around the injury zone, but did not show similar 
staining surrounding transplanted GFP+ cells. Scale bar 500μm. 





The contusion rat model utilized here resulted in a clear injury zone as 
demarcated by eriochrome C and TuJ1 staining, which revealed both early 
cavity formation and surrounding injured tissue. Although tissue within the 
injury zone was TuJ1- (likely reflecting neurodegeneration) with a surrounding 
glial ‘scar’ and Iba1+ inflammation, DAPI staining revealed the presence of 
cell nuclei within the injury zone, indicating cavity formation was poorly 
advanced. Such absence of cavitation is to be expected following a mild 
contusion injury (Cheriyan et al., 2014), and is in accordance with study 
design and aims. Therefore this study demonstrates for the first time the 
ability of transplanted ENSCs to survive within the SCI zone of adult rats, 
differentiate towards an appropriate lineage, and potentially integrate with 
endogenous cells to form bridges across the injury zone. With this important 
information, we subsequently progressed to a larger study, as described in 
Chapter 4.  
 
3.4.2 Eriochrome C staining allowed for quantification of lesion histology 
 
Here we sought in part to identify appropriate analyses upon which to base a 
larger study. Erichrome C staining was selected to determine clear 
demarcation of the grey and white matter, and to allow quantification of a 
range of injury markers, including cavity size. While this pilot consisted of an 
n of 2, therefore ruling out statistical analysis of the results, the data collected 
clearly showed that the methods selected could allow robust quantification 
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providing greater experimental replicates. In particular, cavity size was seen 
to vary between groups. The decrease in cavity size of rats transplanted 7DPI 
and harvested 7 days later, compared to rats transplanted 7DPI and 
harvested 24 hours later may reflect a neuroprotective effect of transplanted 
cells. However, this could also simply reflect variability between animals. 
Greater n numbers will be required to address such potential for variability. 
 
3.4.3 The developing glial scar restricts ENSCs from the injury site 
 
As well as the simple question of whether transplanted ENSCs survive in the 
spinal cord, this study revealed important information regarding the 
behaviour of transplanted cells within the injured spinal cord. Cells 
transplanted at 3 days post injury appeared to localize within the injury zone, 
possibly forming bridging structures across the injury, aligned along the 
anterior-posterior axis, with increasing length of time between cell 
transplantation and tissue harvest. Cells transplanted 1 week post injury, 
however, were found adjacent to the injury zone or scattered sparsely in 
dorsal-most tissue sections. This discrepancy is perhaps most likely 
attributable to injury zone maturation. The vast majority of stem cell 
transplantations into the injured spinal cord have been targeted at the acute, 
rather than chronic phase of spinal cord injury, and it has largely been found 
that transplantations within the acute time frame are able to induce motor 
recovery, an effect not usually observed following chronic transplantations 
(Cusimano et al., 2012). While the chronic phase is typically designated as 
weeks after the initial injury (Kjell and Olson, 2016), this is an arbitrary 
designation, with the injury process likely taking place as a graded 
progression. With increasing time post injury, exponential numbers of 
astrocytes are recruited/ produced at the injury zone, with glial scar formation 
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beginning between 1-2 weeks after injury (Kjell and Olson, 2016; Loy et al., 
2002). As numbers of these cells grow, so does the concentration of 
inhibitory molecules they produce, such as chondroitin sulphate 
proteoglycans (CSPGs) (Morgenstern et al., 2002). Additional cells are also 
recruited to the scar, including fibroblasts (Fawcett and Asher, 1999). Cell 
degradation continues to occur within the injury zone, scattering cell debris, 
including myelin degradation products, which are detectable in the rat spinal 
cord around 7 days post-injury (Yang et al., 2017). Finally, immune infiltration 
is known to undergo ‘peaks’ during the transition from acute to chronic 
stages, including a particular increase in neuroinflammation at around 7 days 
post-injury in rats (Beck et al., 2010). Thus, as time progresses post injury the 
injury zone becomes a progressively more toxic environment, and forms a 
greater barrier in terms of both physical and chemical properties. It is 
probable that this accumulation of cell-toxic material is responsible for the 
inability of cells transplanted at later stages to enter, occupy or bridge the 
lesion. It is also possible that with increasing time post injury, the worsening 
‘bruise’ seen on the dorsal side of the spinal cord makes targeting of cell 
transplantation more difficult, possibly resulting in injections more distally 
both anterior and posteriorly than would be optimal, meaning transplanted 
cells would have further to migrate to reach the injury zone. 
Importantly, the vast majority of transplanted cells were found in, or 
adjacent to, the injury zone. Very few cells were found more diffusely 
throughout the spinal cord, and such cells were usually in sections 
immediately before or after the injury zone. In the case of transplants 7 days 
post-injury, small clusters of cells were found on the spinal cord periphery. In 
addition to demonstrating that there may be a ‘window’ of transplantation 
efficacy before this time, this potentially demonstrates that cells not actively 
engaged in the injury zone are either passively forced out of the lesion site, 
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or actively leave it and survive in more favorable conditions. Therefore, any 
extended study should look carefully for undesirable cell spread both within, 
and external to, the spinal cord. 
 
3.4.4 Transplanted ENSCs form bridging structures 
 
In addition to providing preliminary data to determine the optimal time of 
transplant, this pilot study yielded many findings encouraging a more 
extensive study, and highlighting the value of conducting behavioral studies 
in such an extended scenario. Firstly, the differentiation of transplanted cells 
towards a neuronal lineage; the propensity of these cells to align with 
endogenous TuJ1+ tracts where present; and the formation of anterior-
posterior structures through the injury zone, heavily implies the potential of 
transplanted cells to form ‘bridges’ for regenerating axons to follow. Previous 
studies have extensively demonstrated that such cell bridges can allow the 
regeneration of axons across the lesion site, often resulting in an 
improvement in motor ability post-injury (Ziegler et al., 2011). Following 
transplantation at 3 days post-injury, both rats harvested at 24 hours post-
transplantation revealed GFP+ transplanted cells localized to the centre of 
the injury zone, while both rats harvested 7 days post-transplantation showed 
cells aligned along the anterior-posterior axis, with cells appearing to cross 
the injury zone boundary to reach spared endogenous tissue. With such small 
’n’ numbers, and based on such a short time frame between harvest points, 
although it is difficult to say conclusively, it is possible that transplanted cells 
are extending further throughout the injury zone with time. It would be 
interesting to see whether this trend continues, and to what extent, during an 
extended study. The lack of significant numbers of isolated GFP+ cells 
implies that transplanted ENSCs are maintaining a behavior observed during 
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ENS development. During development ENCCs are seen to largely maintain 
physical connections with other ENCCs as they migrate (Young et al., 2014). 
Cells that become detached usually ’wander’ - decreasing in migration speed 
relative to ‘connected’ migrating ENCCs, until the migration wave front 
catches up with them. As well as demonstrating that migration within spinal 
cord tissue, as opposed to the mesenchymal-derived tissue these cells have 
evolved to respond to, does not seem to affect their usual behaviour, this 
provides further evidence that these cells would be able to form an intact 
bridging structure for axonal regeneration across the injury zone.   
In this study, the fate of transplanted cells was limited to TuJ1. 
However, based on initial in vitro results demonstrating the presence of 
dividing ENSCs, it would be beneficial in future studies, to determine firstly, if 
any cells continued dividing following transplantation, and secondly, the fate 
of any such cells, including differentiation towards particular neuronal sub-
populations, such as motor or sensory neurons. 
 
3.4.5 ENSCs are able to cross the glial scar, and did not differentiate 
towards a glial phenotype 
 
 A key result highlighted by the present study was the low astrocytic 
response to transplanted cells. Cryosections taken from rats transplanted 3 
days after injury show cells within the injury zone, surrounded by GFAP+ 
endogenous tissue. However, as highlighted by cryosections of rats 
transplanted 7 days after injury, where transplanted cells were found 
excluded from the injury zone, no obvious increase in GFAP+ staining was 
observed surrounding transplanted cells compared with adjacent tissue. This 
suggests that transplanted cells within the injury zone were not causing/ 
exacerbating the endogenous glial reaction. While slightly elevated GFAP+ 
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staining was observed surrounding transplanted cells in naïve (uninjured) 
animals, this staining intensity appeared reduced compared to that seen 
surrounding the injury zone of injured animals. It is therefore possible that 
this lower astrocytic activation was caused by damage resulting from the act 
of transplantation itself. However, this will have to be examined in greater 
detail to determine conclusively the effect of transplanted cells on 
astrogliosis. 
This study also found several instances of transplanted cells that 
appeared able to cross the glial scar (as demarcated by GFAP staining) to 
reach spared spinal cord tissue. It is possible that transplanted cells were only 
exploiting pre-existing ‘gaps’ in the surrounding GFAP+ cell scar, in which 
case it will need to be determined whether these ‘opportunistic bridges’ are 
maintained long enough for endogenous axonal recovery along them. If 
transplanted cells were actively able to cause glial scar breaches, then this 
would be also be a key finding - the glial scar presents both a physical and 
chemical barrier to regeneration (Silver and Miller, 2004). If transplanted 
ENSCs are able to effectively ’ignore’ this limitation it may dramatically 
increase the likelihood of endogenous axonal regeneration across the injury 
zone. Previous reports documenting the ability of transplanted cells to cross 
the glial scar have also detected endogenous axonal regeneration through 
transplanted cell bridges (Ramon-Cueto et al., 2000). 
In addition to effects on endogenous astrocytic activation, the 
possibility of transplanted cells themselves differentiating towards an 
astrocytic lineage, and therefore exacerbating SCI pathology must be 
examined. Previously published data has shown that transplanted cells often 
differentiate towards a glial lineage, with some even going as far as to 
suggest that astrocytic differentiation may be the default pathway following 
transplantation into the injured spinal cord, potentially contributing to glial 
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scar formation (Kang et al., 2012; Nakamura and Okano, 2013). In this pilot 
study, it was found that transplanted cells do not appear to differentiate to 
an astrocytic-like lineage, as indicated by an absence of GFP+/GFAP+ cells. 
Therefore, it is unlikely that transplanted cells are contributing to any 
significant degree to the development of the glial scar. 
Given that two of three requirements for a cell-based bridge strategy 
are the ability to integrate into endogenous tissue, and to not stimulate a 
glial scar reaction (Fawcett, 2008), the importance of transplanted ENSCs 
’crossing’ the scar while apparently causing no obvious increase in GFAP+ 
staining (including a lack of transplanted cell differentiation towards an 
astrocytic lineage) cannot be underestimated. An extended study could 
provide an ideal setting to assess this ability, and possibly test methods to 
enhance glial scar breaching. Double labelling with GFAP and TuJ1, in 
addition to GFP labelled transplanted cells, would reveal both scar 
breaching/exploitation, provide further data supporting the lack of scar-
reaction to transplanted cells, and demonstrate endogenous or transplant-
derived axonal regeneration across the scar. 
 
3.4.6 ENSCs did not enhance the immune response, as detected by Iba1 
 
This study utilized immunocompetent rats to receive allogenic cell 
transplantation. A particularly interesting finding, therefore, was the lack of 
increased macrophage activation or proliferation detected by Iba1 
immunostaining following cell transplantation in injured animals. Similar to 
detection of astrocytic reaction in response to cell transplantation, the lack of 
increased Iba1+ staining surrounding transplanted cells located outside of 
the injury zone, compared to the Iba1+ staining surrounding transplanted 
cells within the injury zone, suggests that the transplanted cells themselves 
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are not causing an overt immune reaction. Additionally, levels of Iba1+ 
staining within the injury zone of rats transplanted 3DPI (where transplanted 
cells were found within the injury zone) appeared similar to levels of Iba1+ 
staining within the injury zone of rats transplanted 7DPI (where transplanted 
cells were found outside of the injury zone). This suggests that levels of Iba1+ 
cells within the injury zone are not increased in the presence of transplanted 
ENSCs. It must be noted that in naïve (uninjured) animals, transplanted cells 
were found surrounded Iba1+ cells. It is very possible, therefore, that at least 
initially, ENSCs do cause an immune response. However, the intermingling of 
Iba1+ cells and transplanted cells was not observed in animals transplanted 
following injury. Since naïve animals were harvested 7 days post-transplant, it 
is possible that the Iba1+ cells surrounding transplanted ENSCs represent 
early migration of macrophages/microglia to the ‘injury’ caused by cell 
transplantation. The lack of such intense Iba1+ staining surrounding 
transplanted cells found apart from the injury zone at the later time point of 2 
weeks following transplantation suggests that the Iba1+ response seen in 
naïve animals may be a transient effect. Nonetheless, this will need to be 
addressed in further detail. 
It is also important to remember that Iba1 does not detect the entirety 
of the immune response, and that other components, such as T cells are 
known to be involved in the immune response following SCI (Beck et al., 
2010; Gattlen et al., 2016; Satzer et al., 2015). These and other components 
of the immune system would need to be examined before concluding that 
transplanted cells do not elicit an overt immune response.  
Even so, the lack of a strong Iba1+ response to transplanted cells in 
injured animals, and the observation that transplanted cells are able to 
survive in an immunocompetent animal, is encouraging. If, after a more 
thorough evaluation of additional branches of the immune response, 
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transplanted cells are found not to increase the injury zone immune reaction, 
it may reduce/avoid the necessity of immunosuppressant treatment for 
patients receiving ENSC transplants, which would be receiving the less 
immunogenic autologous transplants. This will need to be assessed in 
greater detail following an extended study. This is of particular importance 
when considering previous reports of enhanced survival of transplanted cells 
following immunosuppression (Khankan et al., 2016), possibly suggesting a 
rejection of transplanted cells using allogenic transplants. Additionally, both 
the lack of increased Iba1+ staining within the injury zone of animals with 
transplanted cells found within the injury zone compared to those with 
transplanted cells outside of the injury zone, and the observation that cells 
appeared able to survive in the presence of Iba1+ cells, encourages further 
testing of the ability of transplanted ENSCs to survive in/modulate the 




This pilot study reveals that transplanted ENSCs possess many properties 
that will likely prove advantageous for SCI recovery. Transplanted cells 
survived within, and formed bridging structures through, the hostile 
environment of the SCI zone. GFP+ staining within the injury zone 
overlapped with endogenous TuJ1+/GFP- staining, implying a possible 
synergistic relationship encouraging survival through possible formation of 
‘bridges’. Concordantly, transplanted ENSCs appeared to cross the glial scar, 
and co-labelled for TuJ1, demonstrating differentiation to appropriate 
lineage. Finally, transplanted ENSCs did not seem to cause overtly increased 
activation or proliferation of astrocytes or macrophages/ microglia.  
  These findings support an extended, long-term rat study of ENSC 
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transplantation into the spinal cord following injury. Further, they provide key 
insights into the planning of such a study. Cells survive transplantation, and 
based on the findings of this pilot study, transplantation 3 days post-injury 
appears to yield the desired outcome of finding cells within the injury zone, 
either occupying the lesion cavity or crossing the scar. This time point will 
therefore be utilized in further studies. As ENSCs survived in the spinal cord 
despite the presence of Iba1+ cells, immunocompetent Sprague Dawley rats 
will continue to be used. Additionally, based on the incomplete occupation 
of the injury zone by transplanted cells, it would be advantageous to increase 
the number of transplanted cells to achieve the best possible chance of 
observing a positive effect on locomotor recovery. As mentioned previously, 
the contusion model selected allows for graded injury severities. As expected 
in animals suffering a mild contusion, rats in this study developed very mild 
cystic cavitation, which proved quantifiable through erichrome C staining and 
area thresholding using Fiji software. With the knowledge that transplanted 
ENSCs can survive in a SCI environment, we can now progress to a more 
severe, cavity-causing contusion. Finally, the presence of a select few clusters 
of transplanted cells, particularly in tissue harvested from spinal cord 
transplanted seven days post-injury, reveals the need to assess cell spread 
both within the spinal cord, and to external tissue sites, providing important 
information as to the safety of ENSC transplantation. 







4 Chapter four – An Histological and Behavioural Assessment of 
the Therapeutic Benefit of Enteric Nervous System Stem Cell 
Transplantations into the Injured Rat Spinal Cord  
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4.1 Introduction 
 
Results of the preceding chapter demonstrate that ENSCs transplanted into 
the SC following a mild contusion injury survive up to 2 weeks post-
transplantation. This is an encouraging basis for a larger study. Despite their 
paracrine benefits towards endogenous recovery, survival of mesenchymal 
stem cells following transplantation into the injured spinal cord has typically 
been poor, with few cells found up to one month after transplantation (Arai 
et al., 2016; Boido et al., 2014; Ruzicka et al., 2017). In contrast, NSCs have 
been shown to survive for extended periods of time post-transplantation 
(Dulin and Lu, 2014; Ide and Kanekiyo, 2016). Such long-term survival of 
grafted cells may well represent a key factor in stem cell-based SCI recovery. 
Axonal regeneration speed has been shown to vary across various anatomical 
domains of the central nervous system, with regeneration through the dorsal 
root averaging 2.1+/-0.5mm day-1 (Wujek and Lasek, 1983). In support of this 
finding, many studies did not observe any difference in functional outcomes 
before 3 weeks post-transplantation, possibly reflecting the time needed for 
axons to extend far enough to impact on functional improvement (Kadoya et 
al., 2016; Keirstead et al., 2005; Pan et al., 2008). Typically, such studies 
noticed small changes after the first few weeks, which increased progressively 
with time. Although the extensive survival of ENSCs post-transplantation 
observed in the previous chapter is encouraging, there is a need to 
determine whether transplanted ENSCs would survive for a similar time to 
that seen following NSC transplantations, sufficient to aid endogenous 
recovery. Additionally, the previous results were obtained from a mild 
contusive injury. As many patients suffer more traumatic injuries, it was 
decided that it would be advantageous to determine if transplanted ENSCs 
were able to survive in a more severe contusive injury model. This would also 
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allow behavioural testing to be conducted in a more relevant model to 
human SCI.  
Stem cell therapy-based therapies for SCI holds great promise in 
terms of cell replacement (Mothe et al., 2008; Ogawa et al., 2002), potential 
modification of the inhibitory micro-environment (Kadoya et al., 2016) and 
endogenous neuroprotection (Mitsui et al., 2005). Indeed, several clinical 
trials have demonstrated the safety of stem cell transplantation into the 
injured spinal cord (Mendonca et al., 2014; Satti et al., 2016) and many are 
currently ongoing, assessing, amongst other things, the functional benefits of 
transplantation. However, while the promising results of numerous studies 
encourage further research into their application, no single stem cell 
treatment has resulted in complete, and permanent reversal of paralysis. This 
suggests the need for additional studies, including combinatorial 
interventions. 
 Extensive work has investigated the utility of a vast array of potential 
treatments, including both stem cell-alternatives and stem cell-enhancers. In 
vitro manipulation of stem cells prior to transplantation has been suggested, 
and the potential to direct stem cells down particular lineages prior to 
transplantation has been demonstrated (Hu and Zhang, 2009; Nistor et al., 
2005). Increasing neuronal differentiation may prove particularly important 
considering differentiation down certain astrocytic lineages has been 
associated with increased allodynia (Klein and Svendsen, 2005). Alternatively, 
numerous studies have shown significant functional benefits resulting from 
stem cell-alternatives, such as modification of the microenvironment. This has 
included both manipulation of the immune response (Lee et al., 2003) and 
extracellular matrix (Stichel et al., 1999). Such modifications may support 
survival of transplanted cells by reducing the difficulty they face to engraft. 
Many such therapies could potentially boost the success of stem cell 
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transplantations. Considering the vast majority of transplanted ENSCs 
differentiated preferentially towards a neuronal rather than astrocytic lineage 
in the previous two chapters, modification of the extracellular environment, 
as opposed to in vitro ‘priming’, was deemed a more appropriate target for 
this study. 
A large hurdle for axons crossing the injury site, and almost certainly 
for stem cells transplanted into the injury site, are the chondroitin sulphate 
proteoglycans (CSPGs). CSPGs consist of a core glycoprotein with variable 
glycosaminoglycan side chains (Kwok et al., 2012; Siebert et al., 2014). At 
least nine CSPG groups have been identified to date, including the common 
extracellular matrix components aggrecan and brevican (Bandtlow and 
Zimmermann, 2000). Indeed, most CSPGs are extracellular, and are secreted 
to exert their functions outside of the cell (Horii-Hayashi et al., 2015). While 
they form components of some tissue types, such as cartilage (Brown and 
Eames, 2016), they are predominantly known for their roles in cell adhesion, 
growth and migration (Silver and Silver, 2014; Yuan et al., 2016a). Of key 
importance, CSPGs are known to play a significant role in neural 
development through their effects on axon growth and guidance (Wiese and 
Faissner, 2015), and in neural health in adulthood through modulation of 
neural plasticity and synapses (Frischknecht and Seidenbecher, 2008; Miao et 
al., 2014). 
CSPGs are known to have roles in CNS repair following damage such 
as stroke (Liu et al., 2014), and have been demonstrated within the SCI zone 
(Asher et al., 2001). More specifically, CSPGs are found in high 
concentrations within the glial scar surrounding a CNS lesion (McKeon et al., 
1991), and indeed, extensive evidence has revealed their secretion by 
astrocytes following activation (Ohtake and Li, 2015; Yu et al., 2012). CSPGs 
have been known to inhibit axon growth for over twenty years (Grumet et al., 
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1993). More recently, this has been shown to be due to an immobilization of 
the growth cone (Silver and Silver, 2014). As stated above, CSPGs have an 
established role in restricting plasticity and maintaining existing circuits in the 
adult CNS. When CSPG expression is increased in the SC lesion the innate 
growth retarding properties of the CSPGs actively inhibit axonal recovery 
(Bradbury et al., 2002). This is largely believed to be due to their usual action 
becoming a hindrance (Bartus et al., 2012), as increased plasticity following 
injury would presumably aid in re-establishing lost circuitry.  
Several groups have shown the growth retarding effect of CSPGs as 
well as the significant improvement in axon re-growth, lesion cavity-reduction 
and indeed, functional gains following CSPG degradation (James et al., 2015; 
Moon et al., 2001). In particular, degradation of CSPGs has focussed on 
injection of the bacteria-derived enzyme chondroitinase ABC (ChABC). Early 
work demonstrated the ability of ChABC to increase axon growth in vitro, in 
SC explants taken from injured animals (McKeon et al., 1995). Following this, 
the ChABC gene was selectively cloned into plasmids and lentiviruses for 
injection into the injured SC (Bartus et al., 2014; Muir et al., 2010). Viral 
ChABC injections into the spinal cord following injury have resulted in a 
marked decrease in cavity size, increased axonal regeneration (see Fig. 4.1 
for proposed mechanism) across the lesion and a functional improvement in 
locomotor abilities. These results are incredibly encouraging, and 
demonstrate the importance of such chemical modulators of the injury zone. 
Subsequently, the ability of ChABC to break down CSPGs in vitro has been 
demonstrated (Crespo et al., 2007). In this study, cells transfected with the 
ChABC-containing lentivirus demonstrated the ability to synthesize and 
excrete the ChABC protein to degrade extracellular CSPGs. 
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Figure 4.1: Proposed mechanism of axonal extension following 
ChABC treatment. 
Endogenous axons are unable to re-cross the injury site following injury, at least in 
part because of the accumulation of inhibitory CSPGs within the glial scar. CSPGs 
consist of a proteoglycan core with multiple chondroitin sulphate (CS) side chains. 
ChABC, a lysase with broad specificity, degrades glycosaminoglycans such as 
CSPGs to disaccharides. Products of this digestion include C4S. Such degradation 
removes the inhibitory properties of CSPGs, allowing axons to extend through the 
glial scar (Prabhakar et al., 2005a; Prabhakar et al., 2005b). 
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Here it is proposed that co-application of a CSPG inhibitor with stem 
cell transplantation will increase cell engraftment and encourage increased 
bridging, and thinning of, the glial scar, thereby allowing enhanced axonal 
regeneration across the lesion. CSPGs have been previously documented to 
act as inhibitors of neural crest migration, and thus nullifying their effects will 
likely result in increased spreading of transplanted ENSCs across the injury 
site (Henderson and Copp, 1997; Perris and Johansson, 1990). Other studies 
have shown the multiplicative, rather than additive, effect of combining 
treatments, demonstrating the benefit of combinatorial therapies (Sarveazad 
et al., 2017). 
The parameters used to gauge the success of a given study are 
crucially important, and should be tailored accordingly for separate studies. 
In addition to unique desired experimental outcomes, specific desires of 
patients should be addressed. Considering that the most often-cited demand 
of SCI patients is regaining some form of motor function, behavioural 
assessments are as crucial towards demarcating the successes of a project as 
a histological examination (Anderson, 2004). Ladder testing, involving 
navigation of a horizontal ladder with unevenly spaced rungs, has been 
extensively used to assess functional improvements in the motor ability of 
rats following SCI and subsequent treatment (Bartus et al., 2014). However, 
while informative, functional tests such as the ladder test are often not 
sensitive enough to highlight subtle alterations in function arising from 
sparing of white matter tracts or axonal re-growth following stem cell-derived 
bridge formation. For this purpose, tracing can be a powerful tool. Both 
retrograde and anterograde tracing has been used to evaluate increases in 
sensory and motor re-growth, respectively (Hou et al., 2016; Li et al., 2016a; 
Steward and Willenberg, 2017).  
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The experiments in this chapter build upon studies in the preceding 
chapter, including progression to a more severe injury type more 
representative of a typical human SCI; extended survival of animals post-
transplant; testing of a combined ChABC-based viral treatment with stem cell 
transplant; the use of behavioural tests to assess motor improvements; and 
the use of injected tracers to determine extent of axonal bridging across the 
injury zone. 





As in the previous chapter, adult (180-200g) female Sprague-Dawley rats 
were used (Harlan laboratories). 4-5 rats were housed together with cage 
enrichment under a 12 hour light/ dark cycle, with access to food and water 
ad libitum. All experimental procedures were carried out in accordance with 
the U.K. Animals (Scientific Procedures) Act 1986.  
Behavioral testing and histological analyses were conducted while 
blinded to the treatment groups. Randomization assigning animals to 
treatment groups was conducted by a collaborator whom, following the 
initial injury stages, played no further part in the investigation. A total of 26 
animals were used, with n=6 assigned to each of 4 groups (contusion, no 
treatment; contusion, cell transplantation only; contusion, cell transplantation 
and lentiviral injection; contusion, lentiviral injection only) and an additional 
n=2 for the control group. All surviving animals were sacrificed at 16 weeks 
post injury via anaesthetic overdose and cardiac perfusion as per Chapter 3 









	   160	  
 
 Figure 4.2: Study timeline. 
From induction of contusion injury at day 0, the entire study was completed in 16 
weeks. Following post-operative care after the initial injury, rats were re-
anaesthetised 3 days post injury (DPI) and injected with either ENSCs, ChABC, or 
both. 4 days later behavioural testing commenced, and was thence repeated weekly 
until 15 weeks. The following week all animals were sacrificed via anaesthetic 
overdose and cardiac perfusion as per Chapter 3. 
 
4.2.2 Chondroitinase lentivirus 
 
The ChABC gene derived from Proteus vulgaris was modified to include 
mammalian preferred codons in place of five cryptic N-glycosylation sites, 
and an additional mammalian signal sequence (Muir et al., 2010). This was 
sub-cloned into a lentiviral transfer vector driven by the mouse 
phosphoglycerate kinase promoter (LV-ChABC, (Bartus et al., 2014) to create 
an integrating but self-inactivating vector, pseudotyped with VSV-G. Viral 
particles were concentrated to 1.0310GC (genome copies) mL-1 by 
ultracentrifugation and titration via p24 antigen mediated ELISA (lentivirus 
made by Professor Joost Verhaagen (Netherlands Institute for 
Neuroscience).  
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4.2.3 Rat contusion injury surgery 
 
Contusion injuries were conducted as described in Chapter 3. Injury severity 
was increased from mild to moderate by increasing the force applied by the 
impactor probe of an Infinite Horizon Impactor (Precision Systems 
Instrumentation, Lexington, KY) from 130kdyne to 150kdyne. 
  
4.2.4 Injections of viral ChABC 
 
Rats undergoing LV-ChABC (see above) treatment received intraspinal 
injections (injection depth 1mm) immediately anterior and posterior of the 
injury site prior to closing. 0.5μL of LV-ChABC was delivered at a rate of 
200nL min-1 using an ultra micropump III (World Precisions Instrumentation, 
Europe). Wounds were then closed and animal recovery monitored as 
above.  
  
4.2.5 Behavioural analysis 
 
The horizontal ladder test was used as a measure of locomotor ability/ 
recovery (Fig. 4.3). Prior to surgery animals were trained on the task to 
provide baseline data. Starting one week after surgery, testing was then 
conducted on a weekly basis until completion of the study by an examiner 
blinded to the treatment groups. Rats were placed individually onto a 
horizontal ladder 1m in length, with irregularly placed rungs. Rats were 
encouraged to cross the ladder by offering Sucrose/ peanut butter pellets at 
opposing ends. Testing was captured using a Sony DCR-SX30E Handycam, 
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and data was extracted from slow-motion reviews of complete runs made 
from right to left, left to right, and right to left. The number of correct foot 
placements and foot ‘slips' was counted for each run and the number of 
correct placements taken as a percentage of the total number. These scores 




Figure 4.3: Motor recovery following SCI assessed using the 
horizontal ladder test. 
Within 2-3 weeks after injury, the surgery site is barely visible (A). Starting 1 week 
post-injury and transplantation, performance was measured by the ability of animals 
to traverse the horizontal ladder. This consisted of two parallel, transparent Plexiglas 
walls placed approximately 6 cm apart, to prevent animals turning round (B). A 
series of unevenly spaced rungs were placed between the walls, parallel to the floor, 
providing a horizontal ladder for the animals to cross (C). Rats were recorded 
traversing the ladder right to left, left to right, and right to left again, and the results 
averaged. The percentage of correct foot slips was recorded, with hind paws 
slipping between the rungs (D, arrow) taken as a ‘foot slip’.  
 
4.2.6 Axon tracing 
 
To determine the extent of axon regeneration across the injury site both 
retrograde and anterograde tracing was utilized. One week prior to study 
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completion, n=3 of each group were randomly selected. Animals were 
anesthetized and a T12 laminectomy performed as above. A simultaneous C2 
laminectomy was performed using the exact same methodology. The 
anterograde tracer Fluorogold was used to label anterior-posterior 
regeneration, administered using a midline intraspinal injection (injection 
depth 1mm) of Fluorogold at C2 at a rate of 200nL min-1 using an ultra 
micropump III (World Precisions Instrumentation, Europe). Biotinylated 
dextrine amine (BDA) was then administered via an intraspinal injection in the 
same manner at T10. Wounds were closed as above, with identical surgical 
recovery procedures.  
 
4.2.7 Cell survival/ spread quantification 
 
Serial sections of the spinal cord of stem cell-transplanted rats harvested 16 
weeks post-injury were assessed to determine the survival of transplanted 
cells and corresponding spread. GFP antibody-labeled sections were imaged 
using a Zeiss Axioplan microscope mounted with a Zeiss colour camera and 
analysed using Fiji (ImageJ) software. Treatment groups were randomized 
prior to analysis. Images were stitched using the MosaicJ plugin (MOSAIC 
Group, Center for Systems Biology Dresden (CSBD), Max Planck Institute of 
Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany). The 
number of GFP+ cells was quantified using FIJI software. The subtract 
background process was utilized, with a rolling ball of 10 pixels, and 
subsequent application of a median filter set to a 1 pixel radius. Cell number 
was then determined by the find maxima function, with a noise tolerance of 
544. The amount of GFP+ pixels was quantified using the ‘Threshold’ tool, 
set to a tolerance of between 44 and 255 (measurements limited to 
threshold). Quantification began at the first section to contain positive GFP 
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signal, and moved sagittally until the last section containing GFP signal. Each 
section with GFP+ signal was analysed and pooled to give a total, summed 
intensity. For anterior/ posterior and dorsal/ ventral spread, the section with 
the greatest spread was chosen for each rat, and the extent of spread 
determined as the farthest GFP+ signal (cells or projections) in either 
direction. 
 
4.2.8 PCR detection of transplanted cell spread 
 
Cell spread to tissues other than those transplanted into is a potential risk 
following stem cell transplantation. To determine whether such spread 
occurred following ENSC transplantation into the injured spinal cord, 
samples from peripheral organs were analysed by PCR to detect GFP. Post-
mortem organs harvested from transplanted rats included the right medial 
lobe of the liver; spleen; right kidney; and left lung. 10 samples (~30mg) 
were collected at random from each organ for further processing. 
Cryosections of transplanted animals confirmed to contain transplanted 
GFP+ cells by fluorescent microscopy were used as a positive control. 
Positive sections were recovered and genomic DNA extracted in the same 
was as peripheral organ samples. 
 
4.2.8.1 Genomic DNA extraction 
 
~30mg of tissue was dried at RT. Tissue was suspended in 25μL proteinase K 
solution (1μL proteinase K (Sigma Aldrich, UK), 40μL DNA extraction lysis 
buffer (100mM Tris.Cl, 5mM EDTA, 0.2%SDS, 200mM NaCl, pH8)).  
Thermocycling protocol used was as follows: 
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Table 4.1: Genomic DNA thermocycling programme  
Step Temp °C  Time 
1 55 4 hours 
2 85 10 minutes 
 
4.2.8.2 Precipitation of genomic DNA 
 
Cellular debris and other impurities were removed from genomic DNA using 
salt precipitation. 1μL from each of the 10 samples collected from each organ 
were pooled, and this was diluted in3M Na-Acetate and 100% EtOH to a 
final concentration of 0.3M NA-Acetate and 70% EtOH. Samples were 
incubated on ice for 30 min and centrifuged at 14,000g for 30 min at 4°C. 
The supernatant was discarded and the pellet washed in 70% EtOH. Sample 
was centrifuged at 14,000g for 15 min at 4°C, the supernatant discarded and 
the pellet re-suspended in 10μL ddH20. 
 
4.2.8.3 PCR detection of GFP  
 
Table 4.2: PCR primers 
Probe target Primer sequence Product 
size 
Tm 
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1μL of precipitated DNA solution was used for each PCR reaction. Reaction 
volumes, components and concentrations were as for chapter 2. 
 
Table 4.3 Chapter 4 PCR cycling programme 
  
Step Temp °C  Time 
1 94 3 minutes 
2 94 30 seconds 
3 58 45 seconds 
4; go to step 2, 35 
cycles 
72 30 seconds 
5 72 2 minutes 
6 4 Hold 
 
PCR products were analysed by agarose gel electrophoresis. 10μL product 
was loaded into a 2.5% agarose gel (diluted in TAE buffer, with Ethidium 
bromide for visualization), at 160mV for 45 minutes. 
 
4.2.9 Statistical analysis 
 
Except where noted, all analyses were conducted on at least 3 individual 
animals from each group, selected at random by an investigator blinded to 
the treatment groups. Eriochrome C data were analysed by one-way 
ANOVA. Transplanted cell spread and survival, and endogenous retrograde 
axon regeneration were analysed using Student’s t test (two-tailed). 
GraphPad Prism software was used for all statistical analyses. p values of 
<0.05 were taken as significant. All error bars represent standard error. 
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4.3 Results 
 
4.3.1 Transplanted ENSCs survive transplantation, and ChABC lentivirus 
injection resulted in breakdown of CSPGs 
 
Following tissue harvest of spinal cords at week 16 post-injury, success of 
both ENSC transplantation and injection of the ChABC lentivirus were 
confirmed by immunofluorescence. Digestion of CSPGs by the bacterial 
enzyme ChABC was assessed by detection of C4S, a product of ChABC-
mediated degradation of CSPGs. ENSC transplantation and survival was 
confirmed by immunostaining with an anti-GFP antibody. 
Several animals from all four groups were selected in a blinded fashion 
and analysed to ensure results were representative. In both the ENSC + 
ChABC and ChABC-only groups, C4S+ staining was visible throughout much 
of the spinal cord, appearing concentrated around the lesion cavity (Fig. 4.4, 
A and C). The ENSC-only, and no treatment groups, showed no positive 
staining (Fig. 4.4, B and D) (background staining detected in several samples 
appears to be fluorogold ‘bleeding’ through the channels, Fig. 4.4, D). In 
samples treated with both ENSCs and ChABC, transplanted cells co-localized 
with areas of CSPG+ staining, potentially implying that transplanted cells 
themselves had been transduced, or at least that ChABC expressed by 
transduced, endogenous cells was able to reach areas rich in transplanted 
cells.  
 Numerous GFP+ ENSCs were found within the spinal cord. These 
were mostly located at the anterior edge of the lesion, though substantial 
spread towards the posterior limit of the lesion through both dorsal and 
ventral spared tissue was frequently observed (in some animals, simultaneous 
	   168	  
spread both ventral and dorsal to the lesion was noted). Transplanted ENSCs 
were almost invariably found in one or more large clusters, and very rarely 
found as solitary cells. Extensive integration appeared to have occurred, with 
cells found aligned along the A/P axis of endogenous tracts. In several 
animals, transplanted ENSCs were observed to cross the injury zone through 
a dorsal-ventral ‘bridge’ which bisected the injury zone (Fig. 4.4, C).  
Transplanted ENSCs exhibited relatively small, polar cell bodies, and 
extended extensive processes. These projected both towards neighboring 
ENSCs and into the surrounding SC tissue. In several instances, single axons 
were found projecting rostrally from the transplant site for several millimeters. 
The vast majority of ENSCs were TuJ1+, implying the potential for 
integration with SC tissue. Indeed, comparison of corresponding GFP and 
eriochrome C sections revealed that areas of densely populating ENSCs also 
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Figure 4.4: Immunostaining used to determine success of ChABC 
injection and stem cell transplantation. 
Longitudinal cryosections of spinal cords harvested at 16-weeks post-injury were 
analysed for markers indicative of successful treatment. Breakdown products of 
CSPGs, including chondroitin-4-sulfate (C4S) disaccharides, are released following 
ChABC degradation, and can be detected by immunofluorescent staining (B, D). 
Transplanted ENSCs can be visualised within the spinal cord injury zone (C, D). 
Asterisks indicate lesion cavity. Scale bar 1mm.   
 
4.3.2 Combined ENSC and ChABC treatment significantly improves lesion 
histology 
 
The pathology of the spinal cord following injury has been well characterised 
(Tator, 1995). In particular, a central, fluid-filled cavity and surrounding 
preserved tissue are central features. To assess whether stem cell 
transplantation and/or ChABC therapy had any effect on these markers 
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following insult, serial sections were stained with eriochrome C and the area 
of the cavity quantified. Results were statistically analysed using one-way 
ANOVA.  
Eriochrome C staining revealed typical SCI cavities in all rats (Fig. 4.5, 
A-D). Quantification of the cavity area revealed a decrease in the average 
total cavity size in rats treated with ChABC alone, but this was not significant 
(16.29 vs 16.47mm2, p=>0.999). Transplantation with stem cells alone 
resulted in a decrease in cavity area compared to non-treated animals, but 
this was not significant (11.85 vs 16.47mm2, p=0.7453). Interestingly, cavity 
area was dramatically reduced in rats receiving both stem cell transplantation 
and ChABC therapy compared to non-treated animals (2.72 vs 16.47mm2, 
p=0.0309, Fig. 4.5, E). This decrease was also significant compared to 
animals treated with ChABC-only (p=0.084). Only the combinatorial therapy 
of ENSCs and ChABC resulted in a significant decrease in cavity area 
compared to non-treated animals. ANOVA analysis confirmed a significant 
difference between groups F(3, 16)=5.73, p=0.0074). 
Lesion cavities tend to be surrounded by injured tissue, notable in 
both a disrupted organization and poor staining by eriochrome C. The 
significant reduction in cavity size by the combined ENSC + ChABC 
treatment prompted a further analysis of this injured tissue surrounding the 
cavity, to determine whether the reduced cavity area corresponded to an 
expanded area of injured tissue or an expanded area of preserved, uninjured 
tissue (Fig. 4.5, F). Quantification of the area of injured tissue area yielded 
results closely mirroring that of cavity area. ChABC treatment resulted in a 
decrease in the area of injured tissue (27.35 vs 32.72μm2) that was not 
significant (p=0.728). ENSC transplantation resulted in a still greater decrease 
in the total area of injured tissue (21.83 vs 32.72μm2), again this was not 
significant (p=0.213). The combined treatment resulted in the greatest 
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decrease in injured tissue area (17.43 vs 32.72μm2). This decrease was 
significant compared to non-treated tissue (p=0.0408). ANOVA analysis 
confirmed a significant difference between groups (3, 16) = 3.622, 
p=0.0362). 
Taken together, these results imply that the combined treatment 
results in an increase in the area of preserved tissue, by decreasing both the 
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Figure 4.5: Quantification of spinal cord lesion histology using 
erichrome C staining. 
Serial sections of harvested spinal cords harvested from animals sacrificed 16 weeks 
post-injury were stained for eriochrome C and the histology analysed. Area of either 
cavities or injured tissue was measured from the first section in which the lesion 
became apparent until it could no longer be detected. Results were then pooled to 
give total area. In the combined treatment group there was a significant decrease in 
cavity area (p=0.0143). Combinatorial treatment also resulted in a significant 
decrease in the area of injured tissue compared to both the ChABC-only treated 
group and non-treated group. Stem cell transplantation resulted in a decreased 
injured tissue area that was not significant, as did ChABC application. * indicates 
significance (p=<0.05). Scale bar: 500μm. 
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4.3.3 Survival and spread of transplanted ENSCs 
 
The significant reduction in lesion cavity and injured tissue area detected in 
the ENSC + ChABC combined treatment group suggested an increased area 
of preserved tissue. This could be explained by either application of ChABC 
increasing survival/ spread of transplanted ENSCs (thereby reducing the 
lesion cavity by partially occupying it), or by the combined ENSC 
transplantation and ChABC application having a multiplicative effect on 
endogenous tissue survival. To determine any effect of ChABC on ENSC 
transplantation, spinal cord serial sections of rats receiving either ENSCs 
only, or ENSCs and ChABC were stained with an anti-GFP antibody and 
imaged. No significant difference between the ENSCs-only and ENSCs + 
ChABC was detected when cell spread was quantified, including spread 
along the A/P (2294.15 vs 2451.05, p=0.8573, Fig. 4.6, C), D/V (1325 vs 
1025, p=0.3747, Fig. 4.6, D) and L/R (1074.55 vs 815.45, p=0.4335, Fig. 4.6, 
E) planes. The numbers of transplanted ENSCs detected in the two groups 
also was not significantly different (4077.75 vs 2724.5, p=0.167, Fig. 4.6, F). 
Similarly, quantification of the number of GFP+ pixels revealed no significant 
difference between rats receiving ENSCs-only and ENSCs + ChABC 
(542499.22 vs 543940.69, p=0.9956, data not shown). By all parameters 
quantified, co treatment with ChABC had no effect on transplanted ENSC 
survival or spread. 
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Figure 4.6: Quantification of transplanted ENSC spread and 
survival compared between animals treated with ENSCs only and 
animals treated with ENSCs + ChABC. 
At the time of tissue harvest (16 weeks post-injury), numerous GFP+ cells were 
found within both the ENSC + ChABC-treated groups, and the ENSCs only-treated 
group (A, B). Serial spinal cord sections spanning the extent of GFP+ cell detection 
were analysed for cell spread across the anterior/posterior (C), dorsal/ventral (D), 
and left/right planes (E), as well as for cell survival (F). No significant differences were 
detected in any parameter between animals treated with ENSCs + ChABC or with 
ENSCs only. Scale bars: 500μm. 
 
4.3.4 Transplantation of ENSCs results in a significant increase in the 
number of retrograde axons crossing the injury site 
 
These results suggested that the significant reduction of cavity and injured 
tissue area seen in the combined treatment groups was due to increased 
preservation of the endogenous tissue rather than increased survival/ spread 
of transplanted ENSCs. To determine whether this tissue sparing resulted in 
an increased number of tracts bypassing the lesion, transplanted rats were 
injected with retro- and anterograde tracers, below and above the injury site, 
respectively. While BDA tracing proved weak and was restricted to the spinal 
cord periphery, usually not reaching the injury site, fluorogold injections 
resulted in extensive staining of neurons caudal to the injury site and 
substantial staining rostral of the lesion (Fig. 4.7). Morphology of the stained 
cells appeared variable, in terms of both size and number of processes. The 
majority of fluorogold+ cells was often located in the spinal cord centre, 
significantly anterior to the cavity. The number of fluorogold+ neurons rostral 
to the lesion was quantified in at least 3 sections at the injury epicentre and 
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compared across the non-treated, ENSC only, and ENSC + ChABC groups. 
No significant difference was observed between the ENSC + ChABC and 
ENSC only groups (89.95 vs 71.86, p=0.5158, Fig. 4.7, C). However, a 
significant difference was observed between the ENSC transplanted and 
non-treated groups (89.95 vs 34.3, p=0.0111, Fig. 4.7, C), suggesting that 
stem cell transplantation led to increased preservation or sprouting of 































Figure 4.7: Quantification of fluorogold- labelled retrograde 
axons crossing the injury zone. 
Fluorogold, a retrograde tracer, was injected 15 weeks post-injury (1 week prior to 
sacrifice of animals at week 16) caudal to the injury site. Following visualization of 
fluorogold, the number of fluorogold+ cells rostral to the injury cavity was 
quantified. This revealed a significant difference between transplanted and non-
transplanted groups (p=0. 0111). A – tile scan of the injury epicentre and rostral 
spinal cord. Asterisk indicates injury cavity. Box indicates area magnified in B. Scale 
bars: A - 500μm, B - 100μm. No treatment – n=2, ENSCs only – n=2, ENSCs + 
ChABC – n=3. * indicates significance (p=<0.05). 
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4.3.5 Astrogliosis is reduced following ENSC only, ChABC only and ENSC + 
ChABC treatment  
 
Reactive astrogliosis following SCI is a well-known phenomenon (Karimi-
Abdolrezaee and Billakanti, 2012). Immunofluorescent detection of GFAP, a 
protein known to be upregulated following astrocytic activation (Ben Haim et 
al., 2015) was used to determine the extent of glial scarring in response to 
injury. GFAP+ staining was detected in SC sections taken from all groups 
(Fig. 4.8). GFAP+ staining was detected throughout the spinal cord, but was 
concentrated around the cavity perimeter and often the outermost white 
matter of the SC. Staining appeared more intense in the non-treated group, 
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Figure 4.8: Comparison of glial activation between the four study 
groups using immunofluorescent detection of GFAP. 
Longitudinal cryosections of spinal cord harvested 16 weeks post-injury were stained 
for the glial marker GFAP. Immunofluorescent detection of GFAP was strongest in 
the non-treatment group. In all groups, staining was particularly intense at the injury 
zone periphery. GFP+ staining of ENSCs was mostly distinct from GFAP+ astrocytic 
staining. Asterisks indicate lesion cavity, arrows indicate areas of autofluorescent 
material, possibly immune infiltration. Scale bars 500μm. 
 
4.3.6 Assessment of transplanted cell spread to peripheral organs 
 
Undesired migration and tumorigenesis of transplanted cells is a potential 
risk of stem cell-based treatments. No tumours were observed in any of the 
transplanted animals, and mortality was no different compared to non-
transplanted animals over the course of the study. PCR was used to assess 
the spread of ENSC from the transplantation site in the injured spinal cord. 
Taking advantage of the GFP lentiviral label that transplanted cells had been 
transfected with, samples of peripheral organs were analysed for expression 
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of GFP. While all samples revealed expression of GAPDH, only positive 
control samples of transplanted SC revealed expression of GFP, with no GFP 




Figure 4.9: Assessment of spread of transplanted GFP+ cells to 
peripheral organs using PCR. 
Samples of peripheral organs, including the lungs, liver, kidney and spleen were 
harvested from animals that had received transplantations of ENSCs into the SC. 
Genomic DNA was extracted and primers for GAPDH (control) and GFP were used 
to assess the presence of transplanted cells. Genomic DNA extracted from 
cryosections of transplanted rat SC confirmed to have GFP+ ENSCs, were used as a 
positive control (TP SC).  
 
4.3.7 Behavioural analysis 
 
The horizontal ladder test has been utilised previously as an assessment of 
motor function recovery following SCI. Beginning 1 week after injury, rats 
were assessed with this technique weekly up to 16 weeks (Fig. 4.10). All rats 
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gradually improved over the course of the study. The greatest improvement 
was observed in the first three weeks in all groups, with recovery apparently 
slowing after this point. There was no significant difference between motor 












Figure 4.10: Horizontal ladder test measurement of motor 
improvements following SCI and treatment. 
Starting one week after injury inducement and treatment, rats were assessed weekly 
for their ability to traverse the horizontal ladder. The results of three separate runs 
for each rat were pooled and the results expressed as percentage of correct foot 
placements. No significant differences in motor recovery were observed between 
groups (n=6 in each group).
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4.4 Discussion 
 
The complexity of the inhibitory microenvironment within the SCI zone 
provides a plethora of targets for therapies attempting to promote axonal 
regeneration. Treatments aimed at these have resulted in varying functional 
benefits, such as antibodies raised against myelin breakdown products 
(Liebscher et al., 2005). Arguably, one of the most successful approaches has 
centered on the accumulation of CSPGs within the glial scar. These are 
largely secreted by astrocytes within the scar and are thought to have a 
largely negative effect on axon re-growth. It has been exhaustively 
demonstrated that, collectively, CSPGs secreted in response to SCI have a 
negative impact on recovery (Fawcett, 2015; Siebert et al., 2014). Application 
of ChABC following CNS injury has previously been shown to increase 
plasticity and axonal sprouting, most likely through degradation of CSPG-rich 
perineuronal nets (Miao et al., 2014). Therefore, it was hypothesized that 
combinatorial application of ChABC with stem cell transplantation would 
increase either sprouting of transplanted cells, leading to enhanced bridge 
formation, or sprouting of endogenous cells to encourage them to cross the 
bridge formed by transplanted cells. Other authors have proposed similar 
combined treatments (Zhao and Fawcett, 2013). 
 
4.4.1 Effects of single and combined treatment on lesion histology 
 
Previous publications have observed a reduction in cavity size following 
various interventions (Hayashibe et al., 2016; Kim et al., 2017; Sarveazad et 
al., 2014), and it was posited that a similar reduction would follow treatment 
with ENSCs + ChABC. In line with this hypothesis, the greatest effects of 
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treatment on tissue histology were observed in the combinatorial group. 
Dual application of ENSC transplantation and ChABC resulted in significant 
reductions in both cavity area and affected tissue area. The effect of 
combined treatment was far greater than either ChABC virus or stem cell 
treatment alone. We observed no significant difference in the cavity area 
between ChABC only-treated and non-treated groups. Based on previous 
publications, it was expected that ChABC alone would significantly improve 
lesion histology (James et al., 2015). The lack of a significant reduction in 
cavity size may be due to variability in virus batches between the present and 
previous studies. We confirmed CSPG degradation in ChABC treated groups, 
and observed a non-significant reduction in the area of injured tissue in 
ChABC-treated animals compared to non-treated animals. This confirms that 
ChABC is present in the injected cords and has an effect, especially when 
used in combination with ENSC transplantation.  
The results presented here, including the significant reduction in cavity 
and injured tissue area, and the paradoxical lack of significant difference in 
transplanted cell survival, as assessed by cell counting, GFP+ immunostaining 
threshold analysis of transplanted tissue, and transplanted cell spread 
analysis (along either A/P, D/V or L/R planes) implies that the positive effects 
of the combined treatment had instead acted on endogenous tissue. 
Previous stem cell transplantations have resulted in similar preservation of 
injured tissue. Zhou et al demonstrated a similar increase in fluorogold+ 
neurons rostral to the injury site following bone marrow mesenchymal stem 
cell transplantation into the injured SC. Further, they reported that this effect 
was increased following combinatorial application of a second therapy 
(propofol) (Zhou et al., 2015). Barbour et al reported significant increases in 
the number of fluorogold+ neurons rostral to the injury site following 
transplantation of either olfactory ensheathing glia or Schwann cells (Barbour 
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et al., 2013). 
These results are in line with recent publications assessing 
combinatorial effects of ChABC application and stem cell transplantation as a 
therapeutic strategy for SCI. A study by Sarveasad et al tested the effects of 
combining human adipose-derived stem cell transplantation with ChABC on 
SCI pathology and motor recovery. While this study did not quantify lesion 
parameters such as cavity or injured tissue area, the authors observed a 
significant increase in the ratio of myelinated areas within the epicentre and 
the cavity area in the combined treatment group, exceeding the beneficial 
effects of either treatment alone (Sarveazad et al., 2017). The authors noted 
the tendency of mesenchymal-derived cells to reside within the cavity center 
as opposed to integrating into the surrounding tissue, implying that, as in the 
current study, application of ChABC led to beneficial effects through 
modulation of endogenous axons, as opposed to an action on the 
transplanted cells. This study did not, however, examine an effect of ChABC 
on transplanted cell survival. Another study by Fouad et al tested the effects 
of combinatorial ChABC and Schwann cell/OEG transplantation on 
regeneration of specific descending pathways (Fouad et al., 2005). Again, 
these authors observed the greatest effect in the combined group (although 
this study did not measure the effects of a ChABC-only group). Finally, a 
study by Suzuki et al demonstrated similar enhanced benefits of combined 
ChABC and NSC transplantation compared to either treatment alone, 
although this study used pre-treatment of the SC with ChABC to ‘prime’ the 
environment for later injection of stem cells (Suzuki et al., 2017). 
 The results of increased myelination following ChABC application 
observed by Sarveazad et al mirror the increased myelination in areas of 
ENSCs in the current study, as revealed by increased eriochrome c staining. It 
has previously been shown that invading peripheral Schwann cells can 
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remyelinate endogenous tracts following SCI (Beattie et al., 1997). As noted 
in the study by Sarveazad et al, CSPGs are able to inhibit migration, and it is 
probable that ChABC-mediated digestions allow greater ingress of Schwann 
cells to myelinate transplanted ENSCs. 
 
4.4.2 Effect of single and combined treatment on astrocytic activation 
 
Although not quantified, there appeared to be a reduction in 
immunointensity of GFAP staining in all treatment groups compared to the 
non-treated group. Considering astrocytes are the main source of the CSPGs 
found within the glial scar following SCI (Ohtake and Li, 2015; Yu et al., 2012) 
it may seem reasonable to assume that degradation of these CSPGs would 
lead to further activation. The decrease in activation observed could be 
explained by astrocytic response to C4S, the breakdown product of CSPGs. It 
is possible that detection of C4S by astrocytes leads to a negative feedback-
activated down-regulation of CSPG production. Astrocytes contain an 
enzyme responsible for the degradation of C4S, arylsulfatase B (Zhang et al., 
2014). It has been demonstrated in in vitro models of brain injury that 
astrocytes modulate the activity of arylsulfatase B in response to injury state, 
either causing and/ or in response to increasing levels of CSPGs/C4S. It is 
possible that astrocytes interpreted increased levels of C4S as increased 
levels of total CSPGs, leading to a reduction in astrocytic activity in ChABC-
treated groups. Similar ChABC-mediated astrocytic reduction has been 
recorded by previous studies (Suzuki et al., 2017). Stem cell transplantation 
has also been shown previously to result in a decrease in astrocytic activation 
(Novikova et al., 2011), similar to the results observed in the current study. 
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4.4.3 Motor recovery following treatment 
 
While there appeared to be a consistent trend towards increased motor 
recovery in the group receiving both ENSC transplantation and ChABC 
treatment, this was not statistically significant. Previous publications have 
noted significant improvements in motor recovery following either stem cell 
transplantation (McDonald et al., 1999), ChABC application (James et al., 
2015) or a combined treatment (Sarveazad et al., 2017). Considering the 
combined treatment groups in the present study resulted in a significant 
reduction in cavity and injured tissue area, and that the number of 
fluorogold+ neurons traversing the injury site was likewise significantly 
increased in the ENSC-transplanted group compared to the non-treated 
group, the lack of any significant improvement in motor outcomes is perhaps 
surprising. However, it is worth noting that other studies have demonstrated 
significant improvements in one behavioral test (the open field BBB) but have 
then shown no significant improvement in the horizontal ladder test (Barbour 
et al., 2013). Thus, it is plausible that improvements in motor function were 
masked in the current study, and additional tests would have been required 
to discern them. Additionally, it has been previously shown that ChABC 
treatment resulted in significant motor improvements in severe, but not mild 
contusion injured rats (Caggiano et al., 2005). The authors did note a 
significant improvement in rats with a moderate contusion injury receiving 
ChABC, but the method of inducing injury varied between the current study 
and that by Caggiano et al (impact probe VS forceps compression of the 
spinal cord, respectively), making a direct comparison difficult. Thus it is 
possible that the injury induced in the current study was too mild to notice an 
effect. The timing of the treatment may also be key. James et al noticed a 
significant improvement in performance on the horizontal ladder following 
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treatment of moderately contused animals with ChABC, using the same 
methodology as the current study (James et al., 2015). Importantly, however, 
James et al administered ChABC immediately after inducing the injury, 
whereas in the current study, treatment was delayed by 3 days.  
 
4.4.4 Cell spread 
 
Transplanted ENSCs in the current study spread up to 4.2mm along the A/P 
axis. This spread is in line with that noted by McCann et al following 
transplantation of ENSCs into the colon (5.46±0.5mm2) (McCann et al., 2017). 
However, post-acquisition mapping in the study by McCann et al, including 
deep-focussing through the entire tissue thickness, revealed that the longest 
spread in a single direction was actually 10.79mm. This disparity 
demonstrates the pitfalls of tissue sectioning. It is highly plausible that in the 
current study, axons extending from transplanted ENSCs traversed across 
individual sections, preventing them from contributing to the recorded 
spread. This could be more comprehensively assessed, by example, by tissue 
clearing to allow whole spinal cord samples to be analysed by 
immunofluorescence and subsequent microscopy.  
The length of spread observed in the current study is also in line with 
transplantations of stem cells into the SC. Previous studies have observed 
spread of around 3-4mm following transplantations of dissociated human 
embryonic SC tissue (Wictorin and Bjorklund, 1992). Lepore and Fisher noted 
cell migration of up to 10mm following foetal stem cell transplantation, and 
up to 15mm following transplantation of co-cultured neuronal and glial 
progenitors (Lepore and Fischer, 2005). However, while the authors did not 
offer an average length of cell spread, they noted that it was highly variable, 
with some grafts showing only modest migration. Unfortunately, the vast 
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majority of stem cell transplantations do not quantify the spread of grated 
cells/cell-projections, instead mostly quantifying the re-growth of 
endogenous axons into the grafted cells and beyond (Kadoya et al., 2016). 
However, it is likely that both endogenous and graft-derived growth are 
important. Graft-derived axons extending into the endogenous tissue form 
an integrated bridge and may dilute the repulsive nature of the glial scar by 
crossing it. Further, extensive axonal growth of transplanted cells may 
encourage the same from endogenous cells, and provide paths leading both 
into and across the injury site. 
Of note, there have been reports of greater spread. Lu et al observed 
extension of axons up to ~20mm (Lu et al., 2012). This impressive growth was 
seemingly brought about, at least in part, by the combinatorial application of 
fibrin scaffolds supplemented with a cocktail of growth factors including 
BDNF and GDNF among many others. It is possible that similar axonal 
growth could be induced from transplanted ENSCs if similarly supplemented. 
The authors also transplanted human NSCs into a rat model of SCI and found 
axons extending up to 9cm, an unprecedented level of growth (Lu et al., 
2014). However, as was demonstrated by transplantations of human glia into 
mouse shiverer models, human glia have an ability to outcompete murine 
cells (Windrem et al., 2014). It is entirely possible, and indeed maybe even 
likely, that a similar effect is occurring following transplantation of human 
cells into the injured SC, considering the dramatic difference in these two 
studies which differed predominantly in the cell species transplanted. Indeed, 
it has even been shown that, in the shiverer model, human glial restricted 
progenitors are better able to rescue the phenotype and extend animal 
lifespan than their murine counterparts (Lyczek et al., 2017), further 
suggesting that the increased axonal growth of human axons compared to 
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murine may be due to species differences, and therefore unlikely to translate 
clinically. 
 
4.4.5 Safety of ENSC transplantation 
 
Tumorigenesis following stem cell transplantation is a recognized concern 
and a limiting factor of many stem cell applications. In a recent publication by 
Hirota et al, teratomas were observed in nearly a third of mice transplanted 
with iPSCs (Hirota et al., 2017). Indeed, careful assessment of teratoma 
formation following stem cell transplantation has been stated as vital for 
progression of a given stem cell therapy (Lukovic et al., 2014), and specific 
studies seeking to reduce tumerigenicity have been published (Fuhrmann et 
al., 2016). For this reason, the current study examined peripheral organs for 
obvious tumour formation, and finding none, conducted a more in depth 
PCR analysis of GFP expression (indicating the presence of GFP lentiviral-
labelled ENSCs) in the lung, liver, kidney and spleen. GFP expression was 
only detected in transplanted SC tissue. These results are in line with 
previous results published by our group, in which long-term safety of ENSC 
transplantations into the ENS was assessed (Cooper et al., 2016). It should be 
noted that the current study has not ruled out a teratoma-driving effect of 
transplanted ENSCs on endogenous cells, although no tumours were noted 
in any animals under study. While an extended study of survival post-
transplant will be necessary to provide further certainty of a lack of teratoma 
formation (as in the study by Cooper et al (up to 24 months)), these results 
provide initial evidence of the safety of ENSC transplantation into the SC. 
 
	   190	  
4.4.6 Conclusions 
 
Dual application of ENSCs and ChABC resulted in significant improvements 
in lesion histology surpassing those of either treatment alone. Combined 
application of ChABC and ENSCs resulted in similar survival and spread of 
transplanted cells compared to transplanted ENSCs-only. Further, both 
treatments increased the number of retrograde axons crossing the injury site, 
and reduced the amount of reactive astrogliosis occurring in the injury zone.  







5 Chapter five: Overall Discussion and Future Directions 
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5.1.1 Summary 
 
Work in this thesis clearly demonstrates the potential of ENSCs for SCI 
therapy. In vitro studies using the chick demonstrated the potential of ENSCs 
to produce and replenish the neuronal subtypes lost to SCI, and provided 
proof of principle data demonstrating the ability of ENSCs to integrate with 
SC-derived cells. In ovo work demonstrated the ability of ENSCs to survive 
following transplantation into the embryonic chick spinal cord. While these 
results were encouraging, several features of the embryonic chicken 
necessitated a progression to an adult animal model of SCI. Perhaps most 
importantly, the embryonic chick is known to have a limited immune system 
at the time points under examination in the current study, with immature T 
cells incapable of an immune response present within the thymus, and none 
in the spleen by E13.5 (Lowenthal et al., 1994; Seto, 1981). Indeed, even in 
the initial weeks post-hatching, the immune system of chickens is notably 
poor and many succumb to infection (Wallach et al., 1992). Additionally, 
astrogliosis and myelin degradation in response to SCI are not observed until 
after E13 (Ferretti et al., 2003), prompting additional studies in a model 
organism that better recapitulates the environment seen in adult SCI. The rat 
was chosen as the most suitable adult model, and a pilot study conducted to 
determine the optimal time post-injury for cell transplantation. This 
demonstrated the ability of ENSCs to survive in the SC injury zone for up to 2 
weeks, and prompted a larger scale rat study with a more severe SCI, for an 
extended period of time. This extended study assessed the benefit of a 
combinatorial therapy consisting of dual application of transplanted ENSCs 
and the bacterial enzyme ChABC, a modifier of the inhibitory 
microenvironment. Treatment outcomes examined in this study focused 
mostly on tissue histology, including both cavity and injured tissue area. 
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Further, this part of the thesis showed that ENSC transplantation resulted in a 
significant increase in the number of retrograde axons crossing the injury site, 
a potential increase in myelination within the injury zone and a reduction in 
astrogliosis. Overall, this work provides data supporting the idea that enteric 
nervous system stem cells, derived from the gastrointestinal tract, could, in 




5.1.2.1 Safety of ENSC transplantation 
 
A key concern following any stem cell treatment is safety (Fan et al., 2017). 
This includes cell migration outside of the transplantation area, differentiation 
towards undesirable cell fates, and uncontrolled proliferation leading to 
tumour formation. These issues must be addressed before progression of 
stem cell transplantations towards clinical trials. 
Results of chapter 2 demonstrated a tendency of transplanted ENSCs 
to localize in TuJ1+ neuronal tissue. While some spread into the PNS through 
dorsal root ganglia was observed in the earlier time points examined (E5.5, 
and to a lesser extent E7.5), by later stages of transplantation this spread 
appeared to be much reduced. At all stages, the vast majority of GFP+ 
ENSCs remained in the SC. Additionally, there are several reasons why the 
spread observed in early embryonic stages may not occur following ENSC 
transplantation into an adult model of SCI. Firstly, transplantation into the 
chick neural tube involved complete removal of a segment of the neural tube 
and grafting of a neurosphere into the ablation. Transplanted cells were thus 
in contact with the developing dorsal root ganglia, which would not be the 
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case following injection of ENSCs into the injury cavity in an adult model of 
SCI. The dorsal root ganglia and peripheral nervous system are also of neural 
crest origin (Kasemeier-Kulesa et al., 2005; Newbern, 2015; Teillet et al., 
1987). Transplanted ENSCs may therefore have been attracted to cues 
secreted by these developing structures (Belmadani et al., 2005; Britsch et 
al., 1998; Newbern, 2015), and may have even contributed to the 
development of these structures. An adult model, in which PNS development 
is long since completed, would not provide such cues, possibly meaning 
ENSCs would be less likely to spread in such a manner. This conclusion was 
supported by transplantations into the rat SC, in which ENSCs were observed 
mostly within the centre of the cord surrounding the injury zone.  
In terms of safety, cell fate may be as important as location. In all in 
vivo studies detailed in this thesis, extensive neuronal differentiation of 
ENSCs was observed post-transplantation, as assessed by TuJ1 
immunostaining. This was supported by the in vitro chick studies described in 
chapter 2, in which qRT-PCR revealed expression of a panel of neuronal 
subtype genes within ENSC cultures. These results are in line with previous 
work involving ENSC transplantation into the ENS, in which neuronal 
differentiation of ENSCs appeared to be the default pathway (Cooper et al., 
2017; McCann et al., 2017; Natarajan et al., 2014). 
This cell fate characterization could be extended further to determine 
whether there are any other cells contained within the ENSC-derived 
population post-transplantation. While this would be unexpected following 
FACS isolation based on neural crest lineage, such an analysis would be 
important to address safety concerns. For example, the presence of 
mesenchymal cells could be assessed. Several reports have suggested 
differentiation capability of ENCCs towards a mesenchymal lineage. A study 
by Li et al demonstrated the potential of hiPSC-derived neural crest stem cell 
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to differentiate into CD44, CD73 and CD90-expressing mesenchymal cells (Li 
et al., 2016b). However, driving these cells towards an induced pluripotent 
state is substantially different from the usual fate of these cells, and 
mesenchymal differentiation may be an artefact of this process. Another 
report by Lee et al showed mesenchymal differentiation of neural crest cells, 
but these were derived from embryonic stem cells and driven to their neural 
crest fate in vitro, again likely reflecting dramatic differences in differentiation 
to that which occurs in vivo (Lee et al., 2007). A recent publication by Kumar 
et al noted that, while driving hPSCs to a mesenchymal lineage, cells passed 
through a stage where the surface antigen p75 was expressed (Kumar et al., 
2017). p75 is the same marker used in the current study to isolate neural 
crest-derived cells from surrounding rat tissue using FACS (chapters 3 and 4). 
Again, however, driving cells down this lineage is likely very different to that 
which occurs in vivo. Indeed, it has been noted that the various unnatural 
environments of in vitro culture can cause cells to behave in ways that may 
not occur in vivo (Edmondson et al., 2014). All in vitro work therefore, while 
very informative, should be interpreted with caution. Additionally, 
mesenchymal differentiation of ENSCs has not previously been noted 
following transplantation into the ENS (Cooper et al., 2016; McCann et al., 
2017; Metzger et al., 2009b), making it unlikely that any such differentiation 
would be observed in the current study. Nevertheless, an assessment of any 
ENSC mesenchymal differentiation potential should be carefully assessed in 
future studies. Ideally, this would be complemented with an in vivo 
corroboration following transplantation. 
Finally, tumour formation was not observed in transplanted rats in the 
pilot or extended study described within this thesis, and nor was any 
difference in mortality observed following transplantation. PCR analysis 
revealed no GFP expression in the peripheral organs under examination 
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(lung, liver, kidney, spleen) in three transplanted rats, indicating transplanted 
ENSCs had not spread to these sites. Therefore, none of the observations 
within this thesis warrant safety concerns for ENSC transplantation.  
 
5.1.2.2 Possible dual roles of CSPGs 
 
Modulation of specific aspects of the glial scar has shown great promise 
towards enhancing SCI recovery. In particular, studies in which CSPGs were 
depleted within the injury zone have led to histopathological and functional 
improvements following SCI (Bartus et al., 2014; James et al., 2015). 
Developmental studies have supported these findings, demonstrating that 
degradation of CSPGs, via ChABC, leads to an extension of the ‘plastic’ 
window of neurodevelopment (Pizzorusso et al., 2002). The histological 
improvements in tissue preservation observed in this study avidly support 
such research and encourage further work into combining stem cell 
transplants with modifiers of the inhibitory microenvironment. Again, 
however, this may not be the whole picture. Early in development, CSPGs 
have been shown to have critical roles in axon guidance (Silver and Silver, 
2014), and it is plausible that CSPGs within the injury zone may, at least in 
part, be an attempt to fulfill a similar role. Further, a study by Rolls et al 
demonstrated that removing CSPGs entirely has a detrimental effect on 
motor recovery, while, similar to findings concerning the glial scar, removing 
it only in the chronic phase of SCI has a beneficial effect (Rolls et al., 2008). 
Further, the authors noted a role for CSPGs in microglial/ macrophage 
activation, and even a role in encouraging the former towards a pro-neuronal 
survival phenotype. The authors had previously shown that one of the 
breakdown products of CSPG degradation, 6-sulfated disaccharides, has 
neuroprotective effects (Rolls et al., 2004), and demonstrated its ability to 
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improve functional outcomes following injection into the injured SC. Taking 
into account the extensive studies detailing the advantages of removing 
CSPGs from the injury site, this implies that any positive effect provided by 
CSPGs at the early stages of SCI is largely overwhelmed by other, negative 
effects at the later stages. However, future refinement of CSPG ablations 
aimed at depleting CSPGs in a specific time frame could result in a greater 
improvement in SCI prognosis, especially if designed in conjunction with 
deliberate alternatives for neuroprotective macrophage/ microglial activation. 
 
5.1.2.3 Motor improvements following ENSC + ChABC treatment 
 
The ultimate goal of any treatment for SCI, especially as stated by patients, is 
the recovery of motor function (Haas et al., 2016). An increase in motor 
function is invariably linked to improvements in tissue histology following SCI 
(Barbour et al., 2013; Karimi-Abdolrezaee et al., 2010; Xiong et al., 2017). 
The studies in chapter 4 demonstrated significant improvements in injured 
SC tissue histology following the combined ENSC + ChABC, including 
reduction in cavity/injured tissue area and increased retrograde axons 
crossing the injury site. Paradoxically, however, while there was a trend 
towards increased recovery in the combined treatment group, the significant 
histological improvements did not translate into a significant functional 
improvement. There are a number of reasons why this could have been the 
case, including a failure to find an improvement that nevertheless existed. 
Additionally, extensive further work could be performed to increase the 
effectiveness of the ENSC + ChABC combinatorial treatment.  
A recent publication tested a similar stem cell/ ChABC combined 
treatment to that assessed within this thesis (Suzuki et al., 2017). Here, the 
authors noted a significant improvement in motor recovery following 
	   198	  
combinatorial treatment with iPSC-derived NSCs, in contrast to the work 
presented in this thesis. As stated in the previous chapter, this discrepancy 
may well be due to the particular types of test utilised (forelimb grip strength 
and catwalk analysis in the study by Suzuki et al, and the horizontal ladder 
test in this thesis), and undoubtedly demonstrates the need for more 
behavioural examination of treated rats in any follow up studies of ENSC + 
ChABC treatment. The method of injury inducement was also different 
(cervical clip-contusion method by Suzuki at al, thoracic impact probe-
induced contusion in this thesis), as was the window of stem cell 
transplantation (chronic stages of SCI by Suzuki et al, compared with acute 
phase transplantation in this thesis). 
However, differences in the treatment application may also be worth 
consideration. Suzuki et al treated injured SC with ChABC delivered via an 
osmotic pump for 1 week prior to stem cell transplantation, as opposed to 
co-injection as in this thesis. A similar approach using ENSCs and the 
lentivirus-containing ChABC could be assessed in a future study. As 
discussed in chapter 3, injection of ENSCs at an earlier stage was ruled out 
because the glial scar appeared to prevent transplanted cells from localising 
to the injury zone. However, pre-treatment with ChABC a week or so before 
transplantation may alleviate this concern, and as in the study by Suzuki et al, 
thereby elicit improved motor activity due to the primed environment. 
Additionally, the detection of CSPG breakdown products, used to determine 
ChABC activity in this thesis, is not easily quantifiable, and while unlikely, it is 
possible that co-transplantation had an effect on enzyme activity. Measuring 
the activity of the enzyme itself would provide a more reproducible and 
accurate assessment of CSPG degradation over time, for which effective 
methods exist (Lee et al., 2010). An assessment of the activity across the 
different groups at timed intervals post-injection would more accurately 
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determine any difference in enzyme activity between the groups, allowing 
any treatment outcomes to be more robustly examined. This would provide 
an important check to rule out differences in enzyme activity between the 
ENSC + ChABC and ChABC-only groups. 
 
5.1.2.4 Reactive astrogliosis in spinal cord injury 
 
SCI results in an incredibly complex cascade of events leading to 
neurodegeneration (Kjell and Olson, 2016; Vismara et al., 2017). Although 
extensive research has focused on the mechanisms and molecular 
components responsible for cell death and the inhibitory microenvironment 
of the injury zone (Iaci et al., 2007; Plemel et al., 2014; Zhang et al., 2012), 
our knowledge of these events is far from complete. Indeed, even the effects 
of well-documented processes are sometimes unclear. For example, the role 
of the glial scar, long thought to be a potent barrier to regeneration, is now 
in question. Astrocytic activation in response to injury of the central nervous 
system is a well known phenomenon (Reier and Houle, 1988). Indeed, within 
the SC, astrocytic activation and proliferation is a pathological hallmark of the 
injury process (Yuan and He, 2013), and its reduction following treatment is 
often used as an indicator of success (Hara et al., 2017; Novikova et al., 2011; 
Xiong et al., 2017). Concordantly, in chapter 4, qualitative analysis showed a 
reduction in astrogliosis surrounding the injury zone following application of 
ENSCs, ChABC, or both. Broadly speaking, previous interpretations of a 
beneficial outcome of such a reduction are likely correct. However, extensive 
literature has demonstrated that this may not be the whole story, and that 
there may be functional roles for astrocytes in improving injury outcomes (Liu 
et al., 2014; Lukovic et al., 2015; Renault-Mihara et al., 2008).  
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Indeed, negligible or negative effects on motor recovery have been 
observed following resection of the glial scar, with the outcome dependent 
on the type of injury inflicted (Rasouli et al., 2009). A reconciliation for these 
opposing results has been offered by Rolls, Schechter and Schwartz (Rolls et 
al., 2009) who proposed that these differing effects of the glial scar may be 
due to timing, whereby early in the injury process the glial scar is beneficial, 
but later becomes detrimental to recovery (similar to the proposed 
mechanism of CSPGs, see above). For this reason, it would be important for 
future ENSC transplantations to determine an optimal window in terms of 
glial scar progression. The pilot study detailed in chapter 3 elucidated that 
early transplantation was advantageous for ENSC localization to the injury 
zone. It is arguable that the primary function of the glial scar is in restricting 
expansion of the lesion (Li et al., 2008). Thus, in the acute phase of injury, 
transplanting ENSCs before maturation of the scar may have the obvious 
benefit of allowing ENSCs to integrate before astrocytes have had sufficient 
time to increase the concentration of axon growth-retarding CSPGs. 
However, doing so may prevent the glial scar from achieving its initial goal of 
limiting lesion spread. A more effective strategy may, therefore, be to allow 
the glial scar to form and exert its beneficial effects, before injecting ChABC 
as a ‘primer’ to reduce the repellant nature of the scar and, after a suitable 
time period, transplant the ENSCs. This would allow any beneficial effects of 
the glial scar on the acute phase to be combined with the growth 
encouraging properties of the transplanted ENSCs.  
 
5.1.2.5 Effect of SCI on the ENS 
 
The ENS provides an easily accessible source of NSCs for autologous 
treatment, as an alternative to the stem cell niches of the brain and spinal 
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cord (Decimo et al., 2012). While other NSC sources, such as OECs, are 
relatively accessible compared to extraction from the brain or spinal cord, 
their harvesting would still involve significant surgical risk due to close 
proximity to the brain (Barnett and Riddell, 2004; Tabakow et al., 2014). 
Additional advantages detailed in chapter 1 include the ability of the enteric 
and central nervous systems to communicate via several nerve tracts, utilising 
a common neurotransmitter pool. However, these extensive connections 
mean that significant damage to one system may affect the other. For 
example, it has been suggested that neurodegenerative diseases such as 
Parkinson’s disease (PD) may originate in the ENS and thence travel rostrally 
to the brain (Pan-Montojo et al., 2010). Similarly, previous work has indicated 
that SCI can have an effect upon enteric physiology (Awad, 2011; den 
Braber-Ymker et al., 2017; Guizar-Sahagun et al., 1996), with constipation in 
particular being linked to a patient’s quality of life (Adriaansen et al., 2016).  
It is unclear what effect, if any, SCI would have on ENSCs. Evidence 
suggests that the gastric dysmotility arising from SCI is due to the effect of a 
disrupted signalling from the central to the enteric nervous system (Holmes, 
2012; Hou and Rabchevsky, 2014), implying that such dysmotility occurs at a 
system level rather than a cellular level. Therefore it is plausible that any 
effects of SCI on GI motility via enteric dysfunction would potentially have no 
impact on harvest, culture and therapeutic use of ENSCs. Nevertheless, an 
important step in providing evidence that ENSCs could serve as a stem cell 
source for SCI would be to demonstrate that biopsy-derived ENSCs isolated 
from animals with SCI would not be adversely different from ENSCs isolated 
from animals without SCI. This would require extensive in vitro comparison 
including RNAseq, qRT-PCR and immunofluorescent comparisons of cell fate 
potential between the two groups, as well as an evaluation of the behaviour 
of such cells. In particular, differences in the proliferative, migratory and 
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axonal extension capabilities should be compared between the two groups. 
This could be further tested by assessing the therapeutic benefits of 
autologous transplantation of ENSCs harvested after inducing SCI, and 
comparing this with therapeutic benefits of autologous transplantation of 
ENSCs harvested before inducing SCI. 
 
5.1.3 Limitations and future work 
 
There are several ways in which the scope of the current study could 
be expanded, and which will serve as useful guidelines for future work on 
ENSC transplantation. Firstly, extended n numbers of each study group 
would allow for more extended histological analysis. The studies described in 
chapter 4 were limited to sagittal sectioning. However, transverse sectioning 
arguably allows for more accurate quantifications of grey and white matter 
loss, as these can be expressed relative to the area of the whole cord. 
Greater numbers within each group would also allow for further quantitative 
assessments. Serial sections obtained in the current study were filled five 
slides at a time, with five sections on each slide. This allowed each slide to 
show a range of section depths, but limited immunofluorescent or other 
quantitative assessments to five tests per animal. Greater n numbers would 
allow for further quantitative assessments, for example to provide 
comparisons between C4S and GFAP staining intensity (especially if these 
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5.1.3.1 Assessments of motor recovery 
 
The failure of any one test to accurately gauge all aspects of functional motor 
improvement has been noted (Onifer et al., 2007). Indeed, it has been 
reported that significant increases in functional improvement may have gone 
unreported due to variability between the specific motor skills assessed by a 
given test (Fouad et al., 2013). Therefore, as mentioned above, the use of the 
horizontal ladder for improved motor outcome could be supplemented with 
additional tests. For example, tests exist to ascertain recovery of specific 
tracts. Corticospinal/ rubrospinal tract recovery can be assessed by reaching 
and grasping tests (Kanagal and Muir, 2007; Morris et al., 2011). Qualitative 
analyses such as the BBB score can analyse compensatory mechanisms that 
may otherwise mask underlying motor recovery, or a lack thereof (Fouad et 
al., 2013). For example, rats with hind limb deficits often swim more forcefully 
with their forelimbs to compensate (Smith et al., 2006). Such rats thus appear 
to perform well following injury, and can occasionally outperform non-injured 
animals, but true motor improvement involving recovery of the pre-injured 
tract affected, has not occurred. Therefore, a true assessment of motor 
recovery following SCI and/ or treatment would involve both specific, 
quantitative tasks as well as a qualitative task to unmask any compensatory 
mechanisms, and this will form an important core component of future work 
into ENSC transplantation into the injured SC. 
 
5.1.3.2 Additional measures of functional improvements 
 
Behavioural tests are not the only method of assessing functional 
improvement following SCI. Electrophysiology has been successfully used to 
evaluate conduction across the lesion site (Hains et al., 2004). Further, 
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increased conduction was shown to correlate highly with improved 
performance on the horizontal ladder test, but not with functional gains 
detected by BBB assessment (James et al., 2011). This again underlies the 
importance of utilizing multiple behavioural tasks, and supports the use of 
electrophysiology as an accurate alternative technique for measuring 
functional improvements. While James et al noted a correlation between 
motor improvement in the horizontal ladder and axonal conduction across 
the injury site, it is possible that electrophysiological analysis of animals in the 
current study would have shown increased axonal conduction despite no 
significant improvement on the horizontal ladder test. Significantly more 
retrograde axons crossed the injury site in ENSC transplanted vs non-
transplanted animals in the current study, suggesting that increased axonal 
conduction is likely. Other physiological assessments, including live calcium 
imaging, are also alternatives. This has been successfully demonstrated in 
both neurons (Sekiguchi et al., 2016) and astrocytes (Cirillo et al., 2012), the 
latter of which may be particularly relevant in the context of ChABC 
application. 
 
5.1.3.3 Post-transplantation characterization of ENSCs and their mode of 
action 
 
The chick studies described in chapter two involved characterization of the 
ENSC neurospheres. qRT-PCR revealed the presence of a range of neuronal 
subtype genes within ENSC neurospheres, indicating the presence of 
nitrergic, serotonergic, glutaminergic, acetylcholinergic and GABAergic 
neurons. Although not performed, it is highly likely that qRT-PCR analysis of 
rat-derived ENSC neurospheres would show no major differences, as studies 
of mouse neurospheres from our lab had similar neuronal profiles to that 
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observed in the chick studies of this thesis (Binder et al., 2015; Cooper et al., 
2016). However, such a characterization would prove vital if ENSC 
transplantations were to progress to a clinical setting. Indeed, the 
characterization would need to be further refined, including the use of 
immunolabelling to confirm the presence of specific neuronal subtypes in 
vitro. It would be of additional benefit to determine the differentiation 
potential of ENSCs post-transplantation. Indeed, any such results should be 
quantified (either by immunostaining, or qRT-PCR analysis of ENSCs FACS 
isolated from dissociated tissue following transplantation) and these results 
compared to pre-transplantation results. Any differences in expression of 
particular neuronal subtypes pre- and post-transplantation would be highly 
informative. If a particular subtype decreases, this could be due either to an 
increased vulnerability to the inhibitory SCI microenvironment relative to 
other subtypes, or because other subtypes were more relevant to SCI 
recovery and ‘selected for’ via signals from endogenous, surviving cells. 
Either result would inform future studies. Additional support, such as immune 
cell suppressors, could be applied if the decrease is due to higher 
vulnerability. Selection via endogenous-driven signalling could be assessed 
by determining the extent of functional synapse formation between 
endogenous and transplanted cells. This could be achieved via 
immunolabelling for synaptic proteins, such as synaptophysin and electron 
microscopy analysis of such synapses to determine presence of specific 
synaptic elements, such as distinguishing the pre- and post synapses 
(Navlakha et al., 2013). Endogenous secreted differentiation factors could be 
elucidated by removing transplanted ENSCs (via FACS) and using a 
proteomic approach, such as mass spectrometry analysis, to assess 
dissociated endogenous cells (Devaux et al., 2016; Henningsen et al., 2010; 
Yan et al., 2010).  
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This approach would also be particularly important for elucidating the 
specific roles of ENSCs following transplantation into the injured SC. 
Considering that the greatest reduction in cavity area and injured tissue 
occurred in the combination ENSC + ChABC group, but there was no 
significant difference in transplanted cell survival or spread between the 
combination and ENSC-only groups, this implies that the major role of 
ENSCs, together with ChABC, was in preserving endogenous tissue. 
However, it remains to be seen whether this occurred through a paracrine or 
autocrine method. Previous stem cell transplantations have often 
demonstrated the potential of transplanted stem cells to secrete 
neurotrophic factors (Dasari et al., 2014; Lu et al., 2003) and even revealed 
specific mechanisms by which paracrine-driven preservation of endogenous 
tissue may occur (Yan et al., 2004). While the results described within this 
study provide evidence that ENSCs transplanted into the injured SC fulfil a 
similar paracrine-driven effect on endogenous tissue, future work will need to 
elucidate specific mechanisms by which this effect occurs. 
 
5.1.3.4 Potential for co-injection of ENSCs + ChABC 
 
Separate transplantation of ENSCs and ChABC injection within the current 
study likely introduced additional tissue damage through needle penetration. 
While such damage is thought to have little effect on recovery per se, a 
reduction in the number of injections would reduce the surgical risk of further 
paralysis if this treatment were to reach clinical trials. If a ‘priming’ injection of 
ChABC before ENSC transplantation was not used, one method to reduce 
the invasiveness of this procedure would be to combine the ENSC 
transplantation and ChABC injections. Application of the ChABC-containing 
lentivirus to the ENSCs in vitro would remove the need for further ChABC 
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injections. The success of lentiviral transduction would need to be assessed 
prior to transplantation. This could be achieved by testing the ability of 
transduced ENSCs to extend axons along CSPG coated dishes (Snow and 
Letourneau, 1992), and potentially by an assessment of the enzyme activity 
as mentioned above. Providing the ability of ENSCs to produce the ChABC 
enzyme could be verified, these could then be transplanted into an injured 
spinal cord to provide both the stem cell and ChABC components of the 
combinatorial therapy. The efficacy of this single, combined application 
would need to be compared to the outcomes of the combinatorial therapy 
applied separately. 
 
5.1.3.5 Use of scaffolds for other categories of SCI  
 
This study assessed the potential of ENSCs to preserve and rescue 
endogenous tissue following a contusion SCI. As detailed in the previous 
chapters, this injury model was selected as being the most relevant to human 
SCI. However, contusions are not the only injury type, and each presents with 
unique challenges (Cheriyan et al., 2014; Kandziora et al., 2016; Sharif-
Alhoseini et al., 2017; Yue et al., 2016). It is important that prospective stem 
cell-based therapies are able to adapt to these varying needs if progression 
to a clinical setting, and to the broad range of patients with SCI, is to 
succeed. While the ENSC + ChABC combinatorial treatment described within 
this thesis holds substantial promise, additional modifiers may be necessary 
to adapt this treatment to each injury type. With transection injuries, for 
example, in which the spinal cord is partially or completely severed, a 
significant gap can often exist between the anterior and posterior spinal cord 
tissue. In such instances, a physical bridge may be required, which could then 
be populated with ENSCs to encourage endogenous regeneration across the 
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injury site. Scaffolds of varying composition have been tested for their 
therapeutic benefit, and many have shown significant promise towards SCI 
recovery. These have included both biological scaffolds, such as peripheral 
nerve grafts (Cote et al., 2011) and synthetic polymer-based scaffolds (Teng 
et al., 2002). Particular promise has been demonstrated in a range of 
hydrogel scaffolds (Agbay et al., 2016). Many hydrogel scaffolds have the 
advantage of being injectable, ensuring complete filling of the cavity with 
minimal invasiveness (Slaughter et al., 2009). Of pertinence to the current 
study, stem cells can be diluted in hydrogel scaffolds as a cell suspension, 
allowing simultaneous injection and an even dispersion of stem cells 
throughout the scaffold. This technique has been shown to improve survival 
rates of stem cells following transplantation into a CNS environment (Ballios 
et al., 2015). This technique may therefore be applicable for enhancing the 
survival of the ENSCs described within this thesis in injury models where SC 
transection or a particularly severe contusion has resulted in formation of 
cavities too large to be filled by stem cell transplantation alone, and would 
be a useful additional modification for ENSC transplantation therapy in future 
studies. 
 
5.1.3.6 Progression to larger animals to demonstrate autologous 
transplantation 
 
Previous stem cell studies proposing autologous transplantation have often 
turned towards the use of iPSCs (Khazaei et al., 2016). But, as highlighted in 
chapter 1, despite their increasing promise, iPSC generation still holds 
significant barriers to success, including tumerogenicity concern regarding 
genetic instability (Kuroda et al., 2013; Lund et al., 2012; Yoshihara et al., 
2017). This thesis demonstrates the potential of ENSCs to serve as an 
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alternative autologous stem cell source for SCI repair. ENSCs have previously 
been isolated and expanded in vitro from human gut biopsies (Binder et al., 
2015) and separately, this thesis has shown that ENSCs can be transplanted 
into the CNS environment of the SC. This work is supported by a recent 
publication describing success of ENSC transplantation into the brain 
(Belkind-Gerson et al., 2016), and shows the potential of stem cells isolated 
from the enteric nervous system to survive in other nervous systems, 
expanding the range of neural disorders to which this stem cell source could 
be applied. However, as yet ENSC studies have been limited to allogenic 
transplant, involving either extraction from one animal and transplantation 
into another (as described in this thesis and the work by Belkind-Gerson et al, 
among others), or extraction from human tissue and transplantation into 
animal gut (Cooper et al., 2017). These studies provide important proof of 
principle data suggesting autologous transplantation could be successful.  
However, to fully demonstrate this and determine the functional 
benefit of such transplantation, progression to a larger model animal would 
be vital. Use of a model organism such as the pig, would allow stem cell 
isolation from gut tissue biopsies and subsequent expansion in vitro, 
followed by transplantation into the same animal with SCI (Fig. 5.1) Such 
autologous transplantation is technically challenging in small animal models 
such as rodents. Given the underlying similarities with human biology and 
their ready availability, pigs are becoming increasingly popular as a large 
animal model for study (Walters et al., 2017). Porcine models of SCI have 
been developed to measure a variety of SCI outcomes (Jones et al., 2012; 
Lee et al., 2013; Schomberg et al., 2017), and it has even been suggested 
that these may offer significant improvements over existing rodent models 
due to a greater similarity between the porcine and human spinal cord 
(Leonard et al., 2017). The pig is also currently being examined for utilization 
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towards ENSC-based cell therapies for enteric neuropathies (Burns et al., 
2016). Collectively, this demonstrates the feasibility and promise of 














Figure 5.1: Large animal models for testing of autologous ENSC 
treatment. 
To provide evidence that autologous transplantation of ENSCs is feasible, 
progression from rodent studies to a large animal model, such as the pig, will be 
required. Pigs are large enough to allow for the use of endoscopic biopsies, for 
harvesting ENSCs for SCI treatment. Following harvest from the ENS (A’) ENSCs 
could be expanded in vitro and transplanted back into the injured spinal cord (A’’) of 
the same animal. This approach would provide a platform to assess the effect of SCI 
on ENSC morphology, behaviour and proliferation /differentiation potential. 
	   211	  
5.1.3.7 Benefits of ENSC cryopreservation 
 
While it would be hoped that a single treatment with ENSCs/ ENSCs + 
ChABC would be sufficient to drive recovery following SCI, in order to 
achieve complete recovery it is probable that multiple treatments may be 
necessary at timed intervals to achieve success. In order to minimise 
invasiveness of these procedures, it would be advantageous to collect ENSCs 
from a single harvest of gut biopsies, expand these in culture and 
cryopreserve aliquots. These could then be thawed and expanded in vitro for 
any subsequent treatments. However, for such a strategy to be feasible it 
would need to be demonstrated that ENSCs can survive cryopreservation 
without any effect on cell viability. Several laboratories have noted decreases 
in stem cell viability after cell thawing, and so have focussed on increasing 
efficiency of cryopreserving stem cells (Berz et al., 2007; Hunt, 2011; Yuan et 
al., 2016b). Various methods have been optimised and could be tested to 
determine which offers the greatest stability to thawed cells. In particular, any 
effect of freezing that would affect their ability to enhance SCI repair would 
need to be assessed, including proliferative and differentiation capabilities. 
Demonstrating that cryopreservation has no negative effect on these 
properties would significantly increase the usability of ENSCs as a SCI 
therapy. 
 
5.1.3.8 Additional safety assessments 
 
As described above, results of the studies within this thesis raised no 
significant safety concerns of ENSC transplantation. However, future work will 
continue to assess this. In particular, analysis of ENSC proliferation post-
transplantation will provide an important assessment of the potential of 
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ENSCs to form tumours, although previous work in our lab makes this 
unlikely (Cooper et al., 2016; McCann et al., 2017). Finally, an often-cited 
issue of iPSCs is the genetic instability arising from their generation (von 
Joest et al., 2016). Genetic sequencing should be conducted to confirm that 
this instability does not occur in ENSCs. 
 
5.1.3.9 Use of ENSCs for additional nervous system disorders 
 
As described above, this work and the work of others has demonstrated that 
ENSCs isolated from the ENS can be applied to CNS disorders. A useful 
future direction would be to explore other potential areas for ENSC 
application. Neurodegenerative diseases, for example, could be one such 
target. Parkinson’s disease (PD) involves irreversible degeneration of 
dopaminergic neurons of the substantia nigra (Litvan et al., 2007). Stem cell 
therapy is arguably the most promising method to date for replacing these 
lost cells, and has shown promise in alleviating PD symptoms (Bjorklund, 
2004). However, a previously successful trial utilising foetal stem cells is 
unlikely to be taken forward due to ethical concerns (Lindvall and Bjorklund, 
2004), and other stem cell sources likely to be successful for PD will face 
many of the same issues as those proposed for SCI (evaluated in chapter 1). 
ENSCs may therefore serve as a viable alternative stem cell source for PD. Of 
note, any additional diseases would need to involve further, unique 
characterization of ENSCs. For example, PD is known to involve ENS 
complications, including an alpha-synuclein burden within enteric neurons 
(Awad, 2011; Pan-Montojo et al., 2010; Ulusoy et al., 2017; Wakabayashi et 
al., 1989). Therefore, ENSCs isolated from PD patients would need to be 
carefully compared to control (disease free) ENSCs to determine whether any 
deficits in the former would impair their ability to repopulate the substantia 
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nigra and other structures affected in PD. This may involve gene correction of 
isolated ENSCs prior to autologous transplantation, a process proposed in a 
review by Burns and Thapar, for ENSC-based treatments of enteric 
neuropathies such as Hirschsprung disease (Burns and Thapar, 2014) where 
mutations in the RET gene are prevalent. Thus, while an assessment of the 
suitability of ENSCs for additional nervous system disorders would likely yield 
promising results, it will be important to tailor ENSC preparation to the 
individual diseases. 
 
5.1.3.10 The future of SCI therapies 
 
As described in chapter 1, endogenous regeneration within the cord is 
unable to occur to any beneficial extent despite the fact that in vitro and in 
vivo, CNS regeneration has been demonstrated if the correct environment is 
supplied (Richardson et al., 1980; Taylor et al., 2005). This implies that 
modification of the inhibitory microenvironment is vital for SCI recovery. 
Previous publications have noted paracrine-driven stimulatory effects of 
transplanted stem cells on endogenous recovery (Baraniak and McDevitt, 
2010), but it is likely that, even with these effects, several significant problems 
would remain. Arguably, one of the most prominent would be the dense 
concentration of CSPGs within the glial scar (Asher et al., 2001; Yuan and He, 
2013). In this thesis therefore, ChABC was selected as a combinatorial 
therapy, based on the hypothesis that the combination of glial scar 
degradation, plus stimulation and bridge formation by transplanted ENSCs 
would allow endogenous axons to cross the injury site and re-establish 
previous connections. This expectation was supported by the effects of ENSC 
+ ChABC treatment on reducing lesion parameters and increasing the 
number of retrograde axons crossing the injury site. Since the 
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commencement of this study, several other laboratories have published 
results from combinations of ChABC and other stem cells (Lee et al., 2015; 
Sarveazad et al., 2017; Suzuki et al., 2017). However, as with the current 
study, even these combined treatments do not completely nullify the 
inhibitory environment, and do not preserve all possible endogenous tissue, 
probably explaining the lack of complete recovery noticed in our and other 
studies. It is important to acknowledge that a complete SCI treatment will 
incorporate not only two, but most likely several individual methods. For 
example, the ENSC + ChABC treatment presented in chapter 4 begins 1 
week after injury inducement. This transplantation time was selected based 
on a pilot study described in chapter 3 due to exclusion of ENSCs from the 
injury zone after this point. This transplantation time point could potentially 
be brought forward by pre-application of ChABC to prime the injury zone 
(see above). However, previous publications have shown in the early acute 
stages of SCI, the glial scar and even CSPGs may be beneficial (Rolls et al., 
2009). Therefore, additional therapies are required to limit the damage 
sustained in these early stages that do not disrupt scar formation, and 
preferably that do not risk any further damage to the SC (minimizing SC 
injections etc.). One possibility is cooling of the lesion site. It has been shown 
that, shortly after SCI, many tracts survive the initial injury but become highly 
vulnerable and are lost in the acute phase. However, cooling of the spinal 
cord has shown that these tracts are still functional (James et al., 2011). The 
benefits of inducing mild hypothermia following SCI has been demonstrated 
in both human and animals (Dietrich et al., 2011). This therapy could be used 
in conjunction with the current ENSC + ChABC treatment, in the hours 
immediately following the injury but before transplantation. Moving into the 
initial days after the injury, anti-inflammatory drugs have been shown to have 
a neuroprotective effect at both acute and chronic stages of SCI (Arnold and 
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Hagg, 2011). Even ibuprofen has been shown to increase survival of spared 
tissue and lead to increased axonal elongation (Wang et al., 2009). This too 
could be easily utilised as a combinatorial therapy, after lesion cooling and 
before transplantation.  
The works contained within this thesis show that the combined effects 
of transplanted ENSCs and ChABC-mediated degradation of CSPGs are 
highly beneficial, but neither treatment has any known effect towards other 
inhibitory debris of the injury zone, such as myelin fragments. However, as 
previously mentioned, a possible solution for these has already been 
uncovered (McGee and Strittmatter, 2003; O'Neill et al., 2004). Nogo 
antibodies have been shown to neutralise these myelin fragments, translating 
into significant improvements in motor recovery. This could be applied 
simultaneously with the ENSC/ChABC treatment, or could be administered in 
the week or so before ENSC transplantation. To reduce invasiveness of these 
multiple treatments, a systemic rather than spinal injection route could 
potentially be utilised, exploiting the reduced barrier function of the blood 
spinal cord barrier during SCI (Bartanusz et al., 2011; Whetstone et al., 2003). 
Many other treatments have been shown to hold beneficial roles for 
SCI recovery, and many will likely prove to have significant benefit as part of 
a combinatorial therapy. A full treatment regimen is beyond the scope and 
purpose of this report, but the above points serve to demonstrate the 
potential for recovery if multiple treatments are to be combined. Numerous 
studies have demonstrated the benefits of combining two treatments (Bunge, 
2016; Fuhrmann et al., 2017; Lu et al., 2004), but very few have examined the 
effects of combining multiple treatments (due largely to the rapidly 
expanding animal numbers, and costs, both financial and time, that 
accompany increasing numbers of variables). Despite this, such testing will 
be necessary before implementation of any combinatorial treatments, as in 
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rare cases certain combinations have proved counter-productive (Hoeber et 
al., 2017). In general however, results of such combinations are likely to be 
increasingly positive, and will undoubtedly form part of any future successful 
SCI treatment. Figure 5.2 shows a potential regimen by which several 
therapies could be beneficially combined to preserve the maximum 
endogenous tissue and optimise regeneration by transplanted ENSCs. It is 
worth noting however, that the odds of a single treatment being approved 
are incredibly small and subject to rigorous evaluation – a complex 
intervention such as the one proposed below is therefore incredibly unlikely 
to be accepted in the near future. 
 
Figure 5.2: A proposed combined treatment regimen following 
SCI. 
A successful future SCI treatment will likely combine multiple therapies to achieve 
full recovery. Following harvest of ENSCs once injured patients are medically stable, 
stem cells will be expanded in culture. It is likely that a single harvest will allow for 
several transplantations over time if required (green arrows). Simultaneously, non 
cell-based treatments (red arrows) will be applied to supplement and enhance the 
success of cell treatment. Finally, physical therapy following transplantation will likely 
prove vital for a full recovery. 
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5.1.4 Concluding remarks 
 
The studies described within this thesis demonstrate the potential of stem 
cells isolated from the ENS to serve as an autologous cell-based source for 
not only enteric disorders, as previously described, but for nervous system 
disorders in general, and SCI specifically. The finding that ENSCs can survive 
and elicit therapeutic benefit following transplantation into the injured spinal 
cord provides proof of principle to allow ENSCs to be further tested for a 
range of neuropathies. In contrast to alternative stem cell sources proposed 
for SCI, ENSCs are easily and repeatedly accessible, with no significant 
ethical objections to their use and, as demonstrated in this thesis and other 
works, results of their transplantation has not warranted significant safety 
concerns. This work therefore supports the use of ENSCs as a novel stem cell 
source for patients with SCI. Future work will continue to elucidate the 
specific benefits of ENSC transplantation into the injured spinal cord.  
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